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Abstract 
The human-specific enteropathogenic Escherichia coli and the mouse-restricted 
Citrobacter rodentium colonise the host intestinal mucosa via attaching and effacing 
lesions, inducing severe diarrhoeal disease and transmissible murine colonic 
hyperplasia, respectively. C. rodentium is widely used as an in vivo model for EPEC 
infection, sharing a highly homologous arsenal of virulence factors and a similar 
infection strategy with EPEC. EPEC and C. rodentium pathogenesis relies on the 
locus of enterocyte effacement-encoded type III secretion system and delivery of 
effectors into the host cytosol to subvert host cell signalling including: actin 
dynamics, cell trafficking and immune signalling. The role of many effectors during 
infection remains unclear. We sought to identify the function of the non-LEE-encoded 
effector protein F (NleF). We discovered that EPEC infection of polarised epithelial 
cells activated a caspase-4-dependent non-canonical inflammasome response 
leading to the processing and secretion of IL-18, which was counteracted in a T3SS- 
and NleF-dependent manner. EPEC NleF interacts with the p20 and p10 subunits of 
caspase-4, associating with the substrate-binding domain, to inhibit its proteolytic 
activity and downstream inflammasome activation. Infection of mice with a C. 
rodentium nleF mutant enhanced IL-18 secretion and revealed that NleF is essential 
for the inhibition of the caspase-1/11-dependent inflammasome and recruitment of 
neutrophils in vivo. We further report that ectopically expressed NleF activated NF-
κB nuclear translocation and the up-regulation of the pro-inflammatory chemokine IL-
8. Infection of HeLa with an EPEC nleF deletion mutant abolished the T3SS-
dependent activation of NF-κB and the expression of IL-8. NleF was identified to act 
upstream to IκBα activation and could be inhibited by the TAB2/3 inhibitor NleE1. 
However the mechanism of the pro-inflammatory role of NleF remains unclear. 
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These findings identify novel roles for the T3SS effector NleF, furthering our 
understanding of the infection strategy of EPEC and the host epithelial cell 
inflammasome response.  
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Chapter 1: Introduction  
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1.1 Escherichia Coli 
Escherichia coli (E. coli), the most abundant Gram negative facultative anaerobe of 
the intestinal commensal microflora, mutually and beneficially co-exists with the 
human host (Kaper, Nataro & Mobley, 2004). Considered the workhorse of the 
molecular biologist it has been extensively exploited to further scientific research and 
this has led it to be the foremost studied bacterial species and one of the earliest to 
have its genome sequenced. While all E. coli strains share a common backbone of 
around 4.1 Mbp, vertical gene transfer and the presence of punctuated lineage 
specific elements through horizontal gene transfer and/ or possible deletion has led 
to divergence over the past 4.5 million years and the emergence of pathogenic 
strains (Donnenberg, 2002). Acquisition of elements associated with virulence are 
assigned as O-islands and are detectable by their G + C content, insertion position 
(eg. at a tRNA gene) and presence of a flanking integrase or transposase, 
responsible for mobilisation (Donnenberg, 2002). Furthermore, pathogenic strains of 
E. coli have acquired F-like plasmids associated with virulence and disease which 
encode a range of virulence factors including transcriptional regulators, enterotoxins 
and adhesins (Donnenberg, 2002). This acquisition of lineage specific elements has 
resulted in a range of pathotypes with the ability of E. coli to cause a spectrum of 
diseases in a range of hosts. 
1.1.1 Pathogenic E. coli 
Infection with pathogenic E. coli can be classified into three clinical syndromes: 
enteric/diarrhoeal disease, urinary tract infection (UTI) or systemic infection leading 
to meningitis (Nataro & Kaper, 1998). Strains that cause diarrhoeal disease are 
classified as intestinal pathogenic E. coli (InPEC) while those causing systemic 
infection/ UTI are grouped as extra-intestinal pathogenic E. coli (ExPEC; Croxen & 
17 
 
Finlay, 2010). InPEC is a major cause of diarrhoeal disease which accounts for ~1.3 
million deaths annually and remains the second leading cause of death in infants 
worldwide (Ochoa & Contreras, 2011; Black et al., 2010). Furthermore inPEC is 
subdivided into 8 distinct categories dependent upon mechanism of infection and 
presence of specific virulence factors including bacterial toxins and colonisation 
factors as reviewed by others (Clements et al., 2012; Croxen & Finlay, 2010; Kaper, 
Nataro & Mobley, 2004). This includes: enteropathogenic (EPEC), 
enterohaemorrhagic (EHEC), enteroinvasive (EIEC), enterotoxigenic (ETEC), 
enteroadhesive (EAEC), diffusely adherent E. coli (DAEC) adherent invasive E. coli 
(AIEC) and Shiga toxin producing enteroadhesive E. coli (STEAEC). AIEC is 
associated with Crohn’s disease and is not a diarrheagenic pathogen and therefore 
will not be covered any further (Clements et al., 2012). It should also be noted that 
strains can also be classified by their O-antigen (serogroup) and their O-antigen and 
flagelllar (serotype); although, a particular serotype may be common among E. coli 
of different pathotypes.  
i. ETEC 
ETEC is the leading cause of diarrhoeal disease in travellers to developing countries 
(Kaper, Nataro & Mobley, 2004). ETEC colonizes the surface of the small bowel 
mucosa; inducing a watery diarrhoeal disease (Kaper, Nataro & Mobley, 2004). 
Colonization is mediated by approximately 23 fibrillar, fimbrial and afimbrial 
colonization factors (CFs; Croxen and Canto 2012); which confer host specificity 
(Kaper, Nataro & Mobley, 2004), the outer-membrane proteins TibA and Toxigenic 
invasion loci A (Tia), the flagellin tip protein EtpA and the porcine attaching and 
effacing associated adhesin (Paa) (Clements et al., 2012; Croxen & Finlay, 2010). 
ETEC is defined as E .coli that produces one or more of either the heat-liable (LTs) 
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or heat-stable (STs) toxins; which are responsible for the ETEC-mediated diarrhoea. 
LT, which functionally resembles Cholera toxin of Vibrio Cholerae, is an AB5 toxin 
that once internalised activates host adenylyl cyclase resulting in an increase in 
intracellular cyclic AMP and activation of Protein Kinase A (PKA). Importantly, LT –
dependent activation of PKA inhibits the expression of antimicrobial peptides 
(Croxen & Finlay, 2010). Alternatively, STs, bind the cell surface receptor guanylyl 
cyclase of the intestinal brush border increasing intracellular cyclic GMP and 
decreasing Na+ absorption (Croxen & Finlay, 2010). Both LT and ST, through 
manipulation of cGMP and cAMP levels, activate the cystic fibrosis transmembrane 
conductance regulator (CFTR) increasing Cl- secretion (Croxen & Finlay, 2010). 
Ultimately, manipulation of intracellular levels of cGMP and cAMP dysregulates 
epithelial cell fluid transport and induces diarrhoea (Croxen & Finlay, 2010). ETEC 
strains also encode the serine protease autotransporter of the enterobacteriaceae 
(SPATE) family protein ETEC autotransporter A (EatA) as well as Cytolysin A (ClyA) 
and EAEC heat stable toxin 1 (EAST-1). While EAST-1 and ClyA function similarly to 
ST, the SPATE EatA cleaves cathepsin G associated substrates and mucin, 
accelerating toxin delivery and intestinal fluid build-up (Kumar et al., 2014; Croxen & 
Finlay, 2010; Patel et al., 2004).  
ii. DAEC 
DAEC colonizes the small bowel and urinary tract and although more commonly 
associated with urinary tract infections it is also associated with diarrhoeal disease 
(Croxen & Finlay, 2010). As the name suggests DAEC is characteristically 
distinguished by its diffuse adherence pattern to HEp-2 cells in vitro (Servin, 2005). 
DAEC is an extremely heterogeneous group and colonization and pathogenesis of 
DAEC relies on the presence of cell surface fimbrial (Dr and F1845) and afimbrial 
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(Afa) adhesins referred to collectively as the Afa-Dr fimbriae (Servin, 2005). The 
Afa/Dr fimbriae bind to the host complement decay-accelerating factor (DAF), type IV 
collagen and the Carcinoembryonic antigen-related cell adhesion molecules 
(CEACAM) to facilitate tight adherence during infection (Servin, 2005; Berger et al., 
2004). Strains of DAEC are subdivided, by their repertoire of specific adhesins, into 
typical or atypical DAEC. Typical DAEC encode the adhesins Afa/ Dr and F1845 and 
are able to bind both DAF and CEACAM and are commonly associated with re-
occurring UTIs as well as enteric infection (Servin, 2005). Atypical DAEC express 
Afa but no Dr or F1845 adhesins and do not bind DAF (Servin, 2005). A subclass of 
atypical DAEC, commonly referred to as DA-EPEC, is associated with infantile 
diarrhoea (2-3 yrs) and phenotypically resembles infection with EPEC but 
characteristically adheres in a diffuse pattern through the presence of adhesins 
involved in diffuse adherence (AIDA-I; Servin, 2005). Pathogenesis of DAEC is 
predominately dependent on the expression of the Afa-Dr fimbriae although it does 
encode the SPATE Secreted auto-transporter toxin (Sat); which is implicated in tight 
junction lesion formation and an increase in cell permeability (Croxen & Finlay, 
2010). 
iii. EAEC and STEAEC 
EAEC are phylogenetically similar to DAEC and were previously sub-classed 
together as an adherent non-EPEC/enteroadherent pathogen before being 
individually typed as having either diffuse or aggregative adherence (Weintraub, 
2007; Nataro et al., 1987). EAEC is linked to outbreaks of watery diarrhoea in 
developed countries and persistent diarrhoea in developing countries and is the 
second most common cause of Travellers disease after ETEC (Croxen & Finlay, 
2010). It colonizes the intestinal mucosa of the colon, where it up-regulates the 
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secretion of mucus to form an auto-aggregative bacterial mucus-biofilm layer 
(Weintraub, 2007). Pathogenesis of EAEC is regulated by the transcriptional 
regulator AggR which controls the expression of adherence factors and the type 6 
secretion system which is required for biofilm formation (Kaur, Chakraborti & Asea, 
2010). Encoded by the aggregative adherence virulence plasmid (pAA) AggR 
regulates the expression of Aggregative adherence fimbriae (AAFI/II/II). Each EAEC 
isolate expresses only one AAF subtype which through the binding to extracellular 
matrix proteins including type IV collagen, fibronectin and lamin is responsible for 
initial adherence to the intestinal mucosa and the ‘stacked brick’-like pattern of 
adherence (Kaur, Chakraborti & Asea, 2010). Interestingly atypical EAEC do not 
possess pAA and therefore do not express AAFI/II/II; however, still adhere in the 
characteristic ‘stacked brick’ pattern through a Dr adhesin-like aggregative adhesin 
pilin, also regulated by AggR (Kaur, Chakraborti & Asea, 2010). Further colonization 
factors identified vary among clinical isolates of EAEC but include the Heat resistant 
agglutinin (Hra) 1 and 2, Tia and Dispersin, which potentiates AAF binding 
(Clements et al., 2012). Through the secretion of enterotoxins and cytotoxins EAEC 
elicits a pro-inflammatory response, mild mucosal damage and persistent watery 
diarrhoea. This includes the pAA encoded toxin EAST-1 and the chromosomal 
encoded SPATE proteins Protein involved in colonization (Pic), Plasmid encoded 
toxin (Pet), Shigella IgA-like protease (SigA), Shigella extracellular protein (SepA), E. 
coli secreted protein P (EspP) and Sat as well as the pore forming toxin HlyE and the 
Shigella-like she island encoded Shigella enterotoxin 1/2 (ShET1/2; Clements et al., 
2012; Croxen & Finlay, 2010; Kaur, Chakraborti & Asea, 2010; Weintraub, 2007). 
Pic, a class II SPATE, is an extracellular serine protease with mucinolytic activity 
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required for colonization. Furthermore it has recently been identified that Pic cleaves 
leukocyte cell surface glycoproteins to interfere with immune signalling  
(Weiss & Brockmeyer, 2012; Wiles et al., 2004) Pet, SigA and EspP are class I 
SPATEs. Pet and SigA have similar functions and both cleave the actin binding 
protein spectrin to induce cytotoxicity and cell detachment while, EspP functions to 
degrade proteins of the host complement system to manipulate immune signalling 
(Weiss & Brockmeyer, 2012). SepA shares 73% homology and functions similarly to 
EatA (Dautin, 2010). ShET1/2 is an AB5 toxin however its role in pathogenesis is still 
not fully understood (Croxen & Finlay, 2010). 
Further to the enterotoxins described above an emerging pathogenic subclass of 
EAEC O104:H4 recently re-classified as Shiga Toxin (Stx) producing 
Enteroaggregative E. coli (STEAEC) closely resembles EAEC but, through 
acquisition of a stx2-harbouring prophage, encodes the Shiga toxin (Stx) as well as 
the IrgA homolog adhesin (Iha) and is responsible for the outbreak in Germany in 
2011 (Clements et al., 2012). Stx, also referred to as verocytotoxin, is released in the 
colon due to bacterial cell lysis where it induces necrosis of the paneth cells of the 
intestinal mucosa or targets the kidneys by entering the blood stream and binding to 
the glycolipd globotriaosylceramide (Gb3) on the surface of renal endothelial cells 
(Croxen & Finlay, 2010). This induces local cytokine secretion and inflammation 
which leads to haemorrhagic colitis and in more severe cases to kidney damage and 
the progression to Haemolytic-uremic syndrome (HUS) and bloody diarrhoea. 
iv. EIEC 
Pathogenesis of EIEC is closely associated with that of Shigella spp., to which it is 
genetically closely related. Although disease can lead to dysentery and shigellosis it 
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is rarely distinguishable from other E. coli pathotypes (Donnenberg, 2002). EIEC and 
Shigella spp. share 90% genetic homology and the same O-antigens (Donnenberg, 
2013). In fact it is now widely accepted that Shigella spp. are a distant clone of 
commensal E. coli which acquired multiple virulence factors and most importantly a 
high molecular weight plasmid (pINV) comprised of four separate ancestral plasmids 
which is key to the virulence of Shigella spp.   
While most pathogenic E. coli are extracellular; EIEC, is an intracellular pathogen 
that lacks both flagella and adherence factors (Donnenberg, 2013). Due to the 
selective pressure to adapt to the intracellular environment the EIEC pathotype and 
infection strategy is uniquely different from the other inEPEC pathotypes. EIEC 
exploits the immune system of the host to be preferentially taken up by M cells in the 
large intestine where it is transcytosed across the enterocyte barrier and rapidly 
phagocytosed by macrophages (Donnenberg, 2013).  Rather than be killed EIEC is 
able to evade the phagosome and induces a form of inflammatory cell death known 
as pyroptosis to escape the macrophage. This gives EIEC the unique advantage to 
infect the basolateral surface of the enterocytes. Following invasion it is able to 
evade the endocytic vacuole and through the outer-membrane protein VirG it 
manipulates the host cell actin cytoskeleton to direct movement in the cytoplasm to 
disseminate to neighbouring cells (Kaper, Nataro & Mobley, 2004). The induction of 
pyroptosis of resident macrophages, invasion of epithelial cells and subsequent 
recruitment of polymorphonuclear leukocytes (PMNs) results in a pro-inflammatory 
burst and inflammatory cell damage. This leads to destabilisation of tight junctions 
and allows for further infection by exposing the sub-epithelial layer. Although EIEC 
encodes the enterotoxins ShET1/2 and the SPATEs SepA and SigA, which are likely 
to cause the diarrhoea which proceeds dysentery, a mutant which is unable to 
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invade enterocytes does not cause disease in the monkey model (Donnenberg, 
2013). In fact the invasion, intracellular survival and pathogenesis of EIEC is enabled 
by the pINV-encoded type III secretion system (T3SS; see below) which is 
homologous to Shigella spp.  
v. EPEC 
EPEC, the first pathogenic E. coli to be discovered in 1945, colonizes the human 
small bowel and gastrointestinal tract causing watery diarrhoea (Wong et al., 2011). 
EPEC is a major cause of infantile persistent diarrhoea in low to middle income 
countries (Abba et al., 2009).The global enteric multicentre (GEMs), designed to 
detect the cause of acute-moderate to severe paediatric (0-59 months) diarrhoeal 
disease in sub-Saharan Africa and South Asia concluded that typical EPEC is 
associated with increased fatality in children aged 0-11 months (Kotloff et al., 2013). 
Moreover, a recent epidemiological study during 2010-12 found that EPEC is a still 
an important cause of sporadic infection of infants in England (Sakkejha et al., 2013). 
Typical EPEC, with the prototypical isolate being EPEC O127::H6 E2348/69 (EPEC 
E69) is characterised by the presence of the 70-100 KDa virulence plasmid EAF 
(EPEC adherence factor). EAF encodes for the type IV bundle-forming pilus (BFP) 
which through filamentous bacteria-bacteria interaction gives rise to the 
characteristic micro-colony formation of EPEC (Kaper, Nataro & Mobley, 2004).  BFP 
further binds N-acetyl-lactosamine containing receptors for initial adherence of EPEC 
to host enterocytes (Croxen & Finlay, 2010). Although adherence, and more 
importantly pathogenesis, is significantly abrogated in the absence of BFP 
(Donnenberg, 2013; Saldana et al., 2009) both typical and atypical EPEC adherence 
is further regulated by the Escherichia coli common pilus (ECP; Saldana et al., 
2009), long polar fimbriae (LFP), the non-fimbrial adhesins Paa, EHEC 
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autotransporter encoding gene A (EhaA) and Iha as well as intimate attachment 
through the T3SS (Clements et al., 2012; Frankel & Phillips, 2008).  
EPEC along with the mouse restricted pathogen C. rodentium and EHEC belong to 
the family of attaching and effacing (A/E) pathogens which share the common 
feature of infection. A/E pathogens are characterised by their ability to induce A/E 
lesions and intimate attachment; through host cytoskeletal rearrangement and 
formation of a pedestal-like structure from accumulation of polymerised actin 
beneath the attached bacteria and by the local effacement and destruction of the 
enterocyte brush-border microvilli (Frankel & Phillips, 2008). A/E lesions are 
mediated by the 35 Kb Locus of Enterocyte Effacement (LEE) Pathogenicity Island 
(PAI) which encodes for a T3SS and the adhesin Intimin. Both of which are essential 
for intimate attachment (Elliott et al., 1998). The LEE is regulated by the LEE 
encoded regulator (Ler) located on the EAF plasmid (Kaper, Nataro & Mobley, 
2004). Due to the presence of the T3SS, the mechanism of infection is more 
complex for EPEC in comparison to the pathotypes addressed above. Translocation 
of numerous bacterial proteins known as effectors, through the T3SS, into the host 
cytoplasm of the gut enterocytes induce the characteristic intestinal A/E lesion and 
manipulate host cell signalling to dampen immune and pro-apoptotic signalling to 
promote survival and colonization (Croxen & Finlay, 2010). The localised 
effacement, inflammation, ion channel disruption and resulting permeabilisation all 
contributes to a watery diarrhoeal disease (Kaper, Nataro & Mobley, 2004). In 
conjunction with the T3SS EPEC also encodes the 385 KDa Lymphostatin; LifA, 
which inhibits the activation of lymphocytes (Kaper, Nataro & Mobley, 2004). 
Furthermore EPEC expresses the SPATE EspC which like Pet targets the host 
cytoskeleton and focal adhesion proteins to disrupt cell attachment (Clements et al., 
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2012; Vidal & Navarro-Garcia, 2008). EPEC E69 shares the common ancestor 
EPEC O55:H7 str. with the A/E family member EHEC (Kyle et al., 2012). Whilst both 
are LEE positive the EHEC pathotype differs from that of EPEC due to the absence 
of the EAF plasmid and acquisition of the lambda-like bacteriophage genes encoding 
Stx1/2 and the virulence plasmid pO157 (Kaper, Nataro & Mobley, 2004) 
vi. EHEC  
Due to Stx, EHEC O157::H7 is the leading cause of paediatric renal failure in 
developed countries, with the main environmental reservoir established in dairy 
cattle (Nataro & Kaper, 1998). EHEC is also a common cause of food borne 
outbreaks in developed countries with the prominent serotype being O157:H7 in the 
UK, USA and Japan or O26 and O111, elsewhere (Kaper, Nataro & Mobley, 2004). 
The high rate of infectivity in an outbreak is due to the relatively low inoculum level 
required to successfully colonize a human host which is fewer than 100 bacteria 
(Croxen & Finlay, 2010). Not all strains of EHEC are Stx positive and not all Stx 
positive strains are LEE positive. This has given rise to a ninth pathotype that is 
extremely heterogeneous and is grouped by the presence of Stx and therefore 
named Shiga toxin-producing E. coli (STEC). Interestingly most STEC that are LEE 
negative, one exception being O103:H21, do not cause disease in humans, 
underlining the importance of the T3SS in pathogenesis and adherence (Croxen & 
Finlay, 2010). Furthermore EHEC encodes a second T3SS designated the EHEC 
Type III secretion system 2 (ETT2). While the ETT2 is not fully function due to frame 
shift mutagenesis or absence of integral structural components of the T3SS its 
regulatory factors may impact on T3SS regulation and virulence (Zhou et al., 2014). 
Initial adherence of EHEC to enterocytes of the large colon is carried out by an array 
of adhesins common among other pathotypes and includes: Paa, Saa, Iha EhaA and 
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LPF (Clements et al., 2012). EHEC also encodes colonization factors unique among 
the inEPEC pathotypes including the LifA-like Toxin B (ToxB) and the E. coli factor 
for adherence 1 (Efa1), the outer-membrane protein (OmpA), and the 
autotransporter E. coli immunoglobulin binding protein G (EibG) (Clements et al., 
2012; Croxen & Finlay, 2010). EHEC also encodes multiple virulence factors on the 
pO157 plasmid. This includes EspP, StcE a proteinase/mucinase which cleaves the 
C1 esterase inhibitor of the complement pathway and is essential for colonization of 
the large colon (Croxen & Finlay, 2010; Communication; Spandiaou) and the repeats 
in toxin (RTX) family member EHEC toxin (Ehx) which is a pore forming haemolysin 
and pro-apoptotic toxin (Bielaszewska et al., 2014). 
C. rodentium shares 67% gene identity with both EHEC and EPEC. This includes the 
LEE pathogenicity island encoding the T3SS and a similar cohort of T3SS effectors 
(Collins et al., 2014). C. rodentium is a natural mouse pathogen; allowing the unique 
opportunity to study A/E pathogen virulence and pathogenesis within its natural host.  
1.1.2 Citrobacter rodentium 
C. rodentium is an intestinal pathogen that colonises the murine large colon leading 
to weight loss, colitis, soft stools and colonic hyperplasia also known as 
transmissible murine crypt hyperplasia (TMCH; Collins et al., 2014). Initial adherence 
of C. rodentium is not fully understood however colonization factors unique to C. 
rodentium and homologous to those of EPEC/EHEC have been identified. C. 
rodentium encodes the Citrobacter colonization factor (Cfc), a Type IV pilus which 
shares homology with EPEC BFP (Mundy et al., 2004), a LifA/Efa1 homolog (Mundy 
et al., 2005), the  fimbrial adhesin K99-like factor involved in Citrobacter colonization 
(Kfc), a homolog of the autotransporter AIDI-I adhesin named adhesin involved in 
diffuse Citrobacter adherence (AdcA) (Hart et al., 2008) and the adhesin intimin 
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(Collins et al., 2014). Cfc is essential for colonization and a strain lacking Cfc is 
avirulent (Mundy et al., 2003); alternatively, deletion of either Kfc or AdcA has no 
observed colonization effect in vivo (Hart et al., 2008). Intimate attachment of C. 
rodentium and colonisation of the host is conferred similarly to that of EPEC/EHEC 
through intimin and the T3SS dependent A/E lesion formation (Collins et al., 2014). 
Through the acquisition of the PAI LEE C. rodentium encodes a T3SS which shares 
homology and effectors with both EPEC and EHEC, including the intimin receptor Tir 
(Collins et al., 2014). Furthermore C. rodentium encodes two T6SSs designated 
CTS1 and CTS2 (Collins et al., 2014). Whether the C. rodentium T6SSs contribute to 
virulence and are expressed and/or functional in vivo remains unknown. Non-T3SS 
dependent virulence factors that are encoded by C. rodentium include the Class I 
SPATE and EspC homolog C. rodentium class-1 serine protease (CrC1sp;  
Vijayakumar et al., 2014) and the Class II SPATEs AdcA and the Pic homolog C. 
rodentium class-2 serine protease (Cr-C2sp; Ruiz-Perez & Nataro, 2014). CrC1sp, 
while predicted to belong to the Class I SPATEs and therefore predicted to cleave 
spectrin, surprisingly has an anti-inflammatory and immuno-modulatory role in vivo 
(Vijayakumar et al., 2014). A homologous T3SS, similar cohort of enterotoxins and 
similar infection strategy make C. rodentium an ideal pathogen to study A/E 
virulence in vivo.  This has given rise to the C. rodentium mouse model. 
i. The C. rodentium mouse model  
C. rodentium infects mice through the oral-faecal route and is therefore under 
laboratory conditions administered in liquid culture, by oral gavage (o.g.). The 
outcome of infection is widely dependent on the mouse strains used. For instance, 
C. rodentium infection of C3H/HeJ results in bacterial dissemination and high 
mortality by day 10 post infection; in contrast, C57BL/6 mice rarely, if at all, succumb 
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to infection (Mundy et al., 2005). This is most likely due to the difference and high 
diversity of the host microbiota which can influence the susceptibility and immune 
response to C. rodentium infection (Collins et al., 2014). In the early stages of 
infection of C57BL/6 mice C. rodentium colonizes the caecal patch: the major 
lymphoid structure of the caecum and by day 4 the distal colon (Collins et al., 2014). 
Colonization of the colon reaches its peak at roughly day 8 post infection. Following 
this, C. rodentium is rapidly cleared by the shedding of colonic epithelial 
cells/enterocytes and the host mounted CD4+ T-cell dependent humoral immune 
response (Collins et al., 2014). By day 14-21 post infection C. rodentium is 
completely cleared and no longer detectable in the stool samples. While the 
enterotoxins and the colonization factors described above play a significant role in 
inEPEC and C. rodentium pathogenesis the T3SS and subsequent A/E lesion 
formation is essential for EPEC, C. rodentium and EHEC virulence.  
1.2 Bacterial Secretion Systems 
Gram negative and positive pathogens use an array of specialised systems to deliver 
bacterial toxins and proteins known as effectors into the extracellular milieu and host 
cells, to aid in and promote colonization (Tseng, Tyler & Setubal, 2009). In order to 
carry out this process, the need to overcome the complexity of transport across the 
bacterial cell membranes/cell wall and host cell membrane is essential. Gram 
negative bacteria have 6 main classes of dedicated secretion systems, numbered 1-
6, that transport effectors across the inner and outer membrane (As reviewed By 
Tseng and Colleagues (Fig. 1.1; Tseng, Tyler & Setubal, 2009). While gram positive 
bacteria share some similar systems they also have a unique system known as the 
Type VII secretion system (T7SS). The Type II secretion system (T2SS) and Type V 
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secretion system (TVSS), unlike the other specialised secretion systems, rely on an 
initial general secretory pathway for delivery to the periplasmic space before 
secretion.  
1.2.1 The General Secretory Pathway 
There are two general secretory pathways named the universal secretory pathway 
(Sec) or Two-arginine (Tat) system (Tseng, Tyler & Setubal, 2009). The Sec system 
requires a hydrophobic N-terminal signal sequence that transports proteins in an 
unfolded state. The Sec pore is formed of three proteins SecY, E and G and the 
system is driven by the cytoplasmic ATPase SecA. SecB, the chaperone protein, 
recognises the N-terminal signal sequence and upon binding SecA initiates 
translocation across the inner membrane. The Tat system recognises proteins via a 
signal sequence motif consisting of the amino acid code SRR-X-FLK. Differing from 
the Sec system, proteins translocated by the Tat system are done so in a folded 
state across a protein gradient. Proteins are then further secreted by the Sec-
dependent T2SS and T5SS.  
 
 
 
 
Figure 1 1 Secretion systems of Gram negative bacteria. A simple schematic 
depicting the machinery of the known Gram negative secretion systems adapted 
from Tseng and colleagues (Tseng, Tyler & Setubal, 2009). HM, host membrane; 
OM, outer-membrane; IM, inner-membrane; MFP, membrane fusion protein. 
ATPases coloured yellow, secretion apparatus blue and translocons red. 
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1.2.2 The Type II and V secretion system 
The T2SS machinery is composed of 12-15 secretin subunits. These form the multi-
meric protein pore and also anchor it to the outer-membrane. A further 11-14 
uncharacterised membrane proteins are required for T2S. The ETEC virulence factor 
LT is delivered in a T2SS dependent manner. A homologous system in EHEC is 
required for the secretion of StcE a proteinase/mucinase which is essential for 
colonization of the large colon (Communication; Spandiaou). Typical EPEC also 
have a functional T2SS; secreted and surface associated lipoprotein from E. coli 
(SsIE) is involved in the progression of micro-colonies to mature biofilm formation 
(Baldi et al., 2012). 
The T5SS is divided into 3 major subclasses: a-c. T5SS proteins consist of an N-
terminal passenger domain carrying the N-terminal signal sequence for Sec 
transport and a conserved β-barrel C-terminal domain involved in translocation. In 
the T5aSS the C-terminal forms a pore while the N-terminal is cleaved off and 
translocated into the extracellular space as a hydrolytic enzyme or toxin, giving rise 
to the name auto-transporters. The T5cSS forms a single β-barrel by tri-meric 
formation of the secreted protein; alternatively, the T5bSS consists of pairs of 
proteins (also known as Two partner system; TPS) where one has the β-barrel and 
the other is secreted. The adhesion AIDA-I of DEAC is a T5aSS secreted protein 
(Tseng, Tyler & Setubal, 2009). Furthermore EPEC E69 delivers EspC a serine 
proteinase that targets Focal adhesion Kinase (FAK) and spectrin and is linked to in 
vitro cell cytotoxicity and detachment (Navarro-Garcia et al., 2014). EHEC EspP, a 
homolog to EspC, has been linked to the disruption of multiple host pathways 
including the complement cascade, haemostasis and biofilm formation (Weiss & 
Brockmeyer, 2012). Unlike the T5SS and T2SS the Type I, III, IV and VI systems are 
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fundamentally single step; transporting effectors directly across the inner and outer-
membrane. 
1.2.3 The Type I Secretion system  
The T1SS consists of three main domains: the outer-membrane proteins (OMPs), 
membrane fusion proteins (MFPs) and the ATP-binding cassette (ABC) transporters. 
The OMP TolC forms the outer-membrane pore and connects to the trans-
periplasmic MFPs; the MFPs in turn are structural proteins which span the 
periplasmic region creating a tunnel between the OMPs and the ABC-transporters. 
The ABC transporter HlyB drives translocation in an ATPase dependent manner and 
secretion is dependent on the recognition of a specific leader signal sequence. HlyA, 
a pore forming toxin (Donnenberg, 2013), is a well characterised T1SS secretion 
system effector that is encoded by uropathogenic E. coli (Tseng, Tyler & Setubal, 
2009). C. rodentium encodes multiple putative T1SSs shared by other enteric 
pathogens including Salmonella entrica Thyphi (Petty et al., 2010). The T1SS and its 
contribution to virulence in A/E pathogens is poorly characterised.  
1.2.4 The Type VI secretion system 
The type VI secretion system is one of the more recently discovered specialised 
secretion systems of Gram negative bacteria. While the system remains poorly 
characterised it was identified due to its homology to the T4SS of Legionella 
pneumophila and consists of an injectisome based on the T4 bacteriophage-like tail 
(Petty et al., 2010). The injectisome of the T6SS is anchored to the outer-membrane 
by the membrane complex composed of the inner membrane proteins TssL, TssM 
and TagL and the outer-membrane lipoprotein TssJ. T6S is powered by the 
cytoplasmic chaperone ATPase ClpV (Felisberto-Rodrigues et al., 2011).  
Remarkably this system is not only dedicated to the delivery of effector proteins to 
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eukaryotic cells to promote full virulence and pathogenesis, but unlike other systems, 
it can also deliver effectors to prokaryotic cells in order to out-compete neighbouring 
bacteria (Felisberto-Rodrigues et al., 2011; Tseng, Tyler & Setubal, 2009). While 
EPEC does not encode a T6SS it is present in EAEC (Felisberto-Rodrigues et al., 
2011), EHEC and C. rodentium (Gueguen & Cascales, 2013; Petty et al., 2010). C. 
rodentium encodes two T6SSs on cluster 1 (CTS1) and cluster 2 (CTS2). CTS2 
contains a confirmed frameshift in the ATPase TssM (also known as intracellular 
multiplication factor F) which is required to form the TssM and TssL complex and 
energize secretion of T6SS (Petty et al., 2010). CTS1, which shares high homology 
to the T6SS of Enterobacter cancerogenus and also shares similarity to the SPI-6 of 
Salmonella enterica, encodes a fully functional T6SS in a chaperone-usher fibrial 
biogenesis cluster (Gueguen & Cascales, 2013; Petty et al., 2010). C. rodentium 
employs the T6SS as an anti-bacterial tool to deliver effectors to out-compete 
neighbouring bacteria in vitro (Gueguen & Cascales, 2013). Further studies are 
required however, to identify the effectors responsible and fully understand the role 
of this system in infection and its impact on virulence and colonization of the host.  
1.2.5 The Type IV secretion system 
Although the T4SS shares a similar inner membrane complex to the T2SS it does 
not rely on any general secretory pathway and can transport proteins in one step 
(Tseng, Tyler & Setubal, 2009). The T4SS is unique due to the fact that it can 
translocate and uptake nucleic acids as well as translocate proteins (Tseng, Tyler & 
Setubal, 2009; Christie, Whitaker & González-Rivera, 2014). The T4SS is subdivided 
into the conjugation system, which is required for the inter-bacteria transfer of DNA, 
uptake of DNA and natural competence and the effector translocator system which is 
dedicated to the translocation of bacterial effectors to manipulate host cell physiology 
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(Christie, Whitaker & González-Rivera, 2014). Natural competence and uptake of 
DNA will not be covered here and are reviewed elsewhere (Johnsborg, Eldholm & 
Havarstein, 2007). The effector translocation system of the T4SS consists of 4 major 
components: the type 4 coupling protein (T4CP), the inner-membrane complex 
(IMC), the outer-membrane complex (OMC) and the pilus. The T4CP is the ATPase 
and effector receptor that couples the substrate to the secretory machinery. Subsets 
of effectors contain C-terminal signal sequences for the T4CP receptor while others 
can be secreted by the Sec system. The IMC drives translocation across the inner-
membrane and the OMC allows passage through the periplasmic space and 
translocation through the outer-membrane (Christie, Whitaker & González-Rivera, 
2014). The pilus is essential for cell to cell contact and comprises the needle-like 
structure to which the translocon/pore forming protein is attached (Gauthier, Thomas 
& Finlay, 2003). A/E pathogens do not encode a T4SS; however they do encode a 
structurally similar secretion system known as the T3SS.  
1.2.6 The Type III Secretion System 
The T3SS, a molecular syringe, which closely resembles the bacterial flagellin 
apparatus, enables injection of effectors directly across the bacterial membranes into 
the host cell cytoplasm. Once translocated the effectors mimic host cell proteins to 
manipulate the host physiology, to aid in bacterial colonization and survival. As many 
pathogens encode and rely on a T3SS or multiple T3SS in order to successfully 
colonize the host, the T3SS is one of the best characterised and studied secretion 
systems of pathogenic bacteria. This is true for many enteric pathogens including 
Salmonella spp., EPEC/EHEC, C. rodentium, Yersinia spp. and Shigella spp. where 
a functional T3SS is essential for full virulence. A/E pathogens share a highly 
homologous T3SS apparatus and effector arsenal which is encoded by the LEE.  
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i. The Locus of Enterocyte Effacement Pathogenicity Island 
The 35 Kb chromosomal pathogenicity island of EPEC E69 and EHEC str. EDL933 
encodes genes for the T3SS apparatus (E. coli secretion gene; Esc), chaperones 
(Chaperone for E. coli secreted protein; Ces), regulators (Ler), the adhesion Intimin 
and its translocated receptor Tir as well as 5 other effectors (E. coli secreted protein; 
Esp) EspF, EspZ, MAP, EspH and EspG (Elliott et al., 1998; McDaniel et al., 1995).  
The genes are encoded on the major operons termed LEE1-5 (Fig. 1.2).  
 
ii. Biogenesis of the EPEC and the EHEC T3SS  
The archetypal T3SS of EHEC/EPEC is composed of a multi-ring structure (basal 
apparatus and outer-membrane ring which in is bridged by EscJ) and a needle-like 
structure onto which the translocon is assembled (As depicted in Fig. 1.3) 
 
Figure 1 2 The locus of enterocyte effacement. Gene organization, and assigned 
function, along the locus of enterocyte effacement pathogenicity Island of the 
attaching and effacing pathogen EHEC. 
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The basal apparatus is composed of EscD and EscQ-V in the inner membrane while 
the outer-membrane ring is composed of EscC which is secreted across the inner-
membrane by the Sec-system (Tree et al., 2009). The T3SS ATPase EscN is 
anchored to the inner membrane basal apparatus and supplies the energy for T3S 
export and protein translocation. EscF (EprI in EHEC) extends from EscI (the inner 
rod) and the basal apparatus across the outer-membrane to form the T3SS needle 
on to which EspA translocon extends further to the host cell membrane. EspA is 
capped by the pore forming complex which is composed of EspB/D to facilitate 
effector translocation (Tree et al., 2009). In order to conserve energy the T3SS is 
Figure 1 3 The T3SS translocon of EPEC. An illustrated structure of the EPEC 
T3SS. EscQ-V and EscD form a multi-ring structure known as the basal apparatus 
and EscC forms the outer-membrane ring structure, whilst EscJ acts a bridge 
between the membrane associated rings. Secretion is driven in an ATP-dependent 
manner requiring the ATPase EscN. EscI (EprI in EHEC) froms the inner needle on 
to which EscF (EprJ in EHEC) extends a needle-like structure onto which the 
translocon (EscA) is assembled. EscA extends out towards the host cell, capped by 
the EspB/D pore, where the effectors are secreted. IM, inner-membrane; OM, outer-
membrane; PG, peptidoglycan layer; EM, eukaryotic membrane. Adapted from 
Pallen and colleagues (Pallen et al., 2005). 
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tightly regulated at the level of expression and controlled by specific environmental 
signals and genetic regulators for a coordinated attack (Tree et al., 2009) 
iii. Regulation of the T3SS 
While the regulation of the LEE varies between EHEC and EPEC the fundamental 
regulatory factors are the same. Both pathotypes encode the major LEE-encoded 
regulator (Ler) which responds to certain environmental and stress signals including 
bicarbonate, hormones (norepinephrine and epinephrine), pH, DNA damage and 
temperature, to up-regulate expression of the LEE (Tree et al., 2009). Ler shares 
high homology to a known global regulator (H-NS) which binds to A-T rich regions, 
creating loops in the DNA structure, to supress expression. Interestingly Ler directly 
counters the activity of H-NS, releasing it from the strand to promote expression of 
LEE2-5 (Tree et al., 2009).  The ability of the bacteria to be able to communicate to 
neighbouring bacteria within its own and surrounding population; meanwhile also 
sensing the host, plays a significant role in its decision making at the level of 
expression. This is known as quorum sensing.  
Many quorum sensing systems that directly regulate the T3SS have been in 
characterised in EPEC and EHEC, respectively (Tree et al., 2009). Both EPEC and 
EHEC through the quorum sensor QseA, detect host levels of Epinephrine which 
triggers the expression of Ler. EPEC also encodes the LuxS quorum sensor, which 
through autoinducer-3 (AI-3) and Epinephrine, also activates the expression of Ler 
(Sperandio et al., 2003). Futhermore, EHEC through the two component system 
QseEF and QseG up-regulates the expression of the T3SS effector EspFu and 
controls Tir translocation, respectively (Tree et al., 2009). A host of further regulators 
control T3SS expression and secretion including the Plasmid encoded regulator 
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(Per) and the Integration Host Factor (IHF) (Sircili et al., 2004; Yona-Nadler et al., 
2003) 
PerA-C is encoded on the EAF plasmid of atypical EPEC and directly up-regulates 
the expression of the adhesion and micro-colony formation factor BFP, as well as 
Ler, in response to pH (Sircili et al., 2004; Shin et al., 2001). EHEC does not carry 
the EAF plasmid and alternatively encodes seven homologs of Per on OI’s. EHEC 
Pers: PchA-E and PchX-Y activate the expression of T3SS effectors found on 
OIs/outside the LEE (Tree et al., 2009). As mentioned previously, the T3SS and 
flagellum share the same apparatus; therefore, it is hypothesised that expression 
and biogenesis of flagella could sterically inhibit the T3SS and secretion (Tree et al., 
2009). It was observed that under laboratory conditions used to induce the 
expression of the T3SS, that EPEC becomes non-motile/non-flagellinated (Yona-
Nadler et al., 2003). This was due to IHF which upon activation down regulates the 
expression of FlhDC which are positive regulators of the flagellar regulon (Yona-
Nadler et al., 2003). Co-ordinately, Ler activates GrlA which triggers a switch from 
flagella to T3SS, reinforcing the level of sophistication of regulation of the T3SS 
(Tree et al., 2009). 
A further level of regulation that exists but is poorly understood is the switch from 
biogenesis to effector secretion. This requires the presence of the pore forming 
complex EspB/D. It is thought to be an extra step to conserve energy and to 
effectively deliver effectors to the host cytoplasm and not into the extracellular milieu. 
Currently, it is hypothesised that this trigger may in fact be a change in ion 
concentration due to the exposure to the host cytoplasm upon connection (Tree et 
al., 2009). Once secreted the effectors modulate the host cell signalling and 
physiology to aid in colonization. The host cell targets and binding partners, as well 
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as the function of these effectors, have been the centre of many studies over the 
past decade.   
1.3 Effector proteins and Manipulation of host cell signalling 
The best characterized LEE effector, conserved among A/E pathogens, is Tir. Tir is 
required for intimate attachment and for pedestal formation, a hallmark of successful 
T3SS translocation in vitro (Frankel & Phillips, 2008) (Fig. 1.4A). Translocated Tir 
localizes to the host cell surface where it can interact with the bacterial outer-
membrane protein Intimin (Kenny et al., 1997) (Fig. 1.4A). Tir is further 
phosphorylated by host tyrosine kinases resulting in the recruitment of Nck 
((Gruenheid et al., 2001), neural Wiskott–Aldrich syndrome protein (N- WASP) and 
actin-related protein 2/3 (ARP-2/3) which stimulates actin nucleation and 
polymerisation (Kalman et al., 1999). This is the driving force behind membrane 
protrusion and pedestal formation (Fig. 1.4A-B) (Kenny et al., 1997). EHEC pedestal 
formation is similar to that of EPEC with a slight difference due to the fact that Tir is 
not phosphorylated. Instead Tir recruits insulin receptor tyrosine kinase substrate 
(IRKTS) which forms a complex with the translocated effector Tir cytoskeleton-
coupling protein (TccP). TccP recruits N-WASP resulting in actin polymerisation as 
described for EPEC pedestal formation (Garmendia et al., 2004). In addition to the 
conserved effectors of the LEE EPEC, EHEC and C. rodentium encode effectors that 
have been identified in other pathogenicity islands with many having been 
characterised (Wong et al., 2011). To date, 21 conserved effectors have been found 
in all A/E pathogens (Iguchi et al., 2009). However, the total number of the non-LEE-
encoded effectors (nle) can vary significantly between EPEC/EHEC strains, altering 
the mechanism of infection. 
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Translocation of A/E pathogen T3SS effectors, have been reported to be responsible 
for the modulation of Rho-GTPases (Wong et al., 2012), actin re-organisation and 
pedestal formation (as shown in Fig. 1.4  and reviewed by Frankel et al., 2008), 
disruption of mitochondrial integrity (Nougayrede & Donnenberg, 2004), regulation of 
cell survival and apoptosis (Hemrajani et al., 2010; Dean et al., 2010; Baruch et al., 
2011; Samba-Louaka et al., 2009), inhibition of phagocytosis (Marches et al., 2008) 
and modulation of the host inflammatory and immune response (Gao et al., 2013; 
Raymond et al., 2013; Baruch et al., 2011; Pearson et al., 2011; Raymond et al., 
2011; Nadler et al., 2010; Newton et al., 2010; Vossenkämper et al., 2010; Gao et 
Figure 1 4 EPEC infection is characterised by pedestal and A/E lesion 
formation in vivo. (A) Pedestal formation is initiated by EPEC through the 
translocation of Translocated intimin receptor (Tir). Tir is displayed on the eukaryotic 
cell surface were it binds the bacterial outer-membrane protein Intimin. Tir becomes 
phosphorylated by the host Tyrosine kinases and in a Nck dependent manner 
recruits neural Wiskott–Aldrich syndrome protein (N-WASP) and actin-related protein 
2/3 (Arp-2/3) leading to actin nucleation and polymerisation; forming the pedestal. 
EHEC pedestal differs as Tir is not phosphorylated and in an Nck-independent
manner it recruits insulin receptor tyrosine kinase substrate (IRTKS) and through Tir
cytoskeleton-coupling protein (TccP) then merges with the EPEC pathway by 
recruiting N-WASP. (B) An electron micrograph of human intestinal cultured mucosa 
infected with EPEC (Chen et al., 2005). Membrane protrusion and a cup-like
structure can be identified beneath the surface of the bacteria which is a hallmark of 
actin and cytoskeleton rearrangement and pedestal formation. Microvilli effacement
and destruction is also noted which is indicative of A/E lesion formation.   
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al., 2009). Little is still understood about the biological function of numerous effectors 
and how they manipulate the host immune response during infection.  
1.4 The Host innate immune response 
The Inflammatory response is essential in innate immune signalling and the early 
host response to infection (Mogensen, 2009). The innate immune system is the first 
line of defence against invading microbes and through pattern recognition receptors 
(PRRs) detects distinct conserved pathogen-associated molecular patterns (PAMPs) 
(Mogensen, 2009). Recognition of PAMPs through PRRs triggers an intracellular 
signalling cascade leading to the expression and secretion of pro-inflammatory 
molecules (Mogensen, 2009). The secretion of pro-inflammatory molecules in turn 
leads to the recruitment and activation of cells of the innate immune system 
including: dendritic cells, neutrophils and phagocytic macrophages. This induces 
further inflammatory signalling and the release of pro-inflammatory molecules; thus 
allowing priming and activation of the adaptive immune system and the ability to fight 
and clear the infection (Mogensen, 2009). Detection of PAMPs and danger 
associated molecular patterns (DAMPs) is regulated and controlled through both 
intracellular PRRs and extracellular PRRs.  
1.4.1 Pattern recognition receptors and host-pathogen detection 
The host recognises stimuli through specific PRRs of which the best characterised 
are the Toll-like receptors. Each Toll-like receptor responds to a different set of 
specific PAMPs/DAMPs, with Toll-like receptor 3 (TLR-3), Toll-like receptor 4 (TLR-
4) and Toll-like receptor 5 (TLR-5) which detect dsDNA, Lipo-polysaccharide (LPS) 
and flagellin, respectively; being the most relevant to Gram negative bacterial 
infection. The TLRs are able to sample the extracellular milieu and endosomal 
compartments for PAMPS, triggering an intracellular signalling cascade leading to 
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the transcriptional activation of inflammatory cytokines; activating the immune 
response.   
1.4.2 The Toll-like receptors 
TLR-4, an extracellular receptor found on the cell surface of myeloid cells as well as 
non- hematopoietic cells, is stimulated by LPS. Binding of LPS through the co-
receptors CD14, LPS-binding protein (LBP) and lymphocyte antigen 96 (Ly-96/MD-2) 
triggers oligomerisation of TLR-4 resulting in recruitment of the intracellular adaptor 
protein: Myeloid differentiation primary response protein 88 (MyD88). MyD88 in turn 
activates IL-1 receptor-associated kinase-4 (IRAK-4) which recruits IRAK-1 (Fig. 1.5) 
(Li & Verma, 2002). TNF receptor-associated factor 6 (TRAF6), forms a complex 
with IRAK-1 and procaspase-4 (Nickles et al., 2012; Lakshmanan & Porter, 2007; Li 
& Verma, 2002) and upon recruitment of the ubiquitin-conjugating enzyme 13 
(Ubc13) and ubiquitin-conjugating enzyme E2 variant 1 isoform A (Uev1A) is 
modified by K63-linked polyubiquitylation (Lim & Staudt, 2013). Ubiquitlyated TRAF6 
is recognised by the ubiquitin binding domain of TGF-β activated and MAP3K7 
binding protein 2/3 (TAB2/3) which is found in complex with transforming growth 
factor-β-activated kinase 1 (TAK1; Fig. 1.5). At this stage the complex moves to the 
cytoplasm where the IĸB Kinase (IĸK) subunit IκKγ (NEMO) is recruited through a 
ubiquitin binding domain and phosphorylated by TAK1. In parallel ubiquitlyated 
TRAF6 recruits the LUBAC complex which binds and activates NEMO by methionine 
linked linear ubiquitin (Emmerich et al., 2013). Downstream, IĸK phosphorylates the 
Nuclear factor-Kappa B (NF-κB) inhibitor alpha (IĸBα), signalling it for proteasomal 
degradation. Importantly, under resting conditions, IĸBα is in a complex with the NF-
ĸB subunits p65 and p50, restricting both to the cytoplasm (Li & Verma, 2002)). 
Upon IĸBα degradation p65 translocates to the nucleus resulting in the expression of 
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target genes, promoting cell survival and inflammation (Li & Yang, 2011). 
Alternatively active TAK1 activates the transcription factors Cyclic-AMP responsive 
element-binding protein 1 (CREB1) and Activator Protein 1 (AP-1) via Mitogen-
activated protein kinase (MAPK) kinases 3/6 (MKK3/6) and MAPK kinase 4/7 
(MKK4/7), respectively (Fig. 1.5). MKK3/6, via a set of serine threonine kinases 
known as p38 MAPKs, promotes the nuclear translocation of CREB1; while MKK4/7 
signal via a different branch through phosphorylation of c-Jun N-terminal kinases 
(JNKs; Lim & Staudt, 2013). This promotes nuclear translocation of the transcription 
factor family AP-1 (Lim & Staudt, 2013; Dunne & O'Neill, 2003). The target genes of 
CREB1 are involved in cell differentiation and survival (Impey et al., 2004); whereas, 
AP-1 up-regulates the expression genes involved in cell survival and proliferation as 
well as inflammation (Li & Yang, 2011). This results in cross talk with the NF-ĸB 
pathway and co-combinational propagation of a pro-inflammatory signalling cascade 
to transcriptionally re-programme and activate cells of the immune system via 
expression of cytokines (Interleukin-1β; IL-1β), chemokines (Interleukin-8; IL-8), 
adhesion molecules and metalloproteases (Li & Yang, 2011). At the level of TAK1 
activation the intracellular signalling pathway converges with that of the Tumour 
necrosis factor receptor (TNFR) and the Interleukin-1 receptor (IL-1R) pathways (Fig. 
1.5; Dunne & O'Neill, 2003). 
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Figure 1 5 The TLR-4 and TNFR1 intracellular signalling cascades. LPS 
stimulation of TLR-4 drives an intracellular signalling cascade leading to the nuclear 
translocation of the transcription factors AP-1, CREB1 and NF-κB. Similar TNFα 
stimulation of TNFR1 activates an intracellular signalling cascade that converges with 
the TLR-4 pathway at the stage of TAK1 activation. Nuclear translocation of AP-1, 
CREB1 and NF-κB leads to cell proliferation, cell survival and inflammation. The 
more information please see text.  
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TNFα is commonly used as tool to activate and study NF-κB nuclear translocation in 
tissue culture assays. Stimulation of the canonical TNFR signalling cascade leads to 
TNFR1 aggregation and, through homotypic interaction of their death domains (DD), 
the recruitment of the cytoplasmic adaptor Tumour necrosis factor receptor type 1-
associated death domain protein (TRADD) and the serine-threonine kinase Receptor 
interacting protein 1 (RIP1; Chaudhary et al., 2000). RIP1 signalling is dependent on 
TRAF2/5 where it converges with the TLR-4 pathway to activate TAK1 (Dunne & 
O'Neill, 2003; Chaudhary et al., 2000). Caspase-4 has been reported to be essential 
for this step (Nickles et al., 2012). Alternatively TNFα stimulates a non-canonical 
caspase—8 dependent cascade through the recruitment of the Fas-associated 
death-domain protein (FADD) by TRADD. Caspase-8 through an N-terminal DD 
binds FADD and in a TRAF2/RIP1 dependent manner activates the serine-threonine 
kinase NIK. NIK directly activates NEMO, again converging with the TLR-4 pathway 
to activate NF-κB (Chaudhary et al., 2000). In conjunction with the extracellular 
PRRs both myeloid and non-myeloid cells utilise a cohort of intracellular PRRs to 
detect distinct antigens. 
1.5  Intracellular detection via PRRs 
The intracellular PRRs are divided into two major classes consisting of the RNA 
sensing RIG-I-like helicases (RHLs)/DNA sensors and the Nucleotide-binding 
oligomerisation domain-containing (NOD) like proteins (NLRs), as reviewed by 
Mogensen (Mogensen, 2009). 
1.5.1 RHLs and DNA sensors  
Briefly, the two well characterised RHLs include Melanoma associated protein 5 
(MDA5) and RIG-I. As intracellular receptors they recognize the 5'-triphosphate 
moiety and dsRNA structures of invading pathogens, which is distinctly non-self. 
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With this in mind they are usually associated with viral infection. Their activation 
leads to the initiation of transcription with both receptor signalling pathways 
converging to mediate transcription of pro-inflammatory cytokines via NF-ĸB and AP-
1 as well as Type I Interferons (IFNs) via Interferon regulatory factor (IRF) 3 and 7. 
The identity of the cytoplasmic dsDNA sensors is less well characterised, however 
the best characterised response is via the TBK1 and IRF3 signal cascade, triggering 
transcriptional induction of type I IFN genes.  Detection of dsDNA, which should 
usually be compartmentalised to the nucleus if “self DNA”, activates the sensors: 
absent in melanoma 2/ interferon inducible protein 2 (AIM2) and 'DNA-dependent 
activator of IRFs (DAI/ZBP1). Activation of DAI converges with the RHLs signalling 
cascade stimulating IRF3, IRF7 and NF-ĸB (Yoneyama & Fujita, 2007), whereas 
AIM2 is activated to form an inflammasome complex driving a signalling cascade 
that is similar to that of the NLRs, which is described below. 
1.5.2 The NODs and NOD-like receptors 
There are at least 22 genes encoding NLRs identifiable by their central nucleotide-
binding and oligomerisation (NACHT) domain. Whilst the NACHT domain is common 
among all NLRs the existence of 3 distinct NACHT domains has separated the NLRs 
into 3 groups: 
1. NODs (NOD1-2, NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX4, CIITA (class 2 
transactivator) 
2. The NOD-like receptor family, pyrin domain containing proteins (NLRPs) 1-14 
(also known as NACHT, LRR and PYD domains-containing proteins; NALPs)  
3. IPAFs/NLRC4 (Ice protease-activating factor; NLR family CARD domain-
containing protein 4) and neuronal apoptosis inhibitory protein (NAIPs)  
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These NLRs are further characterised depending on the presence of further 
functional domains including: leucine-rich repeat domain (LRR) required for ligand 
sensing and the caspase activation and recruitment domain (CARD) and/or the pyrin 
domain (PYD). Both CARD and PYD are essential for homotypic protein-protein 
interaction for downstream signalling (Mogensen, 2009).  
i. NODs: Pathogen Detection and Signalling 
The best characterised NODs are NOD1 and NOD2. NOD1 and NOD2 oligomerise 
upon stimulation by the bacterial cell wall components meso-diaminopimelic acid 
(DAP) and muramyl-dipeptide (MDP), respectively (Schroder & Tschopp, 2010). 
Through homotypic CARD-CARD interaction NOD1/2 recruits Receptor-interacting 
serine/threonine-protein kinase 2 (RIP2) which through auto-phosphorylation recruits 
a signalling complex consisting of TRAF 4, 5 and 6 as well as Ubc13/Uev1A and 
Inhibitor of apoptosis protein 1/2 homolog C (cIAP1/2; Schroder & Tschopp, 2010; 
Xie, 2013). cIAP1/2 and Ubc13/Uev1A catalyse the K63-Linked poly-ubiquitination of 
RIP2 which further recruits IκKγ and the TAK1/TAB2/3 complex (Xie, 2013). NF-ĸB 
and MAPK activation follow as described previously. NOD1 and NOD2 can also 
stimulate transcription of the type 1 IFNs although through distinct mechanisms.  
NOD1 recruits TRAF3 and signals through IFNβ dependent IRF7 alternatively NOD2 
acts as a receptor for ssRNA to signal through IRF3 (Xie, 2013). NOD5 and 6 are 
less well characterised but may be involved in promoting the production of reactive 
oxygen species (ROS); whilst the roles of NOD3/4 are still unknown (Schroder & 
Tschopp, 2010). The NOD CIITA was the first NLR to be classified and unlike the 
others it has a transcription co-factor activity that regulates the expression of the 
Major histocompatibility complex II (MHCII) and MHCI and therefore regulates 
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antigen presentation (Schroder & Tschopp, 2010). NLRs can be functionally 
classified into two distinct groups: those that regulate the formation of a mutli-meric 
protein complex known as the inflammasome (AIM2, NLRP1b, NLRP3, NLRP7 and 
NLRC4; Rathinam et al., 2012) and those that down-regulate immune signalling 
(NLRP10, NLRP12, NLRC3, NLRP6-7 and NLRXC1; Allen, 2014; Wlodarska et al., 
2014; Damm, Lautz & Kufer, 2013; Radian et al., 2013; Anand et al., 2012) 
1.6 NLRs and the Inflammasome  
The inflammasome is a relatively newly characterised intracellular multi-protein PRR-
complex which forms in response to multiple stimuli and insults including uric acid 
crystals, ultraviolet radiation (UV), ATP, DNA/RNA, flagellin, pore forming toxins, 
lipoprotein and LPS/bacterial infection to activate the cysteine protease caspase-1 
(Vladimer et al., 2013).  Active caspase-1 further processes its substrates pro-
interleukin-18 (pro-IL-18) and pro-interleukin-1β (pro-IL-1β) inducing their secretion 
independent of the classical Golgi/ER pathway (Mariathasan & Monack, 2007; Scott 
& Saleh, 2007). Furthermore, caspase-1 induces a form of programmed 
inflammatory cell death known as pyroptosis; releasing DAMPs as a host warning 
system in response to infection/ sterile stressors (Miao et al., 2010a). The NLR 
responsible for inflammasome formation varies depending on the cell type and the 
stimulus.  
1.6.1 The NLRC4 inflammasome  
NLRC4 is a component of the intracellular receptor that is dedicated to detecting 
flagellin and the rod/needle components of the T3SS of enteric pathogens; as well as 
the T4SS (Yang et al., 2013; Zhao et al., 2011; Miao et al., 2010b).  Detection leads 
to the recruitment and activation of caspase-1 in an Asc independent-manner, 
leading to IL-1β/IL-18 secretion and pyroptosis of macrophages (Miao et al., 2008). 
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i. NLRC4 detection of EPEC E69 and C. rodentium ligands 
Unlike the other NLRs NLRC4 does not detect the PAMP/DAMP directly and instead 
works in concert to associate with the Neuronal apoptosis inhibitory protein (NAIP) 
(Lage et al., 2014). Humans only encode one NAIP known as hNAIP; whereas there 
have been at least 4 NAIPs in mice that have been identified and characterised for 
their bacterial ligands. This includes NAIP1, NAIP2 and NAIP5/6 which bind the 
T3SS needle, T3SS rod and flagellin respectively (Lage et al., 2014). The presence 
of only 1 NAIP in humans may restrict the spectrum of bacterial ligands that are 
detected by NLRC4 compared to mice. 
Due to the availability of knockout cell lines, activation of NLRC4 has been well 
studied and characterised in the context of Salmonella, EPEC and C. rodentium 
infection of immortalised mouse macrophages (iMM). The Salmonella infection of 
mouse macrophages elicits an NLRC4 response via NAIP1 detection of the 
salmonella needle (PrgI) and NAIP2 2 detection of the inner rod (PrgJ) (Yang et al., 
2013). The EPEC/ C. rodentium homolog to PrgI; EscF, is not recognised by NAIP1, 
probably due to their low level of homology (Yang et al., 2013). Alternatively infection 
of iMMs with an EPEC ΔescI (the functional homolog of PrgJ) strain abolishes 
caspase-1 cleavage in response to infection (Zhao et al., 2011; Miao et al., 2010b).  
Furthermore caspase-1 cleavage and NLRC4 activation are dependent on NAIP2 
(Zhao et al., 2011). Interestingly the flagellin negative strain (ΔfliC) of EPEC does not 
impact on NLRC4 and caspase-1 activation; therefore it can be concluded that 
EPEC flagellin does not contribute to inflammasome activation in vitro (Zhao et al., 
2011).  
Similar to iMM infection, Salmonella infection of human macrophages activates the 
NLRC4-hNAIP-dependent inflammasome. hNAIP has been recently shown to detect 
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PrgI; therefore, acting as the functional homolog to murine NAIP1 (Yang et al., 
2013). It has been confirmed in a number of cell lines (THP.1, U937, A549) that 
EscF is not detected by hNAIP and again does not activate NLRC4 (Yang et al., 
2013; Zhao et al., 2011). In fact 2 amino acids shown to be essential for the 
detection of PrgI by hNAIP are not present in EPEC E69 or C. rodentium EscF (Yang 
et al., 2013). Although EPEC EscI is required for NAIP2-NLRC4 activation it has not 
been tested in human macrophages. Due to the fact that humans only encode one 
NAIP and it has been shown to function as NAIP1 it is unlikely EPEC EscI is 
detected by hNAIP; however, further studies are required to validate this hypothesis. 
It is also important to note that while EscI is required for NLRC4 activation during 
infection of iMMs it has not been shown to be directly detected itself by NAIP2; 
although this is the case for PrgJ. The deletion of EscI prevents the biogenesis of the 
T3SS and subsequently prevents the secretion of T3SS components EscF, EspA, 
EspB, EspD and the T3SS effector proteins. The bacterial ligand detected by NAIP2 
during EPEC E69 infection could be a number of proteins and remains to be 
confirmed. While a role for NLRC4 in EPEC E69 infection remains controversial the 
NLR NLRP3 is essential for inflammasome activation in iMMs in response to EHEC 
and C. rodentium infection.     
1.6.2 NLRP3  
NLRP3 differs to other NLRs due to the wide cohort of stimuli to which it responds to 
including: alum, ATP, MDP, LPS, nucleic acids, nigericin (bacterial toxin), uric acid 
crystals, amyloid-β and UV irradiation to a name a few. This has led to the 
hypothesis that NLRP3 itself is activated by a signal common to the above 
mentioned stimuli rather than having the capability to recognize such a versatile 
range of insults directly (Abderrazak et al., 2015). Interestingly inhibition of ROS or 
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K+ efflux abrogates the activation of the NLRP3 dependent inflammasome to many 
stimuli (Abderrazak et al., 2015). NLRP3 is composed of a tripartite structure 
consisting of an N-terminal PYD followed by a NACHT/NBD and finally a LRR 
domain, which all play an essential role in its activity and inflammasome assembly as 
reviewed by Abderrazak (Abderrazak et al., 2015).  
i. The canonical inflammasome 
NLRP3 is held in an inactive form by the LRR domain which holds NLRP3 in an 
auto-repressive state. Upon stimulation and activation the auto-repressive state is 
relaxed exposing the NBD and PYD domain of NLRP3. The exposed PYD recruits 
apoptosis associated speck-like protein containing a CARD (Asc) which via its CARD 
domain directly recruits pro-caspase-1 to assemble the inflammasome. 
Oligomerisation of Asc by self-association further increases procaspase-1 
recruitment and size of the multi-meric complex; this is referred to as a “speck” due 
to the fact that usually a single strong foci of inflammasome assembly is observed in 
a single cell upon activation. Upon recruitment procaspase-1 undergoes self-
proteolytic cleavage and oligomerisation in to the active state; which in turn 
processes pro-IL-1β/IL-18 and stimulates pyroptosis. This is referred to as the 
canonical inflammasome; alternatively, a non-canonical NLRP3 dependent 
inflammasome is activated by bacterial infection and the detection of intracellular 
LPS by the PRR caspase-4 in humans and caspase-11 in mice (Shi et al., 2014; 
Kayagaki et al., 2011). This in turn activates the assembly of the inflammasome and 
caspase-1 activation in human and mouse macrophages (Shi et al., 2014; Sollberger 
et al., 2012; Kayagaki et al., 2011).  
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1.6.3 Caspase-4 
Caspase-4 is a cysteine protease and member of the inflammatory caspases and 
interleukin-1 beta converting enzyme subfamily (Martinon & Tschopp, 2007). It is 
ubiquitously expressed in various tissues with exception of the brain and shares 51% 
homology amino acid identity with caspase-1, 75% homology with caspase-5 and 
48% homology with caspase-12. 
i. Structural activation of caspase-4 
Inflammatory caspases are characterised by their long pro-domain containing the 
CARD (Sollberger et al., 2012). Caspase-4 contains one long pro-domain (p22) and 
two small functionally active domains p20 and p10. Cleavage produces a p30 
product which is further processed into the single subunits upon cleavage of the 
inter-linker domain (Fig. 1.6; Karki, Dahal & Park, 2007). Caspases can be 
characterised by the mechanism in which they become active. Initiator caspases 
which include caspases 2, 8, 9 and 10, which contain a long pro-domain, are 
induced by adaptor mediated oligomerisation in large protein complexes eg. the 
death inducing signalling complex (DISC) or apoptosome  (Karki, Dahal & Park, 
2007). Activation of a second class of caspases known as the effector caspases is 
limited to the proteolysis of the linker region which is carried out by the initiator 
caspases. Little is known about the activation of the inflammatory caspases 1, 4 and 
5. With their long pro-domain they resemble initiator caspases; however, caspase-4 
is activated by dimerization and inter-linker domain cleavage (Karki, Dahal & Park, 
2007). Thus, inflammatory caspases show a novel mechanism of activation including 
both dimerization and proteolytic cleavage which differs from the well-established 
mechanism of activation for initiator and effector caspases. 
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ii. Caspase-4: Homologs and orthologs 
The murine ortholog to human caspase-4 is disputed among the scientific 
community. Mice have only 3 inflammatory caspases including caspase-1, -11 (also 
known as -4) and -12 (Sollberger et al., 2012). Murine caspase-11 and -12 share 
60% and 49% homology with human caspase-4 respectively and both caspase-11 
and -12 have been suggested as the functional ortholog to human caspase-4 due to 
their role in inflammation and ER-stress induced apoptosis, respectively (Sollberger 
et al., 2012; Martinon & Tschopp, 2007). It is proposed that human caspase-4 and 
   p20 p10 p22  Procaspase-4 
Inter-linker domain  
Caspase-4 p30   p20 p10  
 p20 
 p20 
 p10 
 p10 Active caspase-4 
Figure 1 6 Structural activation of caspase-4. The zymogen procaspase- 4
undergoes proteolytic cleavage upon activation. Cleavage of the p22 CARD domain 
results in the release of a p30 active domain which undergoes further cleavage and 
oligomerisation to form the active heterotetramer, consisting of the p20 and p10 
subunits 
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caspase-5 may in fact be a gene duplication of a caspase-11-like ancestral gene, 
however this is not unanimously agreed (Martinon et al, 2004; Scott et al, 2007). 
Emerging evidence suggests caspase-11 as the functional ortholog to human 
caspase-4 due to their functional similarities and ability to detect intracellular LPS 
and activate the non-canonical inflammasome (Shi et al., 2014; Sollberger et al., 
2012; Kayagaki et al., 2011).  
iii. Caspase-4/-5/-11 and the non-canonical inflammasome 
The model of the non-canonical inflammasome is based on the caspase-11 
dependent inflammasome response in iMMs. Caspase-11 was first identified to be 
essential for caspase-1 activation in response to LPS treatment in the endotoxin 
shock model. Deletion of Casp11 completely rescues mortality due to LPS treatment 
and abrogates secretion of both IL-1α and IL-1β (Wang et al., 1998).  It was not until 
15 years later that the term non-canonical inflammasome was to be coined. 
Kayagaki and colleagues demonstrated that during infection of iMMs with Gram 
negative pathogens, including C. rodentium and EPEC E69, that caspase-11 is 
required upstream of activation of caspase-1 and essential for IL-1β/IL-18 and IL-1α 
secretion (Fig. 1.7; Kayagaki et al., 2011). Importantly, while Asc and NLRP3 are 
essential for IL-18 and IL-1β secretion in response to C. rodentium, suggesting that 
caspase-11 acts via the NLRP3 inflammasome (Liu et al., 2012), deletion of NLRP3 
or Asc has no effect on IL-1α or pyroptosis (Kayagaki et al., 2011). Non-canonical 
inflammasome activation requires two signals. Signal I is a priming signal that 
transcriptionally up regulates the components of the inflammasome including 
NLRP3, caspase-11 and pro-IL-1β (Fig. 1.7). This is dependent on the Tir domain-
containing adaptor molecule 1 (TRIF) of the TLR-4 pathway, to activate NF-κB and a 
type I IFN response in iMM (Fig. 1.7; Gurung et al., 2012; Rathinam et al., 2012). 
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Alternatively type II IFN has also been shown to be essential for caspase-11 
synthesis in vivo in IECs (Oficjalska et al., 2015). Once primed a secondary signal, 
signal II, is required to activate caspase-11 and non-canonical inflammasome 
activation.   
Figure 1 7 The non-canonical inflammasome model.  Activation of the non-canonical 
inflammasome requires two signals. Signal I is a priming signal that through detection of 
LPS drives the TLR-4/TRIF dependent activation of NF-κB and subsequent Type I 
Interferon and NF-κB dependent expression of NLRP3, pro-caspase-1, IL-1β and pro-
caspase-4. Signal II is the activator, which in this model is LPS. Upon detection of 
intracellular LPS pro-caspase-4/-11 undergoes self-proteolytic cleavage and 
oligomerisation.  This leads to formation of the inflammasome through recruitment of 
NLRP3, Asc and pro-caspase-1 in to a macromolecular complex. The exact trigger for this 
is unknown but requires caspase-4/-11 activation. Pro-caspase-1 undergoes self 
proteolytic cleavage and oligomerisation and processes pro-IL-1β/IL-18 triggering their 
secretion.  
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Although the PAMP/DAMP has not been verified during bacterial infection, the 
activator of the non-canonical inflammasome is hypothesised to be intracellular LPS 
and more specifically the Lipid A motif (Shi et al., 2014; Kayagaki et al., 2011). The 
lipid A motif of LPS directly interacts with a conserved lysine residue at position 19 
present in the CARD domain of both caspase-4 and -11, resulting in self-proteolytic 
cleavage and oligomerisation in vitro (Fig. 1.7; Shi et al., 2014). In iMM activation of 
caspase-11 via cytosolic LPS results in non-canonical inflammasome activation and 
the downstream activation of caspase-1 and secretion of IL-1β, IL-18 and IL-1α and 
initiation of pyroptosis (Fig. 1.7; Kayagaki et al., 2011; Shi et al., 2014). Little work 
has been carried out in human cell lines due to the availability of knock-out mice and 
an in vivo model of infection; however, to date, both caspase-4 and caspase-5 have 
been implicated in inflammasome activation during enteric pathogen infection and 
LPS transfection.  
Sollberger and colleagues observed that caspase-4 is essential for caspase-1 
activation and IL-1β/IL-18 secretion in the macrophage-like human acute monocytic 
leukemia cell line (THP-1) and keratinocytes. This however was in response to 
canonical stimuli, acting as a general upstream activator of both the canonical 
NLRP3 and AIM2 inflammasome (Sollberger et al., 2012). On the other hand 
caspase-4 and caspase-5 can functionally complement Casp11-/- iMM to induce 
pyroptosis in response to cytosolic LPS (Shi et al., 2014). Furthermore caspase-4 is 
essential for pyroptosis in response to cytosolic LPS in the human cell line THP-1 
(Shi et al., 2014). The ability of caspase-4/-5 to activate IL-1β/IL-18 secretion in 
human myeloid cell lines, in response to intracellular LPS has not been studied; 
therefore, the role of either in activation of the non-canonical inflammasome remains 
unclear. Further work is required to understand their function and their role in 
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inflammasome activation. The fact that humans encode two inflammatory caspases 
that can detect LPS may mean that the “non-canonical inflammasome” or the 
inflammasome that forms in response to LPS may differ from the murine non-
canonical inflammasome response. In fact a recent discovery of a caspase-4 
dependent/ caspase-1 independent inflammasome in human IECs questions the 
current hypothesis and non-canonical inflammasome model (Knodler et al., 2014).  
iv. The unconventional non-canonical inflammasome in epithelial cells 
iMMs have been the primary cell line in which the inflammasome response to enteric 
pathogens has been studied in vitro. EPEC E69 and C. rodentium are extracellular 
bacterial pathogens that attach to IECs to colonize the host. Therefore IECs may 
represent a more physiologically relevant cell line to study the host response and 
inflammasome activation during EPEC E69 and C. rodentium infection. Caspase-4 
has been implicated to regulate IL-18 secretion in response to Salmonella and EPEC 
E69 infection, as well as LPS transfection of polarised IECs (Knodler et al., 2014). 
Surprisingly, the secretion of IL-18 and activation of pyroptosis in response to 
Salmonella infection of IECs is uniquely caspase-1 independent. Similarly EPEC E69 
induced secretion and cleavage of IL-18 is also caspase-1 independent. A caspase-
1 independent inflammasome has not been described previously and whether the 
IEC caspase-4 dependent inflammasome requires an NLR or Asc is unknown; but 
this pathway significantly differs to the characterised mouse macrophage non-
canonical inflammasome response (Knodler et al., 2014). In support of this the C. 
rodentium mouse model of infection has identified that both IECs and myeloid cells 
contribute to inflammasome dependent cytokine secretion in vivo (Song-Zhao et al., 
2014; Gurung et al., 2012; Liu et al., 2012; Kayagaki et al., 2011). 
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1.6.4 The role of the inflammasome in vivo  
Many studies have been carried out to investigate the role of the inflammasome 
response during C. rodentium infection of C57BL/6 mice. Clearance of C. rodentium 
is significantly abrogated day 14 post-infection of Il-18-/-, Il-1β-/-, Nlrp3-/-, Nlrc4-/- and 
Casp11/1-/- C57BL/6 mice (Liu et al., 2012) and day 7 post infection in Casp11-/- 
C57BL/6 mice (Gurung et al., 2012). The increase in bacterial burden is 
accompanied by an increase in crypt hyperplasia, immune cell infiltration and 
gastrointestinal inflammation (Liu et al., 2012). This concludes that late in infection 
caspase-11, caspase-1, NLRP3, NLRC4 as well as IL-1β/IL-18 secretion, all play a 
crucial role in the immune response to C. rodentium infection in vivo. Secretion of IL-
18 at day 8 during C. rodentium infection of bone marrow irradiated Nlrp3-/- and 
Nlrc4-/ - C57BL/6 mice is unaffected; while Asc KO abolishes IL-18 secretion 
completely (Nordlander, Pott & Maloy, 2014; Song-Zhao et al., 2014). This suggests 
that IL-18 maturation and secretion and therefore inflammasome activation, early 
during C. rodentium infection, is NLRP3 and NLRC4 independent and occurs 
exclusively in the non-hematopoietic cells of the gastrointestinal tract (Song-Zhao et 
al., 2014); in an Asc dependent manner. Whether another NLR is required for IEC 
dependent IL-18 secretion in vivo or whether caspase-1 is dispensable in vivo 
remains unknown. Importantly, the research to date suggests that IL-18 maturation 
and secretion in response to infection with enteric pathogens is not exclusively via 
the in vitro characterised “conventional” non-canonical inflammasome pathway 
described previously. Furthermore these studies conclude that both IL-1β and IL-18 
play an essential role in the regulation of the immune response and clearance of C. 
rodentium in vivo. 
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1.6.5 The IL-1 cytokine family 
The IL-1 family of cytokines consists of the pro-inflammatory effectors IL-1α and β, 
IL-18, IL-33 and IL-36α, β, γ as well as the anti-inflammatory effector IL-37 
(Garlanda, Dinarello & Mantovani, 2013). IL-1 was one of the first cytokines to be 
discovered to have anti-microbial activity (van der Meer, 1988) and has since been 
discovered to be the causative agent of many auto-immune inflammatory diseases 
(Garlanda, Dinarello & Mantovani, 2013) including: arthritis and psoriasis.  
i. IL-1α and IL-1β share biological properties 
IL-1α and IL-1β share the same receptor as agonists for the IL-1 receptor (IL-1R), 
which is present on the surface of almost all cell types (Garlanda, Dinarello & 
Mantovani, 2013). Whilst this means they are almost functionally redundant the 
major difference between IL-1α and IL-1β is that the latter requires processing by 
cysteine proteases from its 30 kDa form to a 17 kDa cleavage product to be 
biologically active. This is canonically via caspase-1 and inflammasome activation; 
however, IL-1β can also be activated extracellularly by neutrophil proteinase-3 or 
elastase (Garlanda, Dinarello & Mantovani, 2013). The activity of IL-1α and IL-1β is 
further separated by the fact that IL-1β expression is limited to a subset of cell types 
and is not expressed in human intestinal epithelial cells (Daig et al., 2000). 
Stimulation of IL-1R drives a similar TRAF6/TAK1 dependent NF-κB and MAPK p38 
dependent transcriptional activation as seen via the TLR-4 pathway, to prime and 
activate cells of the innate and adaptive immune system (Dunne & O'Neill, 2003). 
ii. The functional role of IL-1β in vivo 
IL-1β plays a significant role in inflammatory signaling in vivo. As mentioned many 
cell types express the IL-1R and therefore IL-1β has a broad spectrum of activity and 
priming cells including natural killer (NK) cells, monocytes and innate lymphoid cells 
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(ILC). Through stimulation of NK cells it induces secretion of IFNγ; while activation of 
ILC3 drives an IL-17 and IL-22 response (Garlanda, Dinarello & Mantovani, 2013). 
While classically behaving as a cytokine and signaling via IL-1R it is also an 
essential chemokine in the chemotaxis and recruitment of macrophages (Rider et al., 
2011). IL-1β also has an essential role in activation of the adaptive immune 
response. Through signal transduction in endothelial cells and transcriptional 
activation of cell surface adhesions and chemokines IL-1β acts to recruit leukocytes 
to the site of infection. Stimulation of non-conventional Th1 cells with IL-1β triggers 
IFNγ release and subsequent macrophage activation (Garlanda, Dinarello & 
Mantovani, 2013). Further to this IL-1β activates an IL-17 response from Th17 and 
Tγδ17 T cells resulting in release of IL-8 from endothelial and epithelial cells 
(Garlanda, Dinarello & Mantovani, 2013). The response to IL-18 secretion 
significantly differs to that of IL-1β; most likely due to the difference in the subset of 
cell types that express IL-18R.  
iii. IL-18 and IFNγ inducing factor 
Regulation of IL-18 differs from that of the other family members due to the fact that 
it is constitutively expressed (Puren, Fantuzzi & Dinarello, 1999). How the 
expression of IL-18 is manipulated or further regulated is poorly characterized. 
Similar to IL-1β, activity of IL-18 is restricted and requires processing of the ~24 kDa 
pro-form to the biologically active 18 kDa form to be secreted. IL-18 is not an IL-1R 
family receptor agonist and instead binds a distinct receptor aptly named IL-18 
receptor (IL-18R). Stimulation of IL-18R activates MAPK p38 and the transcriptional 
activators AP-1 and NF-κB in a TRAF6 dependent manner (Dinarello & Fantuzzi, 
2003), although not in all cell types (Lee et al., 2004). IL-18 was initially annotated as 
IFNγ-inducing factor. Along with IL-12, IL-18 is essential for the expression of IFNγ. 
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Unlike other pro-inflammatory cytokines IFNγ can be administered as a therapeutic, 
without adverse inflammatory side effects; having an essential role in clearance of 
bacterial infection and sepsis (Dinarello & Fantuzzi, 2003). The ability of IL-18 to 
induce IFNγ gives it a unique role in vivo and function among the IL-1 superfamily.  
iv. The functional role of IL-18 in vivo 
IL-18 induces the production of IFNγ through NK cells/Th1 cells and ILC1 through 
co-stimulation with IL-12 and IL-25, respectively (Garlanda, Dinarello & Mantovani, 
2013). As an IFNγ inducer IL-18 stimulates the production of Nitric oxide (NO) to kill 
intracellular pathogens, including Salmonella. Furthermore IL-18 has been shown to 
facilitate the emigration of neutrophils and leukocytes to the site of infection. This is 
by two mechanisms: firstly IL-18 can increase the expression of adhesion molecules 
ICAM-1 and VCAM-1 (Dinarello & Fantuzzi, 2003) or alternatively, in an IFNγ 
dependent manner, IL-18 triggers a cytokine/chemokine signaling cascade via MIP-
2, MIP-1α, TNFα and finally Leukotriene B4 (LTB4; Verri et al., 2007; Canetti et al., 
2003). LTB4 is a potent neutrophil chemokine. IL-18 dependent recruitment of 
neutrophils was studied using intra-peritoneal (IP) injection of mice with rIL-18 or rIL-
15 (Verri et al., 2007; Canetti et al., 2003); therefore, it is not known if IL-18 or the 
inflammasome plays an essential role in neutrophil recruitment in the intestinal 
mucosa. On the other hand it is established that IL-18 plays a crucial role in the 
mouse model of Crohn’s disease and inflammatory bowel disease (IBS; Dinarello & 
Fantuzzi, 2003). This has led many studies to target IL-18 as a therapeutic for IBS.  
Whether or not IL-18 signaling is targeted by pathogenic E. coli or C. rodentium 
during infection has not been studied; although, manipulation of inflammatory 
signaling is a key aspect of the A/E pathogen infection strategy.  
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1.7  Manipulation of the inflammatory response by enteric pathogens 
Multiple effectors have been identified to be recruited by EPEC E69 to inhibit pro-
inflammatory signalling via the JNK and NF-κB dependent signalling cascades 
(Raymond et al., 2013). The majority of the characterised T3SS anti-inflammatory 
effectors are encoded on the PAIs PP4 and IE6 and include NleB1, NleE1, NleC and 
NleD.  
1.7.1 The EPEC anti-inflammatory effectors NleB1, NleC, NleD and NleE1 
inhibit NF-κB and JNK signalling  
NleB1, NleE1, NleC and NleD, when ectopically expressed, can function to inhibit 
inflammatory signalling via exogenous simulation. Both NleD and NleC are zinc-
dependent metalloendopeptidases which co-operate to inhibit inflammatory 
signalling through the direct cleavage of JNK/p38 and p65, respectively (Fig. 1.8; 
Baruch et al., 2011; Muhlen, Ruchaud-Sparagano & Kenny, 2011; Pearson et al., 
2011; Sham et al., 2011; Yen et al., 2010). NleB1, but not NleB2, of EPEC functions 
as an N-acetyl-D-glucosamine (O-GlcNAc) transferase to disrupt TNFR induced 
TRAF-2 dependent NF-κB activation in response to stimulation with TNFα (Fig. 1.8; 
Gao et al., 2013; Newton et al., 2010).  NleE1 is employed by EPEC to inhibit NF-κB 
activation and IL-8 secretion in response to both IL-1β and TNFα stimulation 
(Newton et al., 2010). Through a unique S-adenosyl-l-methionine-dependent 
methyltransferase activity, NleE1 targets the host ubiquitin sensory complex proteins 
TAB2/3 to inhibit IκBα degradation and NF-κB activation (Fig. 1.8; Zhang et al., 
2011). While many of the above mentioned effectors have been characterised to 
inhibit inflammatory signalling when ectopically expressed their role in vivo, due to 
the complexity of signalling, is less clear.  
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Figure 1 8 EPEC E69 recruits a plethora of effectors to inhibit inflammatory 
signalling during infection.  EPEC E69 delivers multiple effectors to subvert 
inflammatory signalling. This includes the metalloendopeptidases NleD and NleC 
that target and cleave JNK/p38 and p65, respectively. NleE, a methyltransferase 
targets TAB2/3 to prevent IκBα degradation while NleB is N-acetyl-D-glucosamine
transferase that targets GAPDH to disrupt TRAF2 dependent TNFR signalling.  
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1.7.2 Inflammatory signalling during EPEC E69 infection 
While EPEC E69 secretes a plethora of anti-inflammatory effectors it initially 
activates and later inhibits inflammatory signalling and the release of immune 
mediators during infection, in a T3SS-dependent manner. Initially, EPEC E69 
induces a pro-inflammatory response during in vitro infection of epithelial cells 
through activation of MAPK extracellular regulated kinase 1/2 (ERK1/2; Czerucka et 
al., 2001; de Grado et al., 2001) and NF-κB (Newton et al., 2010; Savkovic, 
Koutsouris & Hecht, 1997). Interestingly, activation is T3SS-dependent and no NF-
κB or ERK1/2 activation is observed during infection with the T3SS mutant’s ΔescN  
(Pearson et al., 2011; Newton et al., 2010) or ΔespB (de Grado et al., 2001; 
Savkovic, Koutsouris & Hecht, 1997). Furthermore, NF-κB activation is ERK1/2 
dependent and the host inflammatory response during infection is TNFR/ IL-1R 
independent (Savkovic et al., 2001); suggesting EPEC E69 delivers an unknown 
effector to activate pro-inflammatory signalling. Phosphorylation of ERK1/2 signalling 
is no longer detectable 1 h post infection (Savkovic et al., 2001) and at later time 
points, in a T3SS-dependent manner, EPEC E69 inhibits NF-κB pro-inflammatory 
signalling and IL-8 secretion (Pearson et al., 2011; Newton et al., 2010). Furthermore 
NF-κB activation and IL-8 secretion, induced by TNFα or IL-1β exogenous 
stimulation, is inhibited 4 h post infection in T3SS dependent manner (Pearson et al., 
2011; Newton et al., 2010). Deletion of NleE1 alone significantly increases IL-8 
secretion during infection, independent of exogenous stimulation (Pearson et al., 
2011). While deletion of NleC alone does not affect IL-8 secretion; deletion of NleC 
in the EPEC ΔnleE1 strain background promotes further IL-8 secretion during 
infection (Pearson et al., 2011). Importantly infection with an EPEC E69 strain 
harbouring a dual deletion in the PAIs PP4 and IE6 is no longer able to inhibit TNFα 
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induced NF-κB activation at 4 h post infection and in fact infection with EPEC 
ΔPP4/IE6 constitutively activates NF-κB activation and IL-8 secretion (Pearson et al., 
2011; Newton et al., 2010). This is most likely due to an uncharacterised pro-
inflammatory effector and the early ERK1/2 and NF-κB activation; which is no longer 
inhibited by the translocation of the anti-inflammatory effectors on islands PP4 and 
IE6. Furthermore, complementation of EPEC ΔPP4/IE6 with NleE1 alone is able to 
significantly inhibit NF-κB activation and IL-8 secretion during infection to levels of 
that seen for the WT (Pearson et al., 2011; Newton et al., 2010). This suggests that 
NleE1 is the main inhibitor of NF-κB activation during in vitro infection. Recently, 
NleC was identified to inhibit KC, IL-22, MIP-2α and IL-1β expression during in vivo 
C. rodentium infection resulting in inhibition of the recruitment of CD11b positive 
myeloid cells and a reduction in pathology; confirming an anti-inflammatory role for 
effectors in vivo (Hodgson et al., 2015). Therefore the manipulation of the 
inflammatory response during EPEC E69 and C. rodentium infection is a complex 
network of pro-inflammatory and multiple anti-inflammatory effectors working in 
conjunction. While no pro-inflammatory effector(s) has been reported for EPEC E69 
the atypical EPEC strain E110019 and C. rodentium encode the characterised pro-
inflammatory effector EspT (Raymond et al., 2011).   
1.7.3 EspT is a pro-inflammatory effector of atypical EPEC 
EspT of atypical EPEC induces activation of NF-κB and ERK1/2 signalling during 
infection, resulting in up-regulation of expression and secretion of the pro-
inflammatory cytokines and chemokines IL-8 and IL-1β (Raymond et al., 2011). EspT 
belongs to a family of WxxxE motif proteins with guanine nucleotide exchange factor 
(GEF) mimicry and targets Rac1 to activate inflammatory signalling (Raymond et al., 
2011). This activity of EspT is restricted to infection of immune cells and has no pro-
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inflammatory effect on epithelial cells.  Moreover, EspT is confirmed to contribute to 
the expression of the immune mediators TNFα and KC in vivo during C. rodentium 
infection (Raymond et al., 2011). While pathogenic E. coli deliver pro-inflammatory 
effectors as part of their infection strategy; to date, the pro-inflammatory effector(s) of 
EPEC E69 remains unknown.  
1.8 NleF of attaching and effacing pathogens 
The newly characterised non-LEE encoded effector F (NleF; Echtenkamp et al., 
2008; Tobe et al., 2006) is a core effector which is highly conserved among EHEC 
strains and shares 100% identity with homologs of the EPEC strains O127:H6 
E2348/69, O26:H11, O55::H7, and O111:H-, as well as sharing 84% amino acid 
sequence identity with C. rodentium (Iguchi et al., 2009; Fig. 1.9A). The PAI, OI-71 
(EHEC) or PP6 (EPEC), encodes NleA/EspI and also NleF (z6020) in an operon with 
NleH2 (Fig. 1.9B). Expression is regulated by the presence of an nle regulated 
inverted repeated (NRIR) domain (Garcia-Angulo et al., 2012), which was recently 
shown to be a unique promoter for the non-LEE encoded effectors of pathogenic E. 
coli (Garcia-Angulo et al., 2012). NleF is thought to have been acquired by horizontal 
gene transfer along with NleH1-2 and NleA/EspI. High through-put virulence gene 
profiling of typical and atypical EPEC clinical isolates identified the presence of OI-71 
(PP6) and nleF associates with serotypes linked to severe outbreaks and diarrhoea 
in children (Bugarel et al., 2011). Furthermore Zhang and colleagues identified that 
EHEC O157:H7 separated into two dominant lineages, with lineage I strains linked to 
disease in humans (Zhang et al., 2007). Interestingly genomic analysis of strains 
from lineage I and II showed that both nleF and nleH1-2 are absent from lineage II 
strains and therefore may be important for colonisation and disease in humans 
(Zhang et al., 2007). 
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Characterisation of NleFE69 in silico shows no homology to known Homo sapien 
proteins or to other characterised/ uncharacterised T3SS effectors of enteric 
pathogens or homology with previously described functional domains (Echtenkamp 
et al., 2008). Initial functional characterisation of NleF from EHEC O157:H7 
(NleFEHEC) identified that when ectopically expressed NleFEHEC localises diffusely 
throughout the cell and furthermore, unlike NleA/EspI, it does not manipulate 
Figure 1 9 Alignment of NleF of pathogenic E. coli and distribution of PAI 
Prophage 6 (PP6). (A) ClustalW2 multiple sequence alignment for NleF of following 
strains: O127:H6 str. E2348/69, O157:H7 str. EDL933/ Sakai/ 85-170, O55:H7 str.
CB9615, O111:H- str. B171-1, O26:H11 str. 11368, O103:H2 str. 12009 and
Citrobacter rodentium str. ICC169 (B) Schematic of PAI PP6 of EPEC O127:H6 
E2348/69. UN, uncharacterised/ hypothetical protein.    
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intracellular trafficking and/ or secretion (Echtenkamp et al., 2008).Therefore the 
functional role of NleF and the host target binding partners remain unknown.  
1.9 Aims and outline  
The aim of this study was characterise the functional role of NleF in infection using in 
vitro and in vivo models.   
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Chapter 2: Materials and Methods  
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2.1 Bacterial strains, reagents, growth conditions and plasmids  
Strains used in this study are listed in Table 2.1. E. coli and C. rodentium were 
cultured in Miller Luria Broth (LB) at 37?C, at 200 rpm with the appropriate 
antibiotics: 50 µg/ml kanamycin, 100 µg/ml ampicillin and 30 μg/ml chloramphenicol. 
The plasmids constructed and primers used for cloning in this study can be found in 
Table 2.2 and cDNA templates in Table 2.3. nleFE69 was amplified from E. coli 
O127:H6 E2348/69 and nleFCR was amplified from C. rodentium ICC169 genomic 
DNA by PCR using KOD Hot Start Polymerase (Novagen). Human CASP4 and 
CASP5 were amplified from pICC1651 and pICC1653, respectively. Mouse Casp11 
was amplified from pICC1650. GGCT, HBXIP, DHFR and DHRL1 were amplified 
from plasmids outlined in Table 2.3. All cloning was carried using restriction site 
digestion (NEB) and T4 DNA Ligase (NEB) unless specified otherwise. Site-directed 
mutagenesis was carried out by inverse PCR using KOD Hot Start polymerase and 
mismatch primers (See Table 2.4). All constructs were confirmed by sequencing 
(GATC). All reagents used in this study were purchased from Sigma-Aldrich, unless 
stated otherwise.  
2.2 Y2H screening and YDH hybrids 
A Yeast-2-Hybrid screen was conducted using pGKBT7-nleFE69 using the HeLa cell 
cDNA Library following the manufacturer’s instructions (Clontech). The inserts of 
positive clones were amplified using the primer pair AD-LDF/R using Green Taq 2x 
Master mix (NEB) and sent for sequencing. A Yeast Direct Hybrid was carried out 
following the manufacturer’s instructions (Clontech). AH109 were co-transformed 
with pGBT9-bait and pGADT7-prey (See Table 2.2) and plated onto Difco Yeast 
Nitrogen Base without amino acids (SD) agar supplemented with 2% glucose, 20 
mg/L adenine hemisulfate (Ade), 20 mg/L arginine HCl, 20 mg/L histidine HCl 
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monohydrate (His), 30 mg/L isoleucine, 30 mg/L lysine HCl, 20 mg/L methionine, 50 
mg/L phenylalanine, 200 mg/L threonine, 30 mg/L tyrosine, 20/L mg uracil, 150 
mg/ml valine and lacking tryptophan (Trp) and Leucine (Leu) (Double Drop-out; 
DDO) for selection of transformed clones. Clones positive for both plasmids were re-
streaked on to SD DDO and SD QDO /-His/-Ade supplemented with 40 mg/L x-α-gal 
(SD QDO) for selection of positive interactions. Plates were incubated at 30 ºC for 3-
10 days. 
2.3 Tissue culture 
The human epithelial colorectal adenocarcinoma cells (Caco-2) clones TC7 
(Chantret et al., 1994)) as well as the human embryonic kidney (HEK) 293E cells 
(ATCC) were grown in Dulbecco’s Modified Eagle's Medium (DMEM) – high glucose 
(4500 mg/L) supplemented with 15 % (v/v) heat inactivated Fetal calf serum (FCS; 
Gibco), 2 mM Glutamine (Invitrogen), 0.1 mM Non-essential amino acids (NEAA) 
and the antibiotics Penicillin and Streptomycin (P/S) at 100 U/ml and 100 μg/ml, 
respectively. Cells were kept at 37 0C in a 5 % CO2 atmosphere and routinely 
screened for Mycoplasma. C57BL/6 immortalised mouse macrophages (iMM) were 
grown in DMEM – high glucose (4500 mg/L) supplemented with 10 % (v/v) heat 
inactivated FCS, 2 mM Glutamine and 0.1 mM NEAA at 37 0C in a 5 % CO2 
atmosphere. The human epithelial cervical adenocarcinoma cells (HeLa) were grown 
in DMEM – low glucose (1000 mg/L) supplemented with 10 % (v/v) heat inactivated 
FCS, 2 mM Glutamine and 0.1 mM NEAA at 37 0C in a 5 % CO2 atmosphere. All cell 
lines were passaged routinely by treatment in 0.02% EDTA solution supplemented 
0.1% trypsin (Gibco) for 5 min (30 min for Caco-2). The Human acute monocytic 
leukemia cell line (THP-1; ATCC) were grown in suspension in Roswell Park 
Memorial Institute (RMPI) medium supplemented with 10% FCS at 37°C in a 5% 
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CO2 atmosphere. THP-1s were were seeded in 24-well plates at 7.5x105 and 
differentiated in 75 nM phorbol myristate acetate (PMA) for 4 days and starved in 
serum free RPMI with or without 200 ng/ml LPS before extraction for Western 
blotting as described below.  
2.4 Transfection assays 
2.4.1 Plasmid transfection of HeLa cells 
HeLa cells were seeded and grown to a confluence of ~40% in either 24 or 6 well 
plates (BD Falcon). The media was replaced with serum free DMEM and transfected 
with the eukaryotic expression vectors described in Table 2.2, using the transfection 
reagent GeneJuice (Novagen), according to the manufacturers specifications. As a 
control cells were left unstimulated or stimulated with 20 ng/ml TNFα for 0.5 h or 16 h 
where specified. For immunofluorescence staining transfected cells were washed 3 
times in warm phosphate buffered saline (PBS) at indicated time points and fixed for 
20 min in 3.4% paraformaldehyde (PFA; Agar Scientific). Fixed cells were washed 3 
times in warm PBS and stored at 4ºC for further analysis. Alternatively, for RNA 
extraction or Western blotting, transfected cells were washed 3 times in warm PBS 
and stored at -80ºC for further analysis.  
2.4.2 Transfection of short inhibitory RNA 
HeLa cells were seeded to a confluence of ~40% in a T25 flask (BD Falcon) and 
transfected with 20 nM ON-Targetplus SMARTpool (Dharmacon) small interfering 
RNA (siRNA) for CASP4 (L-004404-00-0005), CASP8 (L-003466-00-0005) or 
CASP9 (L-003309-00-0005) or with non-targeting scrambled siRNA (D-001810-10-
05; Dharmcon) as a control, using the siRNA transfection reagent Hiperfect 
(Qiagen), according to the manufacturer’s specifications. For dual knockdown, HeLa 
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cells were transfected with 20 nM of CASP4 and CASP8 smartpool siRNA or 40 nM 
of the non-targeting control siRNA. Thirty six hours post-transfection cells were 
washed and frozen for analysis by RT-qPCR or Western blotting as described below. 
Alternatively 24 h post-transfection cells were treated in 0.02% EDTA/ 0.1% trypsin 
for 5 min and seeded into 24 well (BD Falcon) plates. Twelve hours later siRNA-
treated cells at a confluence of ~40% were transfected with the mammalian 
expression vectors (see Table 2.2) using GeneJuice, as described above.  Twenty 
four hours post-transfection cells were washed 3 times in warm PBS and stored at -
80ºC for further analysis.  
2.5 Isolation of RNA and RT-qPCR 
RNA was extracted and isolated following the manufacturer’s instructions (Qiagen; 
RNeasy mini kit). Samples were pre-treated with RQ1 DNase (Promega) at 37?C for 
10 min followed by DNase denaturation at 72ºC for 15 min. Reverse transcription 
(RT) was carried following the manufacturer’s instructions (Promega) with the 
following adaptations: RNasin (Promega) was added to the reaction buffer at 2-4 
U/µl. RT Quantitative-PCR (RT-qPCR) was carried out using the 7300 Real Time 
PCR System (Applied Biosystems) using the standard cycle conditions and primer 
pairs IL-8F/R, CASP4F/R, CASP8F/R, CASP9F/R and GAPDHF/R (see Table 2.4). 
Changes in gene expression levels were analysed relative to GFP (where stated), 
using GADPH as a standard and using the ΔΔCT method. 
2.6 Immunofluorescence staining and antibodies 
Fixed cells were initially quenched in 50 mM NH4Cl followed by permeabilisation in 
0.2% Triton X-100. Fixed cells were then washed 3 times in PBS blocked in 1% 
Bovine serum albumin (BSA) diluted in PBS (BSA-PBS). All antibodies, unless 
stated otherwise, were diluted directly in 1% BSA-PBS. Primary antibodies were 
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incubated for 45 min followed by 3 washes in PBS and second round of blocking for 
15 min. Secondary antibodies and/or reagents were incubated for a further 30 min. 
Cover-slips were then washed 3 times in PBS and mounted onto microslides using 
Prolong Gold anti-fade reagent (Invitrogen) before visualising on the Zeiss 
Axioimager immunofluorescence microscope using the Zeiss Axiovision Rel 4.5 
software. Primary antibodies: the mouse monoclonal antibodies anti-Myc clone 4A6 
(05-724; Millipore), anti-TOMM22 (ab57523; Abcam), the rabbit polyclonal antibody 
anti-N-terminal NF-κB p65 Clone A (sc-109; Santa Cruz) and the chicken polyclonal 
antibody anti-EaeM β (full-length intimin β of Porcine EPEC) (Girard et al., 2005). 
Secondary antibodies: DyLight488-conjugated donkey anti-mouse IgG (H+L) 
(catalog no. 715-485-150; Jackson immunoresearch), Donkey anti-Rabbit IgG (H+L) 
(catalog no. 711-295-152; Jackson immunoresearch) and goat anti-chicken IgY 
(H+L) (catalog no. 103-605-155; Jackson immunoresearch). Stains: Phalloidin-
Alexa-647 (A-22287; Invitrogen), 4,6-Diamidino-2-phenylindole (DAPI) (D3571 
;Invitrogen) and Phalloidin-Alexa-555 (P1951). 
2.7 Bacterial priming, cell growth analysis and attachment assays  
EPEC E69 strains were grown for 16 h ON as described above and primed by sub-
culturing 1:100 in DMEM low glucose with no additives supplemented with 
appropriate antibiotics for 3 h, with no agitation in an atmosphere of 5% CO2. To 
analyse cell growth an aliquot of each bacterial culture was extracted at 45 min 
intervals and diluted by serial dilution in sterile warm PBS.  Diluted samples were 
plated at a range of 1 x103-1 x105/10 µl on LB-agar. Plates were stored at 37ºC for 
16 h and colony forming units (CFU) were counted the following day.  
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2.8 Generation of an EPEC E69 nleF deletion strain 
An EPEC E2348/69 strain harboring a deletion in the gene nleF was generated using 
the Lambda Red system (Datsenko & Wanner, 2000). The nleF gene along with 500 
bp 5’ and 400 bp 3’ were amplified from Escherichia coli O127:H6 E2348/69 
genomic DNA and cloned into TOPO Blunt II (Invitrogen) using the primers specified 
in Table 2.2 using blunt end ligation. The kanamycin cassette was amplified from 
pKD4 using the primer pair specified in Table 2.2. Using inverse PCR nleF was 
removed and replaced with the kanamycin cassette using blunt end ligation to 
generate pICC1674.  The linear product was amplified from pICC1674 using primer 
pair 1F/R. Mutagenesis was confirmed by sequencing using the primer pair  
2.9  Infection of assays  
2.9.1 Infection of the HeLa cell line 
HeLa cells were seeded 16 h prior to infection for a confluence of 40 %. HeLa cells 
were washed 3 times in warm PBS prior to infection and the medium was replaced 
with serum free DMEM low glucose. Bacterial strains were grown and primed as 
described above and expression of NleF in the EPEC ΔnleF pnleFE69 and NleE1 in 
the EPEC ΔPP4/IE6 pNleE1 complemented strains was induced with the addition of 
1 mM Arabinose or 0.5 mM IPTG at 0.5 h before infection, respectively. At 3 h post 
serum-starving the HeLa cell medium was removed and replaced with 0.5 ml of a 1:3 
dilution of primed bacterial culture. At 1 h post infection HeLa cells were washed 3 
times in warm PBS and incubated for a further 0.5 h or 3 h. For the 4 h time point 
where indicated cells were stimulated with 20 ng/ml TNFα at 3.5 h post infection for 
0.5 h. At 1.5 h and 4 h cells were washed 3 times in warm PBS and fixed in 3.4 % 
PFA for immunofluorescence or stored at -20 ºC for analysis by Western blotting.  
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2.9.2 Infection of iMM 
iMM were seeded at 1.5 x106/ml and infected the next day. Three hours prior to 
infection the medium was replaced with DMEM high glucose with FCS and 
supplements with or without 200 ng/ml LPS (O111:B4) in Hanks balanced salt 
solution (HBSS; Gibco). EPEC E69 bacterial cultures were primed as above and 
primed or un-primed iMM were infected at an MOI of 25 for 1 h. Alternatively iMM 
were treated with STBL2 (Clontech) E. coli  grown over-night in LB at 37ºC at 200 
rpm at an MOI of 25. At 1 h post-treatment cells were washed 5 times in warm PBS 
and the medium was replaced with DMEM high glucose with FCS/ supplements and 
further supplemented with 200 µg/ml gentamicin for 20 h.  At 19 h post treatment 
primed iMM were treated with 5 mM ATP for 1 h. Supernatants were taken at 21 h 
post treatment/infection and centrifuged at 13000 rpm at 4 ºC for 10 min. Cleared 
supernatants were analysed by ELISA or stored at -20ºC for further analysis. 
Alternatively the supernatant was extracted for analysis of LDH release; while 
monolayers were analysed for cell death by PI uptake as described below.   
2.9.3 Infection of the Caco-2 cell line 
Caco-2 TC7 were seeded at 3.5 x104 and upon reaching a confluent layer the media 
was changed every day for 7 days. On day 6 post confluence antibiotics were 
removed from the media. On day 7 post confluence cells were starved for 3 h in 
DMEM high glucose with no FCS or antibiotics. Bacterial cultures were primed as 
above and serum-starved Caco-2 TC7 were infected at an MOI of 10. After 3 h the 
cell layer was washed twice in warm PBS and the medium was replaced with DMEM 
high glucose no FCS supplemented with Penicillin and Streptomycin (Sigma Aldrich) 
at 100 U/ml and 100 μg/ml, respectively. Alternatively cell layers were treated with 
1% Triton X-100 in PBS for 10 min and plated for enumeration of attachment. After 1 
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h the wash in PBS was repeated and the cells were left a further 16 h in DMEM high 
glucose no FCS supplemented with 200 µg/ml gentamicin. Supernatants were 
cleared by centrifugation at 13000 rpm at 4ºC for 10 min. Supernatants were 
precipitated for Western blotting with the addition of 10 % (v/v) trichloroacetic acid at 
4 ºC for 17 h. Precipitated samples were centrifuged at 13000 rpm for 45 min at 4 ºC. 
Pellets were washed once in ice cold methanol and re-suspended in 2 x LDS. Cell 
monolayers were stored at -20 ºC for RNA extraction or Western blotting. 
Alternatively the supernatant was extracted for analysis of LDH release; while 
monolayers were analysed for cell death by PI uptake as described below.   
2.10 Western blotting and coomassie staining  
At indicated time points cells were lysed in loading dye (LDS; 250 mM Tris pH 6.8, 
40% glycerol, 6 % SDS, 1 % bromophenol blue and 0.8% β-mecaptoethanol) and 
boiled for 10 min, separated by SDS-PAGE gel and then either transferred to a 
PVDF membrane (GE Healthcare) or incubated for 10 min in Instant Blue 
(Expedion). The PVDF membranes were blocked in Tris buffer saline pH 7.4 (10 mM 
Tris, 150 mM NaCl)/0.1% Tween-20 (TBS-T) containing 5% semi-skimmed milk 
(blocking buffer) for 45 min before incubation with primary antibody in blocking buffer 
for 16 h at 4?C. Membranes were washed in TBS-T and the secondary antibody was 
incubated for 2 h in blocking buffer. Western blots were visualized by the addition of 
EZ-ECL solution (GE Healthcare) and developed using the LAS-3000 imager (Fuji). 
Primary antibodies: mouse monoclonal antibodies anti-caspase-4 clone 4B9 (sc-
56056; Santa Cruz), anti-α-Tubulin clone DM1A (T6199), anti-NLRP3 clone Cryo-2 
(AG-20B-0014-C100; Adipogen), the mouse polyclonal antibody anti-caspase-11 
p20 clone A-2 (sc-374615; Santa cruz) and anti-pro-IL-18 (CPTC-IL18-1; DSHB), the 
rabbit monoclonal anti-IL-18 (PM014; MBL), anti-caspase-5 (4429; Cell signalling) 
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and the rabbit polyclonal antibodies anti-IκBα (29442; Cell Signaling), anti-GFP 
(Ab290; Abcam) and anti-caspase-1 (2225; Cell signaling). Secondary antibodies: 
Horse radish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Fc fragement; 
catalog no.111-035-008; Jackson immunoresearch) and HRP-conjugated goat anit-
mouse IgG (Fc fragement; catalog no, 115-035-008; Jackson immunoresearch).  
2.11 Cytokine secretion analysis and cell death assays 
Supernatants post-treatment or post-infection were removed and stored at -20ºC. 
Supernatants were thawed and diluted in reagent buffer and enzyme-linked 
immunosorbent assays (ELISAs) were carried out following the manufacturer’s 
instructions. Mouse KC and IL-18 were purchased from eBioscience and mouse/ 
human IL-1β and mouse IL-1α were purchased from R&D systems. Supernatants 
from infection were taken and analysed for Lactose dehydrogenase (LDH) release 
using the Cytotox 96 non-radioactive cytotoxicity assay (Promega), following the 
manufacturer’s specifications. As a control for total LDH, cell lysis buffer (1 % Triton-
X100/ PBS) was added for 30 min at 37ºC directly to the medium and cell layer. 
Absorbance was measured at 490 nm using the FluoStar Omega plate reader and 
results are displayed as percentage of total release. Alternatively the media was 
removed and cell layers were incubated in 3.3 µg/ml propidium iodide (Invitrogen) in 
warm PBS (PI/PBS) for 15 min and fluorescence was measured at an excitation of 
510 nm and emission of 610 nm using the FluoStar Omega plate reader. As a 
control PI/PBS alone was measured or cell lysis buffer (0.05 % Triton X-100/PBS) 
supplemented with 3.3 µg/ml propidium iodide was added for 15 min at 37ºC. 
Results are displayed as a percentage of total PI uptake.  
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2.12 Affinity –tagged purification and size exclusion 
BL21 Star were cultured for 16 h in LB at 37 ?C at 200 rpm. Bacteria were sub-
cultured at 1:100 into 1 L LB supplemented with 50 µg/ml kanamycin and incubated 
at 37?C at 200 rpm until OD600 of 0.4-0.6. Cultures were then induced with 0.5 mM 
IPTG for 18 h at 18?C. Cells were harvested by centrifugation at 10000 rpm for 20 
min and re-suspended in 30 ml ice cold His-lysis buffer (20 mM Tris, 0.5 M NaCl, 
and 5 mM Imidazole pH 7.9). The cells were lysed by Emulsiflex following the 
manufacturer’s instructions (Emulsiflex-B15; Avestin) and centrifuged at 14000 rpm 
for a further 30 min at 4?C. Supernatant was removed and applied to 5 ml His resin 
(Novagen) pre-charged in 5 mM NiSO4 and pre-equilibrated in His-lysis buffer and 
rocked at 4?C for 1.5 h. Samples were applied to a Poly-Prep Chromatography 
column (Qiagen) and flow-through was collected. The column was washed twice with 
20 ml His-lysis buffer and once in 20 ml wash buffer (0.5 M NaCl, 20 mM Tris pH 7.9 
and 60 mM Imidazole). His-tagged fusion proteins were eluted with 10 x 1 ml elution 
buffer (His-lysis buffer supplemented with 1 M Imidazole). Fractions containing His-
purified NleF were checked by SDS-PAGE gel electrophoresis and further purified by 
size exclusion (Akta prime) with a Superdex75 column (GE Healthcare; 10/300GL). 
2.13 Co-expression and purification of the caspase-4/NleFE69 complex 
BL21 Star co-transformed with pACYC-DUET-1-CASP4 His-p20/p10 and pMal-c2x-
nleFE69 were cultured for 16 h in LB at 37 ? C at 200 rpm. Bacteria were sub-cultured 
at 1:100 into 1 L LB supplemented with 50 µg/ml ampicillin and 15 µg/ml 
chloramphenicol and incubated at 37? C at 200 rpm until OD600 of 0.4-0.6. Cultures 
were then induced with 1 mM IPTG for 18 h at 20? C. Bacterial pellets were re-
suspended in 20mM Tris-HCl pH 7.4, 250mM NaCl and lysed by sonication and 
purified by amylose and talon (Kotik-Kogan et al., 2008) affinity chromatography. 
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Complex formation was analysed by size exclusion (Akta prime) with a Superdex200 
column (GE Healthcare) using the Gel Filtration Markers Kit for Protein Molecular 
Weights 12,000-200,000 Da to determine complex size. Size exclusion fractions 
were verified by SDS PAGE gel.   For the MBP pull-down assays cell lysates of BL21 
co-transformed with pMAL-c2x/pACYC-DUET-1 His-p20 C258S/p10,  pMAL-c2x-
nleFE69/ pACYC-DUET-1 His-p20 C258S/p10 and pMAL-c2x-nleFE69/ pACYC-DUET-
1 His-p20 C258S were incubated with amylose resin for 1.5 h at 4 C and then 
washed with 50 ml wash buffer (20mM Tris-HCl pH 8.0, 250mM NaCl). The proteins 
bound to the resin were eluted with 10 mM maltose and analysed by SDS-PAGE. 
2.14 Caspase activity assays 
BL21 star transformed with pET28a-empty, pET28a-CASP4, pET28a-CASP4 C258S 
or pET28a-Casp11 were grown, induced and lysed as described above. Soluble 
lysates at 200 µg.ml were incubated with or without 50 µM Ac-LEVD-AFC in 20 mM 
PIPES, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS, 10% sucrose pH 7.2 
or 20 mM Tris, 250 mM NaCl pH 7.4 for caspase-11 and caspase-4, respectively. 
Purified recombinant His-NleF and homologs were added at varying concentrations 
from 50 nM to 1 pM. Fluorescence was measured in 5 min intervals at 37 ?C using 
an excitation of 410 nm and emission of 520 nm using FLUOstar Omega plate 
reader (BMG Labtech). Results are displayed as percentage of activity (RFU/min) 
relative to the positive control: caspase-4 lysate with the addition of Ac-LEVD-CHO 
only.   
2.15 shRNA construction and retroviral transductions 
HEK293E cells (ATCC) were seeded in to 6 well plates (BD Falcon) and transfected 
with the packaging plasmids pCMV-VSV-G, pCMV-MMLV-pack (Shenoy et al., 2012) 
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and pMXs-IRES-puro (Table 2.2) containing the gene of interest to construct a 
Vesicular Stomatis pseudo-typed retrovirus for transduction, following the 
manufactures’ instructions (Clontech) and using Lipofectamine 2000 (Invitrogen). 
After 48 h the supernatant was collected, filtered (0.45 µM) and added directly to the 
medium of pre-seeded iMM. After 24-48 h transduced cells were selected by 
puromycin (Gibco Invitrogen) at 5 µg/ml. Transduction was confirmed by 
immunofluorescence and or Western blot, as described below. For stable 
knockdown, short hairpin (sh)-RNA (Table 2.2) was constructed and cloned into 
pMX-CMV-YFPc1 using one-step sequence and ligation independent cloning (SLIC)  
(Jeong et al., 2012) following the miR30 based (Chang et al., 2013) and optimised 
miR-E (Fellmann et al., 2013)  shRNA vector design. Primer pairs were annealed, 
filled in by PCR and amplified by shRNAF/R (Table 4). PCR amplicons were cloned 
into pMX-CMV-YFPc1 using SLIC and XhoI digestion. Vectors were constructed to 
target CASP4 (CGACTGTCCATGACAAGAT and lacZ (TRCN0000072226) as a 
non-targeting shRNA control. Caco-2 TC7 were transduced as above and selected 
for with 10 µg.ml puromycin. Transduction and knockdown were confirmed, as 
described above.  
2.16 Generation of C. rodentium nleF knockout mutant 
C. rodentium strain ICC169 ΔnleF was generated using a modified version of the 
lambda red-based mutagenesis system (Datsenko and Wanner, 2000). The nleF 
gene and its flanking regions were PCR-amplified from WT C. rodentium ICC169 
genomic DNA using the primer pair 4F/R and cloned into pGEMT vector (Promega). 
The nleF gene was then excised using inverse-PCR (primer pair 5F/R) and the 
resulting linear product was BamHI digested, allowing insertion of the non-polar 
aphT (Galan, Ginocchio & Costeas, 1992) cassette. After verifying for correct 
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orientation of the kanamycin cassette, the insert was PCR-amplified using primer 
pair 4F/R. The presence of the mutation was confirmed by PCR and DNA 
sequencing amongst the kanamycin resistant clones (primer pair 6F/R).  
2.17 C. rodentium in vivo mouse model of infection 
Pathogen-free female 18-20 grams C57BL/6 mice or male/female Casp1/11-/-  
C57BL/6 mice were infected with the C. rodentium strains found in Table 2.1, as 
described previously (Raymond et al., 2011).  Mice were inoculated with WT C. 
rodentium, C. rodentium ΔnleF or the complemented C. rodentium ΔnleF 
pACYC184-nleFCR strain grown over-night in LB and re-suspended in PBS at ~5 x 
109 CFU. Stool samples were collected on the days indicated and CFU/g of stool 
was enumerated the next day retrospectively, by plating on LB agar with antibiotics. 
On the day indicated mice were culled and segments of the colon were extracted for 
analysis as described below. A minimum of 5 C57BL/6 mice per group were used 
per independent repeat. For C57BL/6 Casp1/11-/- a minmum of 2 mice per group 
were used per independent repeat with a final n= 8 and n=6 for WT ICC169 and C. 
rodentium ∆nleF infections, respectively. Procedures were approved by the local 
Ethical Review Committee and were performed in accordance with the Animals 
Scientific Procedures Act (1986).  
2.18 Sample collection and FACs analysis 
Four cm segments of the terminal colons were cut, opened longitudinally and rinsed 
in sterile PBS and placed in 4ml of RPMI-1640 supplemented with 10% FBS, P/S, 
GlutaMAX, DNase (Roche, 10104159001) and liberase (Roche, 540112001) in a C-
Mac tube (Miltenyi Biotec) followed by tissue dissociation using gentleMACS 
dissociator (Miltenyi Biotec). First, the tissue was homogenized using ‘intestine’ 
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setting followed by incubation at 37°C, 5% CO2 for 30 min in a shaking incubator 
and then a final dissociation step was performed using ‘Lung 2’ setting on the 
gentleMACS dissociator. The digested preparation was disrupted to a single cell 
suspension by passage through a 70 μm sieve (BD labware/ falcon, USA Cat. No: 
352350) and re-suspended in RPMI-1640 supplemented with 10% FBS and P/S at 
0.5-1x106 cells/ml.  
 
Cells were stained for surface markers as indicated in the text in PBS containing 1% 
BSA with 0.5% sodium azide (PBA) for 30 min at 4°C and fixed with IC fixation buffer 
(eBioscience). Prior to primary antibody staining, all cells were blocked for Fc 
receptors (FcR) using mouse FcR blocking reagent (Miltenyi biotec) for 10 min at 
4°C. Antibodies were purchased from BD Pharmingen or eBio-science. Data 
acquired on a BD Fortessa III and 20,000 lymphocytes or myeloid events were 
analysed with the FlowJO (Tress star) analysis programme. Data is shown as a 
percentage of myeloid or lymphocyte gates. Myeloid and lymphocyte gates are 
determined by their position on the forward and scatter plots generated by the 
cytometer. Fluorescence minus one (FMO) control was included for each fluorescent 
marker; the expression of a particular marker was calculated by subtracting FMO 
fluorescence values from fluorescent antibody levels.  
2.19 Ex-vivo ex-plants  
After 4 cm of a colon was cut for flow cytometry analysis, the next 1cm from the 
same mouse was cut for ex vivo organ culture. The colon section was washed with 
PBS, weighed (the average weight of this particular section of the colon was not 
significantly different throughout experimental groups) and incubated in 400 μl of 
83 
 
RPMI containing P/S, gentamicin and FBS at 37°C for 24 h. Concentrations of IL-18 
(eBioscience) and KC (CXCL1, R&D systems) were measured as described above.  
2.20 Statistical analysis 
All in vitro data was analysed by using the non-parametric Kruskal-Wallis test and 
post-hoc Dunns multiple comparison test of all columns using the GraphPad Prism 5 
software and represented as the mean +/- standard deviation, unless stated 
otherwise. A P value less than 0.05 (P<0.05) was considered significant. All in vivo 
data was analysed using the non-parametric Mann Whitney test using the GraphPad 
Prism 5 software and represented as the average +/- standard error, unless stated 
otherwise. A P value less than 0.05 (P<0.05) was considered significant.  
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Kanr, Kanamycin resistance 50 µg.ml; Cmr, Chloramphenicol resistance 10 µg.ml; 
Nalr, Nalidixic acid.    
Table 2 1 Bacterial strains used in this study. 
Strains Description Source 
ICC481 EPEC O127:H6 strain E2348/69 (Levine et al., 1978) 
ICC1082 EPEC O127:H6 strain E2348/69 ΔnleF, Kanr This study 
ICC192 EPEC O127:H6 strain E2348/69 ΔescN, Kanr (Garmendia et al., 2004) 
ICC1063 EPEC O127:H6 strain E2348/69 ΔPP4/IE6, Cmr, Kanr (Pearson et al., 2011) 
- BL21 Star Invitrogen  
- Y187, Saccharomyces cerevisiae Clontech 
- AH109, Saccharomyces cerevisiae Clontech 
ICC169 Citrobacter rodentium, Nalr (Schauer & Falkow, 1993)  
- Citrobacter rodentium, Nalr, Kanr This study  
- STBL2 Invitrogen 
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Table 2 2 Plasmids and Primers used for cloning in this study.  
Plasmids  Description Source 
pACYC184 E. coli plasmid cloning vector containing the p15A origin of replication, Cmr NEB 
pACYC184-
derivative 
Expressed 
protein 
Primers 5’3’ RS - 
- NleFE69 TTTGATATCAAGAAGGAGATATACCTACGTAATGTTACCAACAA
GTGGTTCTTCAGC 
TGCAGGATCCTCATCCACATTGTAAAGATCCTTTGTT 
EcoRV 
BamHI 
This study 
- NleFCR TTTGATATCAAGAAGGAGATATACCTACGTAATGTTTGGTATGTT
ACCAGCTAGTAG 
TGCAGGATCCCTATCCAATTTGCAAAGATCCTTTGT 
EcoRV 
BamHI 
This study 
pBAD22 pBAD-Arabinose inducible bacterial expression vector; Ampr (Guzman et al., 
1995) 
pBAD22-
derivative 
Expressed 
protein 
Primers 5’3’ RS  
pICC1667 NleFE69 CCGCCGGGAATTCATGTTACCAACAAGTGGTTCTTCAGA 
TGCAGGATCCTCATCCACATTGTAAAGATCCTTTGTT 
EcoRI 
PstI 
This study 
pKD4 Plasmid backbone containing Kanr template (Datsenko & 
Wanner, 2000) 
pET28a(+) Bacterial expression vector with T7 lac promoter; N-terminal 6x His tag with thrombin 
cleavage site or  C-terminal 6x His tag; Kanr 
Novagen 
pET28a(+)-
derivative 
Expressed 
protein 
Primers 5’3’ RS - 
pICC1659 His-NleFE69 CGCGGGATCCATGTTACCAACAAGTGGTTCTTCAGC 
AAATATGCGGCCGCTCATCCACATTGTAAAGATCCTTTGTT 
BamHI 
NotI 
This study 
pICC1672 His-NleFE69 
 
CGCCATATGTTACCAACAAGTGGTTCTTCAGC 
ATCTCGAGTTAAGATCCTTTGTTGTAAGTAAGAT 
NdeI 
XhoI 
This study 
pICC1660 His-NleFE69 
1-185 
CGCGGGATCCATGTTACCAACAAGTGGTTCTTCAGC 
ATTGCGGCCGCTTAAGATCCTTTGTTGTAAGTAAGAT 
BamHI 
NotI 
This study 
- His-NleFCR CGCGGGATCCATGTTTGGTATGTTACCAGCTAGTAG 
AAATATGCGGCCGCCTATCCAATTTGCAAAGATCCTTTGT 
BamHI 
NotI 
This study 
- His-NleFCR 
1-185 
CGCGGGATCCATGTTTGGTATGTTACCAGCTAGTAG 
ATTGCGGCCGCTTAAGATCCTTTGTTGTAAGTAAGAT 
BamHI 
NotI 
This study 
- His-
Caspase-4 
CGCGCGGATCCATGGCAGAAGGCAACCACAGAAA 
AAATATGCGGCCGCTCAATTGCCAGGAAAGAGGTAGAAAT 
BamHI 
NotI 
This study 
- His-
Caspase-
11 
CGCGCGGATCCATGGCTGAAAACAAACACCCTGAC 
AAATATGCGGCCGCCTCAGTTGCCAGGAAAGAGGTAG 
BamHI 
NotI 
This study 
- His-
Caspase-4 
C258S 
catcattgtccaggccTCCagaggtgcaaacc 
ggtttgcacctctGGAggcctggacaatgatg 
- This study 
- His-
Caspase-4 
p20 
CGCGGGATCCCAAATATCCCCCAATAAAAA 
AAATATGCGGCCGCCTAGTCTCTGACCCACAGTTCC 
BamHI 
NotI 
This study 
- His-
Caspase-4 
p10 
CGCGGGATCCGCTGTTTACAAGACCCACGT 
AAATATGCGGCCGCTCAATTGCCAGGAAAGAGGT 
 
BamHI 
NotI 
This study 
pGADT7 Plasmid for expression of proteins in yeast with a GAL4 activation domain fusion; N-
terminal HA tag; Ampr 
Clontech 
pGADT7-
derivative 
Expressed 
protein 
Primers 5’3’ RS - 
- DHFR CGCCATATGATGGTTGGTTCGCTAAACTGCATCG 
CGCGGGATCCTTAATCATTCTTCTCATATACTTCA  
NdeI 
BamHI 
This study 
- DHFRL1 GCCATATGATGTTTCTTTTGCTAAACTGCATCG       
CGCGGGATCCTTAATCATCCTTCTCACATACTTCA  
NdeI 
BamHI 
This study 
- TMP21 N/A N/A Schroeder, G.  
- GGCT ATATCCCGGGTTATGGCCAACTCGGGCTGCAAGGACGTC 
CCTAAAGAGTTTGTGTTTCCCCCTTTTTG 
XmaI 
XhoI 
This study 
- HBXIP GCCGGGAATTCATGGAGCCAGGTGCAGGTCACCT 
CGCGGGATCCTCAAGAGGCCATTTTGTGCACTG 
EcoRI 
BamHI 
This study 
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- HBXIP 
Y2H 
GCCGGGAATTCATGGCCTGTGGTGGAGAAGGA 
CGCGGGATCCTCAAGAGGCCATTTTGTGCACTG 
EcoRI 
BamHI 
This study 
- HBXIP 
short 
isoform 
GCCGGGAATTCATGGAGGCGACCTTGGAGCA 
CGCGGGATCCTCAAGAGGCCATTTTGTGCACTG 
EcoRI 
BamHI 
This study 
- Caspase-5 CGCGCGGATCCATATGTTCAAAGGTATCCTTCAGAGT 
ATCTCGAGTCAATTGCCAGGAAAGAGGTAGAAA 
BamHI 
XhoI 
This study 
- Caspase-
11 
GCCGGGAATTCATGGCTGAAAACAAACACCCTGAC 
CGCGGGATCCCTCAGTTGCCAGGAAAGAGGTAG 
EcoRI 
BamHI 
This study 
- Caspase-
12 
GCCGGGAATTCATGGCGGCCAGGAGGACACATGAAAG 
CGCGGGATCCTGCTAATTCCCGGGAAAAAGGTAGAA 
EcoRI 
BamHI 
This study 
- Caspase-4 ATATCCCGGGTATGGCAGAAGGCAACCACAGAAA 
CGCGGGATCCTCAATTGCCAGGAAAGAGGTAGAAATATC 
XmaI 
BamHI 
This study 
- Caspase-4 
P30 
ATATCCCGGGTCAAATATCCCCAATAAAAA 
CGCGGGATCCTCAATTGCCAGGAAAGAGGTAGAAATATC 
XmaI 
BamHI 
This study 
- Caspase-4 
P20 
ATATCCCGGGTCAAATATCCCCAATAAAAA 
CGCGGGATCCCTAGTCTCTGACCCACAGTTCC    
XmaI 
BamHI 
This study 
- Caspase-4 
P10 
ATATCCCGGGT GCTGTTTACAAGACCCACGT 
CGCGGGATCCTCAATTGCCAGGAAAGAGGTAGAAATATC 
XmaI 
BamHI 
This study 
pGADT7-
caspase-4 P30 
derivative 
Expressed 
protein 
Primers 5’3’ RS This study 
- Caspase-4 
P30 
R159A 
GAATGGAGCTGACTTTGACATCA 
gcCGGAGGCAGATGGTCAAACTC 
N/A This study 
- Caspase-4 
P30 
H237A  
TGGCATCCTGGAGGGAATCTGCG 
gcAGACATGAGTACCAAGAATG 
N/A This study 
- Caspase-4 
P30 
W313A 
GAGAGACAGCACAATGGGCTCT 
gcGGACACGTTGTGTGGCGTTGA                 
N/A This study 
- Caspase-4 
P30 
R314A 
AGACAGCACAATGGGCTCTATC 
gcCCAGGACACGTTGTGTGGCG 
N/A This study 
pGBT9 Plasmid for expression of proteins in yeast with a GAL4 binding domain fusion; Ampr Clontech 
pGBT9-derivative Expressed 
protein 
Primers 5’3’ RS  
pICC1664 NleFE69 CGCGGATCCCGATGTTACCAACAAGTGGTTCTTCAGCAA 
AAAACTGCAGTCATCCACATTGTAAAGATCCTTTGTT 
BamHI 
PstI 
This study 
pICC1666 NleFE69 1-
185 
CGCGGATCCCGATGTTACCAACAAGTGGTTCTTCAGCAA 
CTGCACTGCAGTTAAGATCCTTTGTTGTAAGTAAGAT 
BamHI 
PstI 
This study 
pICC1669 NleFCR CGCGGATCCCGATGTTTGGTATGTTACCAGCTAGTAG 
AAAACTGCAGCTATCCAATTTGCAAAGATCCTTTGT 
BamHI 
PstI 
This study  
pGKBT7 Plasmid for expression of proteins in yeast with a GAL4 activation domain fusion; N-
terminal Myc tag; Ampr; Kanr 
Clontech 
pGKBT7-
derivative 
Expressed 
protein 
Primers 5’3’ RS  
pICC1665 NleFE69  CGCGGATCCCGATGTTACCAACAAGTGGTTCTTCAGCAA 
AAAACTGCAGTCATCCACATTGTAAAGATCCTTTGTT 
BamHI 
PstI 
This study 
pKD46  Codes for lambda-red recombinase; Ampr (Datsenko & 
Wanner, 2000) 
pSA10 pKK177-3 derivative containing lacI, IPTG inducible;  Ampr (Schlosser-
Silverman et 
al., 2000.) 
pSA10-derivative Expressed 
protein 
Primers 5’3’ RS  
pSA10-nleE NleE1E69 N/A N/A (Vossenkämpe
r et al., 2010) 
pRK5:myc Vector for the expression of proteins with N-terminal Myc tag in mammalian cells Clontech 
pRK5:myc-
derivative 
Expressed 
protein 
Primers 5’3’ RS - 
pICC1661 Myc-
NleFE69 
CGCGCGGATCCATGTTACCAACAAGTGGTTCTTCAG 
TGCACTGCAGATCATCCACATTGTAAAGATCCTTTG 
BamHI 
PstI 
This study 
pGEM-T High copy cloning plasmid for with insertional inactivation of β-galactosidase; Ampr Promega 
pGEM-T Insert Primers 5’3’ RS  
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derivative 
- nleFCR  
flanks with 
Kan 
cassette 
CGCGGATCCGCTACTAGCTGGTAACATACC 
CGCGGATCCTCGTTGAAGGATGCAGTGATG 
BamHI 
BamHI 
This study  
pICC1662 Myc-
NleFE69 1-
185 
CGCGCGGATCCATGTTACCAACAAGTGGTTCTTCAG 
CTGCACTGCAGTTAAGATCCTTTGTTGTAAGTAAGAT 
BamHI 
PstI 
This study 
pICC563 Myc-GFP N/A N/A (Clements et 
al., 2011) 
 Myc-
NleFCR 
CGCGGGATCCATGTTTGGTATGTTACCAGCTAGTAG 
TGCACTGCAGTTAAGATCCTTTGTTGTAAGTAAGAT 
BamHI 
PstI 
This study  
pRK5:ha Vector for the expression of proteins with N-terminal HA tag in mammalian cells under 
the CMV promoter 
Clontech 
pRK5:ha-
derivative 
Expressed 
protein 
Primers 5’3’ RS  
- HA-TMP21 N/A N/A Schroeder, G. 
- HA-Cherry N/A N/A Frankel  
TOPO Blunt II Parental plasmid for TOPO cloning of blunt-end PCR products; Kanr Invitrogen 
TOPO Blunt II 
derivative 
Insert Primers 5’3’  
- nleFE69 
with flanks 
GATATGGAAGATACAACAAAAGTGTT 
ACAGAAGAGGCAGGCCAGCA 
This study  
pICC1674 nleFE69 
flanks with 
Kan 
cassette 
TTAGAGGCCTGTGAGCCTGT  
ATCAAAACCCCCTTAACAAATAAATC 
TTAGAGGCCTGTGAGCCTGT 
ATCAAAACCCCCTTAACAAATAAATC 
This study  
pACYC-Duet-1 IPTG inducible bi-directional bacterial expression vector, Cmr Novagen 
pACYC-DUET-1 
derivative 
Expressed 
protein 
Primers 5’3’ RS  
- Caspase-4 
P10 
CCGGATATCGGCTGTTTACAAGACCCACGTGGAG 
ATCTCGAGTCAATTGCCAGGAAAGAGGTAGAAA 
EcoRV 
XhoI 
This study 
- Caspase-4 
His-P20 
C258S 
/P10 
CGCGGGATCCGCAAATATCCCCCAATAAAAA 
AAATATGCGGCCGCCTAGTCTCTGACCCACAGTTCC 
BamHI 
NotI 
This study 
pMAL-c2x Bacterial expression vector for expression and purification of desired proteins with an 
N-terminal maltose binding protein (MBP) tag, Ampr 
NEB 
pMAL-c2x-
derivative 
Expressed 
protein 
Primers 5’3’ RS - 
 MBP-
NleFE69 
CCGCCGGGAATTCATGTTACCAACAAGTGGTTCTTCAGC 
AAAACTGCAGTCATCCACATTGTAAAGATCCTTTGTT 
EcoRI 
PstI 
This study  
 MBP-
NleFE69 1-
185 
CCGCCGGGAATTCATGTTACCAACAAGTGGTTCTTCAGC 
CTGCACTGCAGTTAAGATCCTTTGTTGTAAGTAAGAT 
EcoRI 
PstI 
This study  
pMXs-IRES-
Puro 
Retroviral plasmid for viral package signal, transcription and processing, puromycin 
selectable, Ampr 
Invitrogen 
pMXs-IRES-
Puro-derivative 
Expressed 
protein 
Primers 5’3’ RS  
pICC1646 Caspase-4 CGCGCGGATCCATGGCAGAAGGCAACCACAGAAA 
ATCTCGAGTCAATTGCCAGGAAAGAGGTAGAAA 
BamHI 
XhoI 
This study 
- Caspase-5 CGCGCGGATCCATGTTCAAAGGTATCCTTCAGAGT 
ATCTCGAGTCAATTGCCAGGAAAGAGGTAGAAA 
BamHI 
XhoI 
This study 
- Caspase-
11 
CGCGCGGATCCATGGCTGAAACAAACACCCTGAC 
ATCTCGAGTCAGTTGCCAGGAAAGAGGTAG 
BamHI 
XhoI 
This study 
- Myc-
NleFE69 
CGCGCAATTGGCCGCCACCATGGAGCAGAAGCTG 
TGCAGGATCCTCATCCACATTGTAAAGATCCTTTGTT 
MfeI 
BamHI 
This study 
- Myc-
NleFE69 1-
185 
CGCGCAATTGGCCGCCACCATGGAGCAGAAGCTG 
TGCAGGATCCTTAAGATCCTTTGTTGTAAGTAAGAT 
MfeI 
BamHI 
This study 
- YFP N/A N/A Shenoy, A. 
pMXs-CMV-yfp 
derivative 
Expressed 
protein 
Primers 5’3’ RS Shenoy, A. 
- YFP 
miR30 
ctgaaacataaaatgaatgctcgAGAAGGTATATTGCTGTTGACAGTGA
GCGCcgactgtccatgacaagatattagtgaagccacagat 
MfeI 
 
This study 
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CASP4 aagatattagtgaagccacagatgtaatatcttgtcatggacagtcgTTGCCTACTGC
CTCGGACTTCAAGaattgttgttgttaacttgcaa 
- YFP 
miR30 lacZ 
non-
targeting 
control 
AATTGTTGTTGTTAACTTGCtcgagaaggtatattgctgttgacagtgagcgA
CGTCGTATTACAACGTCGTGAtagtgaagccacagat 
TTATTTGTAACCATTATAActtgaagtccgaggcagtaggcaACGTCGTA
TTACAACGTCGTGAtacatctgtggcttcactaTCACGAC 
PsiI This study 
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Table 2 3 cDNA and templates used in this study. 
pICC Plasmid backbone and cDNA template  Source 
pICC1653 pMD-CASP5 Open Biosystems 
pICC1651 pDNR-LIB-CASP4 Open Biosystems 
pICC1650 pDNR-LIB-Casp11 Open Biosystems 
- pENTR221-DHFR Parle-McDermott, A. 
- pDEST17-DHFRL1 Parle-McDermott, A. 
- pOBT7-GGCT  Open Biosystems 
- pHBXIP Garcia-Saez, I. 
pICC893 pKD4-Kanamycin cassette (Datsenko & Wanner, 2000) 
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Primer Sequence Assay/amplicon  
1F 
1R 
GATATGGAAGATACAACAAAAGTGTT 
ACAGAAGAGGCAGGCCAGCA 
Mutagenesis amplicon 
Mutagenesis amplicon 
pKD4F 
pKD4R 
TGTGTAGGCTGGAGCTGCTTC   
CATATGAATATCCTCCTTAGTTCC 
Kanamycin cassette 
Kanamycin cassette 
3F 
3R 
GTAAAGGTGGTAATGCTGTCGT 
GAAGGAATACAAAGCCGTCAC 
Mutagenesis screening 
Mutagenesis screening 
AD-LD-F 
AD-LD-R 
CTATTCGATGATGAAGATACCCCACCAAACCC 
GTGAACTTGCGGGGTTTTTCAGTATCTACGATT 
Y2H screening primers 
shRNAF TGTACAAGTCCGGACTCAGATGATCGACTTCTTAACCCAACAGAAGGCTC
GAGAAGGTATATTGCTG 
shRNA amplicon 
shRNAR GCGGCCGCGGCGCGCCGGCCGAATTCTAGCCCCTTGAAGTCCGAGGCA
GTAGG 
shRNA amplicon 
IL-8F 
IL-8R 
AGAAACCACCGGAAGGAACCATCT  
AGAGCTGCAGAAATCAGGAAGGCT 
RT-qPCR 
RT-qPCR 
GAPDHF 
GAPDHR 
TCGACAGTCAGCCGCATCTTCTTT  
ACCAAATCCGTTGACTCCGACCTT 
RT-qPCR 
RT-qPCR 
CASP4F 
CASP4R 
GCAGACTCTATGCAAGAGAAG 
TGGTCCAGCCTCCATATT 
RT-qPCR 
RT-qPCR 
CASP8F 
CASP8R 
GGATGGCCACTGTGAATAA 
CAGTCAGGATGGTGAGAATATC 
RT-qPCR 
RT-qPCR 
CASP9F 
CASP9R 
GTGCTCTTGAGAGTTTGAGG 
ACAGCCGTGAGAGAGAAT 
RT-qPCR 
RT-qPCR 
4F TTCAGTCATTACCAACACAGG Mutagenesis amplicon 
4R TTCCTATGTGGTGAATTGCG Mutagenesis amplicon 
5F 
6F 
CGCGGATCCGCTACTAGCTGGTAACATACC 
CGCGGATCCTCGTTGAAGGATGCAGTGATG 
Inverse PCR 
Inverse PCR 
7F ATATATGATGCCAATGGCGAT Mutagenesis screening 
7R GACTAGCATTAACACTCATGC Mutagenesis screening 
Table 2 4 Primers used for mutagenesis and RT-qPCR in this study. 
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Results: Chapter 3 - Identification and confirmation  
of host interacting partners   
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3.1 A Y2H screen identifies caspase-4 as an interacting partner of NleFE69 
In order to determine the function of EPEC E2349/69 NleF (NleFE69) a yeast-2-hybrid 
(Y2H) screen was carried out to identify putative host binding partners. A Y2H 
screen utilises the GAL4 promoter to identify interacting proteins of a chosen bait 
protein from a HeLa cell cDNA prey library. The bait protein is expressed in pGKBT7 
or pGBT9 along with an N-terminal GAL4 binding domain in Saccharomyces 
cerevisiae AH109; this is then mated with Saccharomyces cerevisiae Y187 pre-
transformed with pGADT7 containing the library of prey proteins with a GAL4 
activation domain. Interaction of the bait with a prey protein, through diploid 
formation (AH109 meeting with Y187), will result in the GAL4 DNA binding domain 
and activation domain being brought into close proximity. This in turn activates 
transcription of four reporter genes (ADE2, HIS3, MEL1, and lacZ). Transcription of 
the reporter genes ADE2 and HIS3 results in the expression of the essential amino 
acids adenine (Ade) and histidine (His), respectively. Transcription of MEL1 and lacZ 
results in the expression of α-galactosidase and β-galactosidase, respectively. The 
bait plasmids pGKBT7/pGBT9 and prey plasmid pGADT7 further confer selectivity 
through the expression of tryptophan (Trp) and leucine (Leu), respectively. This 
allows for the screening of clones expressing proteins that interact by plating on the 
selective yeast media SD SDO (-Trp), DDO (-Leu and –Trp), TDO (-Ade, -His,- Leu) 
and QDO (-Trp, -Leu, -Ade and –His), while supplementation of the media with X-α-
Gal and activation of the reporter gene MEL1 results in the secretion of α-
galactosidase which in turn reacts with the chromogenic substrate, causing a blue 
colouration of a positive colony.  
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Expression of NleFE69 in AH109 had no effect on cell growth kinetics and no auto-
activity (ability to grow on DDO/TDO/QDO; data not shown). Screening of NleFE69, 
with a mating efficiency of 52.1%, resulted in 320 positive clones. Multiple re-
streaking of positive clones on selective QDO X-α-Gal media reduced the number of 
positive clones to 149. All colonies were checked by colony PCR to verify the 
presence of pGADT7 and an insert by using the primers AD-LD-F/R shown in Table 
2.4 and sent for sequencing. The Y2H screen identified 18 unique hits of which there 
were multiple clones for COP9 constitutive photomorphogenic homolog subunit 5 
(COPS5) and 21 hits for caspase-4 (Table 3.1).  
Table 3 1: A Y2H screen for NleFE69 identifies caspase-4 as a putative host 
target. FP; false positive, UT; untested 
Hit Gene ID No.  Interaction by YDH 
COP9 constitutive photomorphogenic homolog subunit 5 (COPS5) 10987 COPS5 35  FP 
CASP4  837 CASP4 21  Yes  
Microtubule associated protein 4 4134 MAP4 2  UT 
Cell Division cyclin kinase-7 8317 CDC7 1  UT 
Dynactin subunit 2 10671 DCTN1 1  UT 
Cytokine induced apoptosis inhibitor 1 57019 CIAPIN1 1  UT 
Vesicle transport protein USE1 55850 USE1 1  UT 
ATPase family AAA domain containing 5 79915 ATAD5 1  UT 
Metal response element binding transcription factor 2 22823 MTF2 1  UT 
WW domain binding protein 11  51729 WBP11 1  UT 
Vacuole membrane protein 1 81671 VMP1 1  UT 
CG1-130  51020 HDDC2 1  UT 
Methylmalone aciduria and homocystinuria type D protein  27249 MMADHC 1  UT 
Hepatitis B virus X-interacting protein 457120 HBXIP 1  FP 
Transforming growth factor B 84897 TBRG1 1  UT 
Cleavage and Polyadenylation specific factor 2, 100 KDa 53981 CPSF2 1  UT 
Gamma-glutamylcyclotransferase 79017 GGCT 1  FP  
IMPACT (Imprinted and ancient gene protein homolog) 55364 IMPACT 1  UT 
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COPS5 is the mostly highly cited false positive for the Clontech Y2H screen and was 
therefore dismissed. To verify caspase-4 as a true hit the full length cDNA of CASP4 
isoform gamma was cloned into pGADT7. Co-transformation of AH109 with an 
empty plasmid as a negative control or with pGADT7-CASP4 and plating on DDO or 
the selective QDO media confirmed caspase-4 as a true interacting partner of 
NleFE69 in the yeast-direct-hybrid (YDH) system (Fig. 3.1A) 
 
 
 
3.2  NleFE69 specifically interacts with caspase-4  
Caspase-4 is an inflammatory caspase that controls ER stress induced apoptosis 
and may be required for activation of the non-canonical inflammasome (Shi et al., 
2014; Hitomi et al., 2004). Caspase-4 shares significant amino acid sequence 
similarity with the inflammatory caspase caspase-5; which are both putative 
functional orthologs of murine caspase-11 (Fig. 3.2A). Due to the lack of commercial 
CASP5 cDNA the templates for CASP5 were amplified directly from HeLa and THP-
1 cDNA pools. The caspase-5 transcript present in both is a previously described 
isoform of caspase-5 that is annotated as an N-terminally truncated form of the 
Figure 3 1: NleFE6 interacts with full length caspase-4. (A) A Yeast-direct-hybrid 
assay co-transforming AH109 with full length NleFE69 (pGBT9-nleFE69) and caspase-
4 isoform-γ (pGADT7-CASP4). Results are representative of at least three biological 
repeats.   
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canonical isoform alpha (Fig. 3.2B) (Munday et al., 1995). This HeLa isoform was 
used throughout further studies. AH109 were co-transformed with pGBT9::nleFE69 
and pGADT7::CASP5 or pGADT7::CASP4 and plated on DDO and QDO to 
determine if NleFE69 specifically interacts with caspase-4. NleFE69 specifically 
interacted with caspase-4 and not caspase-5 in the YDH system (Fig. 3.2C).  
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Figure 3 2 Caspase-5 shares significant homology with caspase-4 but does not 
interact with NleFE69. (A) Clustal W2 multi-alignment of murine caspase-11, caspase-
4γ and caspase-5α/f. (B) Alignment of CASP5α and CASP5 amplified from HeLa 
cDNA. (C) A Yeast-direct-Hybrid assay co-transforming AH109 with full length NleFE69
(pGBT9-nleFE69) and caspase-4 isoform-γ (pGADT7-CASP4) or caspase-5 from HeLa
cDNA (pGADT7-CASP5). Results are representative of three biological repeats.  
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3.3  NleFE69 interacts with active caspase-4 dependent on its’ C-terminal motif 
LQCG 
Caspase-4, as a zymogen, contains a p22 CARD domain which is subsequently 
cleaved to release its active (p30) form (Fig 3.3A). NleFE69 was determined to 
interact with both full length and the p30 domain of caspase-4 by YDH, suggesting it 
may inhibit substrate binding/protease activity directly (Fig. 3.3B). The p20 domain 
was auto-active and therefore interaction of p20 and NleFE69 alone could not be 
confirmed, although p10 alone was not sufficient to confer binding (Fig. 3.3B). 
Blasche and colleagues previously showed that NleFE69 interacts with active 
caspase-9 through direct interaction of the caspase-9 substrate domain and the four 
C-terminal amino acids (LQCG) of NleFE69 (Blasche et al., 2013). To investigate if 
interaction of NleFE69 and caspase-4 is dependent on the C-terminal of NleFE69 the 
YDH was repeated using an NleFE69 mutant with the four C-terminal amino acids 
deleted (NleF1-185 E69). Deletion of the four C-terminal amino acids, or mutation of the 
amino acids of the putative substrate binding domain W313, R314 or R152 of 
caspase-4, abolished interaction in the YDH system (Fig. 3.3B-C). Alternatively 
mutation of the putative substrate binding domain amino acid H237 had no effect on 
binding (Fig. 3.3C). The putative substrate binding domain and active site of 
caspase-4 is formed of both the p20 and p10 subunits. Single mutations in either the 
p10 subunit (W313A or R314A) or the p20 subunit (R152A) suggested that the 
interaction of caspase-4 and NleFE69 required both the p20 and p10 subunits (Fig. 
3.3C). NleF of C. rodentium (NleFCR) was auto-active in the YDH system and 
therefore could not be screened using this assay.  
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Figure 3 3: The C-terminal motif LQCG of NleFE69 interacts with active caspase-4. 
(A) Schematic of caspase-4 structural activation through domain cleavage and 
oligomerisation. A Yeast-direct-hybrid assay to access and map interaction of NleFE69 
and NleF1-185 E69 with (B) pro-caspase-4 and caspase-4 p30 and (C) caspase-4 p30 with 
single amino acid mutations of the putative caspase-4 substrate domain: R152A, H237A, 
W313A and R314A. Empty pGADT7 and pGBT9 were used as negative controls. 
Results are representative of at least three biological repeats. p30; caspase-4 p20 and 
P10 subunits and the inter-linker domain. 
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3.4  NleFE69 binds and inhibits the catalytic activity of caspase-4/11  
Through the YDH assay NleFE69 was shown to bind to the p30 domain of caspase-4 
suggesting it may inhibit protease activity. To determine if NleFE69 binding to 
caspase-4 inhibits its proteolytic activity; first, an activity assay was developed. 
Recently it was shown that upon binding to LPS full length caspase-4, and the 
murine ortholog caspase-11, undergo self-proteolytic processing, oligomerisation 
and activation (Shi et al., 2014). Activation of each caspase was determined using a 
fluorogenic caspase substrate that upon cleavage can be detected by fluorescence 
emission at a determined wave length. The principle of self-activation in the 
presence of LPS was employed to design an in house caspase activity assay for 
both caspase-4 and -11.  
3.4.1 Developing a caspase-4/-11 activity assay 
Full length caspase-4 and caspase-11 were cloned into the IPTG inducible bacterial 
expression plasmid pET28a(+) and expressed in BL21 Star and analysed by 
immunoblotting. Expression and bacterial lysis was sufficient to induce self-
proteolytic cleavage of both caspase-4 and caspase-11, as evidenced by the 
presence of the p20 cleavage product (Fig. 3.4A-B). As a control a protease dead 
caspase-4 mutant (C258S) was expressed in BL21 Star. Mutation of the active site 
cysteine prevented cleavage of caspase-4 suggesting that the cleavage products 
observed were not a result of degradation or bacterial proteases. The carboxy-
peptidase substrate LEVD is a known substrate and inhibitor of the in vitro activity of 
caspase-4. Caspase-4/-11 bacterial lysates were incubated with LEVD with a 
fluorogenic 7-amino-4-trifluoromethylcoumarin tag (LEVD-AFC). Enzymatic cleavage 
of the fluorogenic substrate releases AFC switching from an emission wavelength of 
400 nm to 495-505 nm. This can be used to detect enzymatic and caspase activity. 
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Addition of LEVD-AFC to both caspase-4 and caspase-11 bacterial lysates resulted 
in specific cleavage of LEVD-AFC as observed by the increase in relative fluorescent 
units (Fig. 3.4B). No LEVD specific proteolytic activity was observed for BL21 over-
expressing caspase-4 C258S or with BL21 lysate alone (Fig. 3.4A).  
  
Figure 3 4 Caspase-4/-11 undergoes self-proteolytic cleavage and oligomerisation 
to cleave the fluorescent substrate LEVD-AFC. An activity assay using the caspase-4 
substrate reporter Ac-LEVD-AFC was constructed using lysate of BL21 expressing (A) 
pro-caspase-4 or (B) pro-caspase-11. Caspase-4 C258S and BL21 lysate were used as 
negative controls. Self proteolytic activation was determined by western blot. Results are 
an average of three independent experiments in duplicate. RFU; relative fluorescent 
units 
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3.4.2 Purification of NleFE69 for in vitro activity assays 
To determine if NleFE69 functions to inhibit the catalytic activity of caspase-4/-11; 
NleFE69, NleF1-185 E69 and NleFCR were cloned into the IPTG inducible bacterial 
expression plasmid pET28a(+) and expressed with an N-terminal His-tag in BL21 
Star. Initially expression of NleF for purification was optimised for BL21 star over-
expressing NleFE69.  Expression of NleFE69 was induced at a range of temperatures 
at 0.5 mM IPTG and analysed by SDS-PAGE gel and immunoblotting. Induction of 
protein expression was optimum at 18 ºC as indicated by the band present in the 
induced lanes for both the SDS-PAGE gel and Western blot at ~ 21 kDa (Fig 3.5A-
B).  
 
 
 
In all further experiments expression of NleFE69 and its homologs were carried out 
under these conditions. His-tagged proteins were purified by affinity tagged 
purification and further purified by gel filtration. Solubility and purity were analysed by 
SDS-PAGE gel (Fig. 3.6 A-C). His-tagged NleFE69, NleF1-185 E69 and NleFCR were 
Figure 3 5 Optimisation of IPTG induced expression of NleFE69 in BL21 Star. E. 
coli BL21 Star transformed with pET28a-nleFE69 were sub-cultured at 37 ºC until 
OD600 of 0.6 before inducing with 0.5 mM IPTG at either 37 ºC or 30 ºC for 3 h or 18 
ºC for 16 h. Bacterial pellets were re-suspended in LDS and analysed by SDS-PAGE 
gel or Western blot using anti-His-HRP as indicated in Material and methods. L, 
Ladder 
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highly soluble and stable upon lysis and purification (Fig. 3.6). Only the purist 
fractions from gel filtration were collected. These were concentrated and stored at -
80 ºC for use in further assays. 
 
 
 
 
 
Figure 3 6 Purification of NleF homologs of A/E pathogens. Induced E. coli BL21
Star transformed with (A) pET28a-nleFE69, (B) pET28a-nleF1-185 or (C) pET28a-nleFCR
were lysed by Emulsiflex and purified by His-tagged affinity purification and gel 
filtration. Fractions were analysed by SDS-PAGE gel. UV peaks from gel filtration 
were run to test presence and purity of  NleF ~22-23 kDa. L, Ladder; -, un-induced; +, 
induced; I, insoluble; S, soluble; FT, flow-through; W, wash; E, elution; F, Gel filtration 
fraction.  
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3.4.3 NleF of A/E pathogens inhibit the activity of caspase-4/-11 
Caspase-4/-11 activity assays were repeated as above with the addition of purified 
NleFE69, NleF1-185 E69 and NleFCR at a concentration range of 1 pM to 50 nM. Addition 
of recombinant NleFE69 efficiently inhibited the rate of activity of caspase-4 in a dose-
dependent manner with an IC50 of 5 nM; NleF1-185 E69 required a significantly higher 
inhibitory concentration with an IC50 of 25.2 nM (Fig. 3.7A).  
 
Figure 3 7 NleF inhibits caspase-4 and -11 activity in vitro. (A) Dose dependent 
inhibition of caspase-4 activity with recombinant purified NleFE69 or NleF1-185 E69 (B) 
Comparison of caspase-4 activity upon the addition of NleFE69 or NleFCR at 1 nM. (C) 
Dose dependent inhibition of caspase-11 activity with recombinant purified NleFCR. 
(D) Comparison of caspase-11 activity upon the addition of NleFE69 or NleFCR at 50 
nM.. Purity was analysed by SDS-PAGE gel and fluorescence was measured at 30 
min. Representative of at least three biological repeats in duplicate. 
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This confirmed that NleFE69 directly interacts with the active form of caspase-4 via its 
C-terminal motif LQCG to inhibit in vitro caspase protease activity. Infection of 
immortalised mouse macrophages (iMM) with the mouse restricted A/E pathogen C. 
rodentium activates caspase-11, the putative functional ortholog to human caspase-
4, leading to activation of the non-canonical inflammasome (Kayagaki et al., 2011). 
Therefore we tested the ability of NleFCR, which shares 84% amino acid sequence 
identity with NleFE69, to inhibit the protease activity of caspase-11. Addition of 
recombinant NleFCR successfully inhibited the activity of caspase-11 and cleavage of 
LEVD-AFC in a dose-dependent manner with an IC50 of 13 nM (Fig. 3.7C). 
Interestingly NleFE69 inhibited caspase-4 activity more efficiently that NleFCR and vice 
versa for caspase-11 (Fig. 3.7 B and D), suggesting a host specific adaption. While 
this demonstrated a conserved function of the NleF homologs to inhibit the activity of 
caspase-4/-11, the mechanism of inhibition remains unknown.  
3.5  Preliminary data suggests NleFE69 forms a complex with the active 
caspase-4 hetero-tetramer 
OspC3, a T3SS effector of the bacterial pathogen Shigella spp., is delivered during 
infection of epithelial cells to inhibit the activity of caspase-4 (Kobayashi et al., 2013). 
OspC3 binds to the p20 subunit of caspase-4 to prevent oligomerisation and 
formation of the heterotetramer and subsequent activation of the caspase 
(Kobayashi et al., 2013). The YDH data suggests that NleFE69 binding to caspase-4 
is dependent on residues present in both the p20 and p10 subunits. Due to the 
insolubility of the recombinant caspase-4 p10 subunit the binding of the individual 
domains and NleFE69 could not be tested directly. To determine if NleFE69 forms a 
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complex with the heterotetramer to prevent activity/ oligomerisation, recombinant 
NleFE69 was co-expressed and co-purified with caspase-4 p20 and p10.  
3.5.1 Co-purification of active caspase-4 and NleFE69 
To investigate if NleFE69 forms a complex with the active form of caspase-4 the 
expression vectors pMAL-c2x-nleFE69 and pACYC-DUET-1-CASP4 His-p20/p10 
were co-transformed into BL21 star and an MBP pull-down assay was carried out. 
The pMal-c2x empty and pACYC-DUET-1-CASP4 His-p20 plasmids were used as 
negative controls. The lysates were purified by amylose affinity chromatography and 
analysed by SDS-PAGE gel. Pull-down of His-p20 was dependent on the expression 
of both the p10 subunit and MBP-NleFE69 and did not co-purify with MBP or MBP-
NleFE69 alone (Fig. 3.8A). Although p10 was not detectable by SDS-PAGE gel (Fig. 
3.8A), this suggested that NleFE69 interaction requires both p20 and p10 subunits. To 
establish if NleFE69 forms a complex with the active form of caspase-4 the MB-
NleFE69/His-p20/p10 elution was further purified by Talon purification. Following 
tandem purification the elution was separated by size exclusion and the fractions 
were analysed by SDS-PAGE gel (Fig. 3.8B). Three chromatographic peaks were 
observed, which corresponded to free MBP-NleF69 (67 kDa), free His-p20 (31 kDa), 
and a complex containing NleFE69 and caspase-4 His-p20/p10 subunits (230 kDa), 
respectively. While no p10 was visible the molecular weight of the complex, 
predicted at 192 kDa, indicated that MBP-NleFE69 forms a complex with the hetero-
tetramer form of caspase-4. MBP is a large molecular weight tag that would interfere 
with any future structural determination work. For this reason the MBP tag was 
cleaved and size exclusion was repeated to remove cleaved MBP. Under these 
conditions a complex was formed that consisted of NleFE69, caspase-4 His-p20 and 
p10 as determined by SDS-PAGE gel and mass spectrometry (Fig. 3.8C). Due to 
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incomplete cleavage the complex varied from 100-200 kDa depending on whether 
none, two or one of the MBP subunits had been removed. While this promisingly 
suggested that NleFE69 forms a complex with the active form of caspase-4, which 
requires both p20 and p10, the final yield under these conditions was too low to 
pursue further structural studies and requires optimisation.   
Figure 3 8 Recombinant NleFE69 forms a complex with the active caspase-4 
complex. (A) BL21 star co-transformed with either pMal-c2x-nleFE69 or the empty 
vector along with pACYC-DUET-1-CASP4 His-p20 or pACYC-DUET-1-CASP4 His-
p20/p10 were induced as described in materials and methods and purified by affinity 
chromatography. Elution for each sample was analysed by SDS-PAGE gel. (B) 
Amylose affinity chromatography elution was further purified by Talon affinity 
chromatography and size exclusion. Size exclusion fractions were analysed by SDS-
PAGE gel. Peak sizes were determined using a Gel filtration molecular weight 
markers kit as described in materials and methods (C) Following size exclusion the 
co elute was Factor Xa treated and samples were analysed by size exclusion.  
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3.6  Discussion 
Through a Y2H screen caspase-4 was identified as a binding partner of NleFE69. This 
interaction was further confirmed by, and mapped to the putative substrate binding 
domain of caspase-4 and the C-terminal four amino acids of NleFE69. However, Y2H 
and YDH assays have their limitations. Each protein is tagged with a large N-
terminal domain and interaction/ activation of reporter genes requires nuclear 
subcellular localisation. For this reason some interactions, which may not be 
optimum in the conditions of the nuclear compartment, cannot be detected via this 
method or may be false. Caspase-4 along with caspase-8 and caspase-9 were 
identified to bind NleFE69 through the same C-terminal dependent interaction by 
Blasche and colleagues. Interaction was confirmed by luciferase pull-down assay 
further validating that NleFE69 binds caspase-4 (Blasche et al., 2013). While blasche 
and colleagues also identified both caspase-8 and -9, NleFE69 was not observed to 
play a significant role in cell death inhibtion during infection (Blasche et al., 2013). 
Therefore we pursued caspase-4 as a putative partner.  
Through the construction of a caspase activity assay NleFE69 was identified to inhibit 
the proteolytic activity of caspase-4. Furthermore the recombinant C. rodentium 
homolog of NleF was observed to inhibit the activity of the murine ortholog, caspase-
11, in a dose dependent-manner. This observation suggested that NleF homologs 
have a conserved function; to bind and inhibit inflammatory caspase activity. NleFE69 
shares significantly high homology with NleF of C. rodentium, sharing a highly 
conserved C-terminal domain. Deletion of the C-terminal motif LQCG significantly 
abrogated the ability of NleFE69 to inhibit the in vitro activity of caspase-4. 
Interestingly, the four C-terminal amino acid domain of NleFCR differs to that of 
NleFE69 by a single substitution (C188I). This substitution may be a selective and 
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adaptive advantage for the host specific inhibition of caspase-4 or caspase-11 by 
NleFE69 and NleFCR, respectively. In support of this NleFE69 was unable to inhibit 
caspase-11 activity in vitro as efficiently as NleFCR and vice versa for caspase-4.The 
four C-terminal amino acids of NleFE69 LQCG and the four C-terminal amino acids of 
NleFCR LQIG may represent novel peptides and candidates for the synthetic peptide 
fluoromethylketone caspase inhibitors. Although whether the four amino acid 
peptides alone are sufficient to inhibit caspase activity requires testing.  
Enteric pathogens have been previously reported to inhibit caspase activity in a 
T3SS-dependent manner; including caspase-4. Although, this is the first 
EPEC/EHEC effector identified to do so. The Shigella spp. effector OspC3 binds the 
p20 subunit of caspase-4 to inhibit oligomerisation and functional/structural activation 
(Kobayashi et al., 2013). Alternatively, Yersinia spp. can inhibit inflammasome 
activation by injecting YopK to mask T3SS needle detection, indirectly inhibiting 
caspase activation (Brodsky et al., 2010). Blasche and colleagues identified 
caspase-4, 8 and -9 as binding partners of EHEC NleF; where they solved the NleF-
EHEC-caspase-9 complex by crystallography. In our study interaction of caspase-4 
and NleFE69 was identified by YDH to require residues present in both the p20 and 
p10 subunits, indicating a different mechanism of inflammasome and caspase-4 
inhibition in comparison to Ospc3. This was confirmed by co-purification of the 
caspase-4 heterotetramer complex along with NleFE69. Here we propose a model of 
inhibition that reflects that of the caspase-9/NleF complex and crystal structure 
solved by Blasche and colleagues – where the C-terminal of NleFE69 associates with 
the caspase-4 substrate binding domain (Blasche et al., 2013).  
To confirm this model the crystal structure of caspase-4 would need to be solved. 
However the final yield of the caspase-4/NleFE69 complex was too low to pursue 
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further structural studies. The yield was limited by the insolubility of the caspase-4 
p10 subunit. This is common among the inflammatory caspases including caspase-1 
and caspase-5 (Roschitzki-Voser et al., 2012), which share high homology with 
caspase-4. Using the crystal structure of caspase-1 p10 as a model it is possible to 
identify putative caspase-4 p10 subunit hydrophobic residues exposed on the 
surface. Through a series of site directed mutagenesis substitutions, to reduce 
surface entropy and improve solubility, it may be possible to provide more favourable 
conditions for initial crystallisation (Dale et al., 1994). This does have its 
disadvantages, especially the fact that the primary sequence of caspase-4 may need 
to be considerably altered before the p10 subunit is soluble enough to pursue 
structural studies. Mutation of certain residues required for solubilisation may also 
interfere with caspase-4/NleFE69 complex formation. An alternative method, albeit 
more costly, is to purify active caspase-4 by LEVD affinity chromatography. Cell lysis  
of BL21 expressing full length caspase-4 stimulates caspase-4 self-proteolytic 
cleavage and oligomerisation. The active complex could be purified from the 
bacterial cell lysate through affinity chromatography using the known caspase-4 
substrate LEVD.  
Although the data above convincingly identifies caspase-4 as a binding partner of 
NleFE69 further studies are on-going to confirm caspase-4 and NleFE69 interaction. 
This includes co-immunoprecipitation in Caco-2 cells lines transduced with pMXs-IP-
nleFE69 or during EPEC E69 infection. To study the biological relevance of this 
interaction the cellular function of caspase-4 and the impact of NleF-caspase-4 
interaction during infection was investigated.  
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Results: Chapter 4 – Caspase-4, the functional ortholog of murine 
caspase-11 is target by EPEC NleF 
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4.1 Caspase-4 is the functional ortholog of murine caspase-11  
Caspase-4 and caspase-11 have recently been characterised as intracellular innate 
immune receptors that detect the Lipid A motif of LPS in vitro, resulting in their 
activation (Shi et al., 2014). LPS transfection or A/E pathogen bacterial infection of 
iMM triggers caspase-11 activation, resulting in formation of the non-canonical 
inflammasome - leading to pyroptosis and IL-1 family cytokine maturation and 
secretion (Kayagaki et al., 2011). However the role of human caspase-4 and 
caspase-5 is less clear.  
4.1.1 Caspase-4 can functionally complement caspase-11 to activate the 
non-canonical inflammasome in response to EPEC infection 
To determine if caspase-4 or caspase-5 can activate the non-canonical 
inflammasome in response to EPEC E69 infection Cas11-/- iMM were 
complemented with either CASP4 or CASP5 by retroviral transduction. Cas11-/- iMM 
were also complemented with Casp11 or yfp as controls. Infection of iMM was 
carried out using the T3SS mutant (ΔescN) of EPEC E69 as a model of EPEC E69 
non-canonical inflammasome activation. This is due to the fact that WT EPEC E69 
infection of iMM is known to trigger both the non-canonical inflammasome and the 
NLRC4-NAIP2 inflammasome (Zhao et al., 2011). This is dependent on the 
expression of the EPEC E69 inner rod protein EscI. Therefore, to test whether 
caspase-4 or -5 can activate the non-canonical inflammasome in response to EPEC 
E69 in iMM, a T3SS mutant must be used to prevent NLRC4 activation. Initially, to 
verify that the ΔescN strain does not activate the NLRC4-dependent inflammasome, 
WT and Nlrc4-/- iMM were infected with WT EPEC E69 or the ΔescN strain. 
Supernatants post-infection were analysed by ELISA for the secretion of the 
inflammasome dependent cytokine IL-1β. WT EPEC E69 infection of iMM triggered a 
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robust NLRC4-dependent secretion of IL-1β (Fig 4.1A-B). Alternatively infection with 
the ΔescN strain activated an NLRC4-independent inflammasome leading to 
secretion of IL-1β (Fig. 4.1A-B)  
 
Infection with the ΔescN strain was repeated using the CASP4, CASP5 and CASP11 
transduced Casp11-/- iMM cell lines (Fig. 3.10A). A laboratory strain of E. coli 
(STBL2) and LPS alone were used as controls. Secretion of IL-1β and IL-1α in 
response to EPEC ΔescN infection was, as reported, dependent on caspase-11 
expression and abolished in Casp11-/- iMM (Fig. 4.2B-C). Extracellular LPS alone did 
not activate the non-canonical inflammasome while STBL2 activated a robust non-
canonical inflammasome response and IL-1β/IL-1α secretion in caspase-11 
complemented Casp11-/- iMM (Fig. 4.2B-C). Caspase-4 fully complemented Casp11-
/- iMM to activate the secretion of both IL-1β and IL-1α in response to EPEC ΔescN 
and STBL2 (Fig. 4.2B-C). On the other hand caspase-5 complemented Casp11-/- 
iMM were unable to function to activate the murine non-canonical inflammasome in 
response to EPEC ΔescN or STBL2 infection (Fig. 4.2B-C). This suggested that 
caspase-4 but not caspase-5 is able to function as an ortholog of the murine non-
Figure 4 1 EPEC activates the NLRC4 inflammasome in a T3SS dependent 
manner. WT and Nlrc4-/- iMM were infected at an MOI of 25 with DMEM sub-
cultured WT EPEC E69 or the ΔescN strain for 18 h. (A) Supernatants post infection 
were analysed by ELISA. Data analysed by Mann-Whitney test. *, P<0.05 (B) 
Enumeration of CFUs for each bacterial culture. CFU; colony forming units, iMM; 
immortalised mouse macrophages. Results are an average of two biological repeats 
carried out in triplicate. UI, uninfected.   
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canonical inflammasome activator caspase-11. Furthermore it indicated that EPEC 
E69 can trigger the non-canonical inflammasome in a T3SS independent-manner. 
 
  
Figure 4 2 Caspase-4 can functionally complement caspase-11 to trigger the 
murine non-canonical inflammasome. (A) Casp11-/- iMM transduction with pMXs-IP-
Casp11, pMXs-IP-CASP4 and pMXs-IP-CASP5, or pMXs-IP-yfp as a negative control, 
was confirmed by Western blot. (B-C) Transduced iMM were infected with STBL2 or 
EPEC ΔescN as described in material methods. Cells were left untreated or treated 
with 200 ng/ml LPS as controls. Supernatants post infection were analysed for IL-1β 
and IL-1α secretion by ELISA. Representative of two biological repeats carried out in 
duplicate. UT; un-transduced. *, P<0.05 for indicated columns vs LPS treated. Data 
was analysed by Two way ANOVA and bonferroni compare all columns. 
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4.1 Generation of an nleF deletion EPEC strain 
To investigate if NleFE69 functions to inhibit caspase-4 in infection; initially, an nleF 
deletion mutant was generated. To generate an nleF KO strain a kanamycin cassette 
flanked with the genomic DNA 5’ and 3’ to nleF of EPEC E69 was generated in the 
plasmid TOPO-II-Blunt. This was constructed by PCR amplification of the genomic 
DNA of EPEC E69 with primers to amplify nleF along with 500 bp 5’ and 400 bp 3’ 
(Fig. 4.3A). The nleF gene was removed by inverse PCR and replaced with a 
kanamycin cassette. This newly generated construct was amplified by PCR and 
transformed into WT EPEC E69 harbouring the pKD46 temperature sensitive 
plasmid encoding the lambda red recombinase. Successful recombination events 
were selected for by plating the transformation mix on LB agar with the addition of 
kanamycin. Positive clones were confirmed by colony PCR. WT EPEC E69 genomic 
DNA or the TOPO-II plasmids generated for EPEC E69 and EHEC nleF 
mutagenesis were used as controls. Positive clones were further validated by 
sequencing (Fig. 4.3A). Initially the fitness of the deletion strain was tested. Deletion 
of nleF had no effect on bacterial growth kinetics in the minimal medium DMEM in 
comparison to WT EPEC E69 (Fig. 4.3B). Furthermore complementation of the 
ΔnleF strain with either the constitutive expression plasmid pACYC184-nleFE69 or the 
arabinose inducible plasmid pBAD22-nleFE69 had no effect on growth kinetics (Fig. 
4.3B).  
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Figure 4 3 Deletion of nleF does not affect EPEC E69 growth kinetics. EPEC E69 
pKD46 transformed with pTOPO-II-blunt-Kn induced with 0.5 mM IPTG were plated on 
LB-Kn to select for positive clones. (A) Positive clones 1-3 were screened by colony 
PCR using primers. The plasmid pTOPO-II-blunt-Kn for EPEC and EHEC ΔnleF and 
EPEC E69 genomic DNA (WT) were used as controls. A schematic for the amplicons of 
positive and negative clones is included. (B) EPEC E69 WT, the ΔnleF strain (clone 1) 
and  the ΔnleF strain complemented with either pACYC-nleF or BAD22-nleF were sub-
cultured from LB into DMEM and growth kinetics were measured by CFU every 45 min 
over 3 h. Average of two biological repeats carried out in triplicate.  
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4.2 NleFE69 inhibits activation and secretion of caspase-4 during infection of 
polarised intestinal epithelial cells  
To determine if NleFE69 targets caspase-4 during infection Caco-2 TC7 were infected 
with the WT EPEC E69, the EPEC nleF deletion mutant (ΔnleF) or the 
complemented ΔnleF pnleFE69 strain and supernatants were analysed for secreted 
caspase-4 and IL-18. Importantly, deletion of nleFE69 alone significantly increased 
the secretion of active caspase-4 during infection of IECs in comparison to the WT 
EPEC E69 strain (Fig. 4.4A). Furthermore, complementation of the ΔnleF strain with 
pnleFE69 or the addition of the caspase-4 inhibitor Ac-LEVD-CHO successfully 
prevented caspase-4 activation and secretion during EPEC E69 infection (Fig. 4.4A-
D). Caspase-4 can functionally complement the role of caspase-11 in Casp11-/- iMM, 
to activate the non-canonical inflammasome in response to EPEC E69 infection and 
emerging data fundamentally supports a role for caspase-4 in the activation of the 
human non-canonical inflammasome (Knodler et al., 2014; Shi et al., 2014). 
However, little is known about the human non-canonical inflammasome, especially in 
non-hematopoietic cells. Interestingly, no IL-18 cleavage was detected in response 
to WT EPEC E69 infection of Caco-2 TC7 (Fig. 4.4). Importantly, infection with the 
EPEC ΔnleF strain stimulated the secretion of the active p18 peptide of IL-18, 
correlating with caspase-4 activation during infection (Fig. 4.4). Expression levels of 
IL-18 were unaffected by infection and all EPEC strains adhered to the Caco-2 TC7 
cells at similar levels (Fig. 4.4B-C); which suggested that NleFE69 is not acting at the 
transcriptional level.  
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The loss of inhibition of inflammasome activity through deletion of nleFE69 was 
complemented by constitutive expression of NleFE69 alone, inhibiting both caspase-4 
and IL-18 processing and secretion (Fig. 4.4D). This suggested that EPEC E69 
Figure 4 4 NleFE69 inhibits secretion of active caspase-4 and IL-18 during
infection of IECs. (A) Caco-2 TC7 were infected with the WT EPEC E69, ΔnleF or
ΔnleF pnleF strains for 19 h and supernatants and lysates were analysed for IL-18
and caspase-4 by Western blot as described in materials and methods. (B) Lysates
were also analysed 4 h post-infection as control for IL-18 expression. (C) Three hours
post-infection cell layers were lysed and plated to determine bacterial CFU to 
enumerate EPEC E69 attachment for each strain. (D) Infection was repeated with or 
without the addition of 20 µM or 100 µM Ac-LEVD-CHO. Results are representative of 
at least two biological repeats. UI, uninfected; SN, supernatant. 
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secretes the effector NleFE69 during infection to target and inhibit caspase-4 
activation and the secretion of biologically active IL-18. 
Activation of caspase-4 and the non-canonical inflammasome in response to 
intracellular LPS is reported to control pyroptotic cell death (Knodler et al., 2014). 
While it was observed that WT EPEC E69 infection inhibited caspase-4 activation in 
an NleFE69 dependent manner, deletion of nleF did not increase cell cytotoxicity 
during infection (Fig. 4.5A).  
As with NleFE69, addition of Ac-LEVD-CHO did not significantly reduce cell death in 
Figure 4 5 Deletion of nleF alone does not increase cell death during infection 
of IECs. Caco-2 TC7 were infected with the WT EPEC E69, ΔnleF or ΔnleF pnleF 
strains for 19 h with or without the addition of 100 µM Ac-LEVD-CHO, as described 
in materials and methods. (A) Cell cytotoxicity was analysed by LDH release and 
displayed as a percentage of total LDH. Representative of at least two biological 
repeats carried out in triplicate. UI, uninfected; LEVD, Ac-LEVD-CHO. 
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comparison to infection with the WT EPEC E69 or ΔnleF strain (Fig. 4.5A). This 
indicated that while NleFE69 and inhibition of caspase-4 activation may control IL-18 
secretion, cell death during EPEC E69 infection is caspase-4/NleFE69 independent.  
4.3 Activation of caspase-4 in response to EPEC E69 infection triggers IL-18 
processing and secretion   
To validate that the processing and secretion of IL-18 observed during infection with 
the ΔnleF strain is caspase-4-dependent Caco-2 TC7 were transduced with CASP4 
specific short-hairpin RNA (shRNA). Caco-2 TC7 were transduced with either YFP-
mIR30E shRNA targeting CASP4 or lacZ as a non-targeting (NT) negative control.  
CASP4 specific shRNA-mediated knockdown successfully and specifically abolished 
expression of caspase-4 in comparison to WT Caco-2 caspase-4 levels (Fig. 4.6A). 
Moreover, no effect on caspase-4 protein levels were observed with the NT control 
transduced cell line. Similarly no knockdown of the highly homologous protein 
caspase-5 was observed in any condition, showing that the shRNA has high 
specificity for caspase-4 (Fig. 4.6A). Following confirmation of successful knockdown 
the transduced Caco-2 TC7 cell lines were infected with the WT EPEC E69 or ΔnleF 
strains. Supernatants were analysed 19 h post-infection for the secretion of active IL-
18. As described previously, infection of the NT control cell line with the EPEC ΔnleF 
mutant significantly increased the processing and secretion of IL-18 in comparison to 
infection with the WT EPEC E69 strain (Fig. 4.6B). However, no secreted processed 
IL-18 was detectable in response to infection of the caspase-4 knockdown cell line 
with either strain (Fig. 4.6B).   
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This suggested that caspase-4 is essential for IL-18 processing and secretion during 
infection. Following knockdown, to further investigate the role of caspase-4 in cell 
cytotoxicity, both LDH release and PI uptake were analysed post-infection. While 
knockdown of caspase-4 successfully inhibited IL-18 processing no effect on cell 
cytotoxicity during infection with the WT EPEC E69 or ΔnleF strain was observed 
Figure 4 6 Caspase-4 is essential for IL-18 processing and secretion during 
EPEC E69 infection of IECs. Caco-2 TC7 were transduced with the shRNA 
retroviral plasmid pMXs-IP-yfp-mIR30E CASP4 (C4) and pMXs-IP-yfp-mIR30E lacZ 
(NT) as a non-targeting negative control. (A) Caspase-4 knockdown, shRNA 
efficiency and specificity was confirmed by Western blot. (B) Transduced Caco-2 
TC7 were infected with the WT EPEC E69 and ΔnleF strains. At 19 h post-infection 
supernatants were analysed for IL-18 secretion and cleavage by Western blot. 
Representative of two biological repeats (C-D) Cell cytotoxicity was analysed by 
LDH release and PI uptake. Results are displayed as a percentage of total LDH or 
total PI uptake, respectively. Results are an average of two biological repeats 
carried out in quadruplicate. 
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(Fig. 4.6C-D). This confirmed, unlike IL-18 secretion, cell death induced by EPEC 
E69 infection is caspase-4-independent. This indicated that cell death and IL-18 
cytokine secretion during EPEC E69 IEC infection are mutually exclusive.   
Recently it was reported that caspase-1 is dispensable for the Caco-2 TC7 caspase-
4-dependent inflammasome (Knodler et al., 2014). This would suggest that the IEC 
non-canonical inflammasome significantly differs to that of the macrophage non-
canonical inflammasome. Within in this study, using LPS primed THP-1 lysate as a 
control, no expression of full length caspase-1 (45 kDa) could be detected in the 
lysates of the Caco-2 clones TC7 or BBE1 (Fig. 4.7A). Alternatively two bands at ~23 
kDa were detected using a p20 anti-caspase-1 antibody (Fig. 4.7A). The lower band 
was also present as a cleavage product in the THP-1 lysate (Fig. 4.7A). 
 
 
Figure 4 7 Full length caspase-1 is not detectable in the lysates of the Caco-2
clones TC7 or BBE1. Caco-2 TC7 and BBE1 were polarised and differentiated as 
described in material and methods and lysates were analysed by Western blot for 
caspase-1 and IL-18 expression. As a control THP-1 cells were differentiated by PMA 
and either left unstimulated or stimulated with 200 ng/ml LPS for 3 h 
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A p20 caspase-1 band is associated with activation of caspase-1 and the 
inflammasome. While this band may represent active caspase-1 no cleavage of IL-
18 was detectable by Western blot (Fig. 4.7). Furthermore we have shown above 
that under normal conditions in uninfected IECs IL-18 is neither secreted nor 
processed. Whether full length caspase-1 is expressed by Caco-2 or not, and 
whether its activity is required for IL-18 secretion requires further investigation.  
The results above identify that NleFE69, upon translocation, targets and inhibits 
caspase-4 activity. As predicted, caspase-4 functions similarly to the murine 
caspase-11 to trigger IL-18 cytokine processing and secretion in response to Gram 
negative bacterial infection. However, we report that cell death during EPEC E69 
infection of IECs is caspase-4 and therefore NleFE69 independent. Here the caspase-
4 inflammasome significantly differs from that of the characterised murine non-
canonical inflammasome of macrophages - where cell death and IL-18 secretion are 
directly linked.  
4.4 Discussion  
Little is known about the role of caspase-4 in human epithelial cells. Emerging 
evidence proposes a role for caspase-4 upstream to IL-18 processing and secretion 
in response to Gram negative bacterial infection (Knodler et al., 2014). Both 
caspase-4 and caspase-5 share significant sequence homology to the murine 
caspase-11 and are both implicated as the human functional ortholog. Caspase-11 
functions upstream to caspase-1 and inflammasome activation in response to 
intracellular LPS (Shi et al., 2014; Kayagaki et al., 2011). To verify that caspase-4 
and not caspase-5 is the functional ortholog of caspase-11 Casp11-/- iMM were 
transduced to express caspase-4 or caspase-5. Here we report that caspase-4 
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functionally complemented caspase-11 in response to Gram negative bacterial 
infection to activate the non-canonical inflammasome and cytokine secretion.  
Although cytokine maturation and secretion had not been studied using this model 
previously, it has been reported that caspase-5 can regulate non-canonical 
inflammasome-dependent pyroptotic cell death in response to intracellular LPS. It is 
therefore proposed that caspase-5 may play a role in non-canonical inflammasome 
cytokine maturation (Shi et al., 2014). We did not test the capability of either caspase 
to induce pyroptosis, however the failure of caspase-5 to complement Casp11-/- iMM 
may be due to the caspase-5 isoform we used. We were unable to detect/amplify the 
caspase-5a/f isoforms used by Shi and colleagues from HeLa or THP-1 cDNA pools 
and instead amplified the caspase-5 isoform first described by Munday and 
colleagues (Munday et al., 1995). In support of our findings a very recent publication 
sheds light on the role of caspase-4 and caspase-5 in the human macrophage non-
canonical inflammasome. Casson and colleagues observed that caspase-4 plays the 
conserved role of caspase-11 to activate the non-canonical inflammasome in human 
primary macrophages, in response to Gram negative bacterial infection (Casson et 
al., 2015). Specifically, caspase-4 was shown to regulate IL-1α secretion 
independent to caspase-1 during both Legionella pneumophila and S. typhimurium 
infection. Caspase-4 knockdown had no effect on IL-1β secretion during infection; 
although, both of these pathogens simultaneously activate the NLRC4-dependent 
inflammasome. In this case caspase-4 activity is most likely redundant. Caspase-5 
on the other hand was shown to be dispensable for secretion of both IL-1α and IL-
1β.  In response to sterile activation through LPS transfection it was further shown by 
Casson and colleagues that caspase-4 is essential for both IL-1β and IL-1α secretion 
(Casson et al., 2015). Having confirmed a putative function for caspase-4, which has 
124 
 
now been further confirmed in a human macrophage model of the non-canonical 
inflammasome, the role of NleFE69 during infection was explored. 
The activation of caspase-4 during EPEC E69 infection has not been previously 
studied. In response to WT EPEC E69 infection it was observed that caspase-4 
undergoes processing and is secreted. Activation during infection was significantly 
increased upon infection with the EPEC E69 ΔnleF mutant. This identified a novel 
function for the previously uncharacterised NleFE69 effector as an inhibitor of 
caspase-4. To determine if caspase-4 functions to activate the non-canonical 
inflammasome in IECS the secretion of IL-18 upon infection was analysed. IL-18 
processing and secretion was only detectable during infection upon deletion of nleF. 
This was further validated to be caspase-4 dependent by knockdown. This 
established that caspase-4 activation and the IEC non-canonical inflammasome 
response is dampened during infection in a T3SS and an NleFE69 dependent 
manner. 
While this identifies that caspase-4 is essential for IL-18 secretion and processing in 
response to EPEC E69 infection, Knodler and colleagues reported that caspase-1 is 
dispensable for the IEC caspase-4 dependent inflammasome. Caspase-4 can 
directly cleave IL-1 family cytokines, albeit with a lower efficiency than caspase-1; 
therefore, caspase-1 may not be essential (Sollberger et al., 2012). In our study we 
did not observe any full length caspase-1 in either Caco-2 clones BBE1 or TC7 nor 
any NLRP3 by Western blot (data not shown). Without NLRP3 or caspase-1 a 
caspase-4 dependent pathway would supersede. Whether caspase-1 is expressed 
in IECs in vivo requires further investigation. 
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Pyroptosis is a form of inflammatory programmed cell death that differs significantly 
from that of apoptosis. Caspase-1 is the master controller of pyroptosis, inducing 
plasma membrane pore formation, osmotic lysis and the release of pro-inflammatory 
cellular cytoplasmic contents (Bergsbaken, Fink & Cookson, 2009). Caspase-11 is 
essential for pyroptosis triggered by Gram negative bacterial infection of murine 
macrophages including C. rodentium and E. coli (Kayagaki et al., 2011). We did not 
observe any correlation between caspase-4 activity and cell death during EPEC E69 
infection of IECs. Neither caspase-4 knockdown nor LEVD treatment affected the 
level of LDH release or PI uptake. Although caspase-11 has been shown to be 
essential for pyroptosis this may be due to downstream caspase-1 effects. This 
would explain why in IECs where little or no caspase-1 is expressed, that caspase-4 
does not control pyroptosis. This may also implicate caspase-4 in a novel or 
unconventional non-canonical inflammasome that does not induce pyroptosis.  
Cell death during infection with either WT EPEC E69 or the ΔnleF strain, whilst 
significant, was not considerably high in comparison to the uninfected control. This 
supports previous findings that EPEC E69 successfully inhibits cell death in epithelial 
cells as a mechanism to prevent cell turnover; to aid in bacterial colonisation of the 
host (Wong Fok Lung et al., 2014; Hemrajani et al., 2010). It may be suggested that 
in order to see a difference between the WT EPEC E69 and ΔnleF strain a higher 
MOI may be required. To test this we doubled or halved the MOI and repeated the 
infections as carried out previously. Just by doubling the MOI cell death was at 100% 
after 3 h of infection (Data not shown). This indicated that there is a fine line between 
total inhibition and complete cell death during EPEC E69 infection of epithelial cells.  
We conclude that NleFE69 inhibits caspase-4 activity and IL-18 processing and 
secretion during epithelial cell infection; however, as observed previously (Blasche et 
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al., 2013; Black et al., 2010), NleFE69 does not play a role in programmed cell death. 
Many characterised EPEC E69 effectors have been identified to target and interact 
with multiple partners. Our collaborators, through the use of an NF-κB luciferase 
reporter assay in HeLa cells identified putative T3SS effectors, that when ectopically 
expressed, activated NF-κB. One of these putative pro-inflammatory effectors was 
NleFE69.  
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Results: Chapter 5 – NleFE69 activates NF-κB signalling 
 during EPEC infection 
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1.10  NleFE69 localises to the mitochondria and activates NF-κB nuclear 
translocation  
To explore whether NleFE69 activates the nuclear translocation of the inflammatory 
transcription factor NF-κB, HeLa cells were transfected with the mammalian 
expression plasmids pRK5-myc-nleFE69 (HeLa-NleF), pRK5-myc-nleF1-185 E69 (HeLa-
NleF1-185) or pRK5-myc-gfp (HeLa-GFP) as a negative control, and analysed by 
immunofluorescence staining.  
1.10.1 NleFE69 localises to the mitochondria dependent on its C-terminal 
motif LQCG 
At 24 h post-transfection it was observed that staining of NleFE69 was either diffusely 
localised throughout the cytoplasm and nucleus of the cell, or in a punctate peri-
nuclear localisation (Fig. 5.1A). Localisation post 24 h was not studied due to the fact 
that prolonged expression of NleFE69 was cytotoxic (data not shown). Co-staining of 
the major organelles of the cell and Myc-NleFE69 was carried out to determine the 
identity of the punctate staining observed during ectopic expression of NleFE69. No 
co-localisation was observed for the Golgi apparatus (GM130) or endoplasmic 
reticulum ER (calnexin) in HeLa-NleF (Fig. 5.1A); however, the punctate peri-nuclear 
staining of NleFE69 co-localised with the antibody staining for TOMM22. TOMM22 is 
a mitochondrial outer membrane protein, suggesting that NleFE69 localises to the 
mitochondria when ectopically expressed (Fig. 5.1A). No co-localisation with 
TOMM22 or punctate staining was observed for HeLa-GFP (Fig. 5.1A). Enumeration 
of HeLa-NleF exhibiting mitochondrial staining or diffuse staining showed that neither 
localisation phenotype was dominant (Fig. 5.1C). Previously it has been reported 
that the C-terminal motif of NleFE69, LQCG, is essential for its function to bind and 
inhibit caspases (Blasche et al., 2013). Localisation of NleFE69 to the mitochondria 
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may be dependent on interaction with host target proteins; therefore, the localisation 
of NleFE69 was compared between HeLa-NleF and HeLa-NleF1-185. Interestingly 
deletion of the 4 C-terminal amino acids of NleFE69 abolished localisation to the 
mitochondria, resulting in a diffuse staining in all transfected cells (Fig. 5.1B) This 
suggested that the mitochondrial localisation of NleFE69 may be caspase dependent.  
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1.10.2 Ectopically expressed NleFE69 activates nuclear translocation of NF-
κB 
To determine if ectopic expression of NleFE69 is sufficient to induce nuclear 
translocation of NF-κB the subcellular localisation of the NF-κB subunit p65 was 
determined in HeLa-NleF and HeLa-GFP, by immunofluorescence. NF-κB, under 
resting conditions, is sequestered in the cytoplasm in complex with IκBα. Upon 
activation and degradation of IκBα p65 is released and translocates into the nucleus 
where it transcriptionally up-regulates pro-survival and pro-inflammatory genes under 
Figure 5 1 Ectopically expressed NleFE69 localises to the mitochondria 
dependent on its C-terminal motif LQCG. Representative immunofluorescence 
images of NleFE69 subcellular localisation in HeLa 24 h post-transfection with pRK5-
myc-nleF, pRK5-myc-nleF1-185 E69 or pRK5-myc-gfp as a control. (A-B) Coverslips 
were co-stained for the major organelles including the ER (anti-calnexin), the golgi 
(anti-GM130) and the mitochondria (anti-TOMM22). The nucleus and Myc were 
stained using DAPI and anti-Myc, respectively. Bars, 10 µM. Representative of at 
least two biological repeats carried out in triplicate (C) Cells exhibiting mitochondrial 
localised or diffuse staining for NleFE69 were enumerated. 100 cells per condition 
were counted. Average of three biological repeats carried out in triplicate. 
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its control (Li & Verma, 2002). Cells treated with TNFα, or cells transfected with the 
TAB2/3 inhibitor NleE1 (HeLa-NleE) or HeLa GFP were used as controls. As 
expected stimulation with TNFα significantly increased the number of cells exhibiting 
nuclear localised p65 and following previous publications this could be inhibited by 
expression of NleE1 (Newton et al., 2010) (Fig. 5.2A-B). Interestingly, expression of 
NleFE69 alone (HeLa-NleF) stimulated the nuclear translocation of p65. The number 
cells with nuclear p65 for HeLa-NleF were significantly higher than that for HeLa-
GFP or the un-transfected control (Fig. 5.2A-B). The localisation of NleFE69 and 
ability to bind and inhibit the host targets caspase-4 and caspase-8 is dependent on 
the 4 C-terminal amino acids of NleFE69 (Blasche et al., 2013). To test whether the 
ability of NleFE69 to activate NF-κB p65 translocation is C-terminal dependent the 
number of cells positive for nuclear p65 were compared between HeLa-GFP, HeLa-
NleF and HeLa-NleF1-185. Deletion of the 4 C-terminal amino acids for NleFE69 
significantly abrogated its functional activity to induce nuclear p65 translocation (Fig. 
5.2A-B). Importantly this suggested that NleFE69 can activate the nuclear 
translocation of the transcription factor NF-κB p65 and may act via interaction with 
either caspase-4 or caspase-8.  While the ability of NleFE69 to induce nuclear 
translocation of p65 was dependent on its C-terminal domain (Fig. 5.2A-B) there was 
no observed difference in p65 nuclear translocation between HeLa-NleF exhibiting 
either diffuse staining or mitochondrial staining for NleFE69 (Fig. 5.3A-B).   
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Figure 5 2 Ectopically expressed NleF activates nuclear translocation of p65. (A)
Representative immunofluorescence images of p65 localisation using anti-N-terminal
p65 in HeLa cells 24 h post transfection with pRK5-myc-nleF, pRK5-myc-gfp, pRK5-
myc-nleE1 or pRK5-myc-nleF1-185 E69. The nucleus and Myc were stained using DAPI 
and anti-Myc, respectively. Cells were stimulated with 20 ng.ml TNFα for 0.5 h as a 
positive control. Bars, 10 µM (B) Cells exhibiting nuclear p65 staining were 
enumerated. 100 cells per condition were counted. Average of three biological repeats 
carried out in triplicate. *, P<0.05. Arrows indicate nuclear p65. 
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Figure 5 3 NleFE69 activity is independent of subcellular localization. 
Representative immunofluorescence images of NleF/GFP localisation in HeLa 
cells 24 h post transfection with pRK5-myc-nleF or pRK5-myc-gfp using anti-
Myc. Bars, 10 µM. The nucleus and NF-κB p65 were stained using DAPI 
andante-N-terminal p65, respectively. (B) Cells with mitochondrial or diffuse 
NleFE69 staining exhibiting nuclear p65 were enumerated. 100 cells per condition 
were counted. Average of three biological repeats carried out in triplicate. 
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1.11  NleFE69 up-regulates the expression of the chemokine IL-8 
As a transcription factor the translocation of p65 to the nucleus results in the up-
regulation of a subset of genes under the control of the NF-κB promoter. To 
investigate if NleFE69 induces the up-regulation of NF-κB dependent genes 
expression of IL-8 mRNA of HeLa-GFP, HeLa-NleF and HeLa-NleF1-185 was 
analysed 24 h post transfection by quantitative reverse-transcription PCR (qRT-
PCR). The house keeping gene GAPDH was used as a loading control while TNFα 
stimulated cells were used as a positive control for up-regulation of IL-8 expression. 
IL-8 expression levels were significantly increased in cells treated with TNFα (11-
fold) and in HeLa-NleF (5.8-fold) in comparison to HeLa-GFP (Fig. 5.4A). As with the 
ability of NleFE69 to activate the nuclear translocation of NF-κB p65, the up-regulation 
of the expression of IL-8 was dependent on the C-terminal domain of NleFE69 (Fig. 
5.4A). Up-regulation of IL-8 expression was not observed for HeLa-NleF1-185 in 
comparison to HeLa-GFP. 
  Figure 5 4 Ectopic expression of NleFE69 induces up-regulation the NF-κB 
promoter dependent chemokine IL-8. (A) IL-8 mRNA levels 24 h post-transfection for 
HeLa transfected with pRK5-myc-nleFE69, pRK5-myc-nleF1-185 E69 or pRK5-myc-gfp were 
analysed by qRT-PCR. TNFα at 20 ng/ml was added for 16 h as a positive control. *, 
P<0.05 for GFP vs Un + TNFα and GFP vs NleFE69, Mann Whitney test. Results are an 
average of three biological repeats. (B) Protein levels of Myc-GFP, Myc-NleFE69 and 
Myc-NleF1-185 relative to tubulin were analysed in whole cell extracts by Western blot 
using anti-Myc and αnti-tubulin, respectively. Results are representative of two 
biological repeats. Un; un-transfected. 
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Transfected cell lysates were analysed by immunoblotting to determine that 
expression levels of NleFE69 and NleF1-185 E69 were similar and stable during 
transfection. NleFE69 and NleF1-185 E69 were expressed at similar levels during 
transfection and no difference in transfection efficiency was observed (Fig. 5.4B; 
data not shown). This determined that ectopically expressed NleFE69 induces the 
nuclear translocation of p65 and the up-regulation of the pro-inflammatory NF-κB 
dependent chemokine IL-8. While the mechanism of activation is unknown the fact 
that the activity of NleFE69 is dependent on its C-terminal domain suggests it may 
function via the inflammatory caspase-4 or caspase-8.  
1.11.1 NleFE69 induced NF-κB activation is independent of interaction with 
caspase-4, -8 or -9.  
Both caspase-4 and caspase-8, in response to multiple stimuli function to activate 
NF-κB via a number of intracellular signalling cascades (Nickles et al., 2012; 
Lakshmanan & Porter, 2007; Chaudhary et al., 2000). To explore if the mechanism 
of NleFE69-dependent activation of NF-κB was through interaction with either 
caspase-4 or caspase-8 HeLa-GFP and HeLa-NleF were transfected with caspase 
specific short inhibitory RNA (siRNA). Non-targeting siRNA was transfected as a 
negative control and knockdown of mRNA in HeLa of the known interacting partner’s 
caspase-4, -8 and -9 was confirmed by qRT-PCR and Western blot, where stated. 
Transfection of siRNA for caspase-4, -8 and -9 successfully depleted cellular levels 
of each caspase to 11%, 18% and 10% of WT levels in comparison to the non-
targeting siRNA transfected control (Fig 5.5A-D). Thirty six hours post siRNA 
transfection HeLa were transfected with pRK5-myc-gfp or pRK5-myc-nleFE69. As 
before, mRNA was extracted and IL-8 expression levels were analysed by qRT-
PCR. Knock down of caspase-4, -8 or -9 had no observed effect on the NleFE69-
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dependent up-regulation of IL-8 expression in comparison to the non-targeting 
siRNA transfected control or GFP (Fig. 5.5E).  
 
 
 
 
 
 
Caspase-4 and caspase-8 function independently to activate NF-κB nuclear 
translocation; therefore, NleFE69 may activate either caspase, or both, to stimulate 
p65 translocation and up-regulation of IL-8 expression.  To investigate this as a 
Figure 5 5 NleFE69 functions independently of caspase-4, -8 or -9 to activate 
IL-8 expression. HeLa cells were transfected with siRNA for (A) CASP4, (B) 
CASP8 or (C) CASP9. mRNA levels in comparison to the non-targeting control 
were analysed 36 h post-transfection by qRT-PCR. Results are an average of three 
biological repeats. (D) Caspase-4 levels relative to tubulin in HeLa whole cell 
extracts of siRNA transfected cells were analysed by Western blot 36 h post-
transfection. Results are an average of two biological repeats. (E) Thirty-six hours 
post-transfection with siRNA HeLa were transfected with pRK5-myc-nleFE69 or 
pRK5-myc-gfp and IL-8 mRNA analysed by RTq-PCR. Results are representative 
of those of two biological repeats carried out in triplicate 
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possible mechanism HeLa were dual transfected with either both caspase-4 and -8 
siRNA or the non-targeting contro siRNAl. Dual knockdown successfully reduced the 
expression of both caspase-4 and -8 (Fig. 5.6A). HeLa transfected with both 
caspase-4 and -8 siRNA or the non-targeting control were then transfected with 
either pRK5-myc-nleFE69 or pRK5-myc-gfp. Dual knockdown of caspase-4 and -8 
had no effect on the ability of NleFE69 to induce up-regulation of IL-8 expression as 
determined by qRT-PCR (Fig. 5.6B). This determined that the mechanism of 
activation is not through stimulation of either caspase-4 or caspase-8.  
 
 
Figure 5 6 Knock-down of caspase-4 and -8 has no effect on the pro-
inflammatory activity of NleFE69. (A-B) HeLa cells were co-transfected with siRNA 
for caspase-4 and -8 (20 nM) or scrambled control siRNA (40 nM) alone. mRNA levels 
were analysed 36 h post transfection by qRT-PCR. (C) Thirty six hours post-
transfection with respective siRNA, HeLa cells were transfected with either pRK5-
myc-gfp or pRK5-myc-nleFE69. IL-8 mRNA levels were analysed by qRT-PCR. Results
are representative of one experiment carried out in triplicate. 
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1.12  NleFE69 activates the nuclear translocation of NF-κB early during EPEC 
E69 infection  
EPEC E69 activates pro-inflammatory signalling, in a T3SS-dependent manner, 
early during in vitro tissue culture epithelial cell (Newton et al., 2010; de Grado et al., 
2001; Savkovic et al., 2001; Savkovic, Koutsouris & Hecht, 1997).  Interestingly, 
Savkovic and colleagues observed that early during infection EPEC E69 actives NF-
κB activation. Moreover, this activation is dependent on a functional T3SS (Savkovic 
et al., 2001). Newton and colleagues further observed that in the absence of the 
pathogenicity islands PP4 and IE6, which encode the characterised NF-κB inhibitory 
effectors including NleC, NleB1 and NleE1, EPEC E69 activates NF-κB p65 
translocation and IL-8 secretion in a T3SS dependent manner . To determine if 
NleFE69 functions during infection to activate NF-κB p65 nuclear translocation HeLa 
cells were infected for 1.5 h with WT EPEC E69, ΔescN, ΔnleF or the complemented 
ΔnleF pnleFE69 strain and analysed by immunofluorescence staining (Fig. 5.7A). No 
difference in adherence or pedestal formation (excluding the ΔescN strain) was 
observed between the different strains (Fig. 5.7A). As previously reported, WT EPEC 
E69 (Savkovic, Koutsouris & Hecht, 1997) robustly activated NF-κB p65 nuclear 
translocation 1.5 h post-infection (Fig. 5.7A-B); this was dependent on a functional 
T3SS as the ΔescN strain was unable to promote p65 translocation (Fig. 5.7A-B). 
This re-confirmed that at 1.5 h post-infection NF-κB p65 nuclear translocation is 
T3SS (Newton et al., 2010) dependent. Deletion of nleF abolished NF-κB p65 
nuclear translocation during EPEC E69 infection to that of the level seen for the 
ΔescN strain (Fig. 5.7A-B). This was partially restored through complementation of 
the ΔnleF strain (Fig. 5.7A-B). This suggested that NleFE69 is the T3SS effector 
responsible for activation of p65 early during infection.   
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  Figure 5 7 NleFE69 activates p65 nuclear translocation early during infection. (A) 
Representative immunofluorescence images of NF-κB p65 localisation using anti-N-
terminal p65, 1.5 h post-infection with WT EPEC E69, ΔescN, ΔnleF or the 
complemented ΔnleF pnleFE69 strain. Actin and the nucleus were stained using 
phalloidin-Cy5 and DAPI, respectively. EPEC were visualised using anti-eae. Bars, 10 
µM. (B) The number of cells exhibiting nuclear p65 were counted for 8 separate fields 
of view per condition. Average of three biological repeats carried out in triplicate. (C) IL-
8 mRNA levels 1.5 h post-infection were analysed by qRT-PCR. *, P<0.05 for UI vs WT 
and UI vs ΔnleF pnleFE69. UI; uninfected. 
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To determine if NleFE69 dependent activation of NF-κB p65 nuclear translocation 
during infection leads to up-regulation of genes under the control of the NF-κB 
promoter the infection was repeated and mRNA was extracted and analysed by 
qRT-PCR. As with NF-κB p65 nuclear translocation infection with the WT EPEC E69 
strain induced a 28.5 fold increase in IL-8 mRNA levels in comparison to the 
uninfected (Fig. 5.8C). Alternatively infection with the ΔescN strain only induced a 
2.3 fold increase in comparison (Fig. 5.8C). Interestingly, deletion of nleF alone 
reduced the level of IL-8 expression to that seen for the ΔescN strain; again this was 
partially restored upon complementation with pnleFE69 (Fig. 5.8C). This suggested 
that NleFE69 stimulates the expression of IL-8 early during EPEC E69 infection. 
At later time points post-infection EPEC E69 delivers a plethora of T3SS effectors to 
inhibit NF-κB signalling (Gao et al., 2013; Raymond et al., 2013; Baruch et al., 2011; 
Pearson et al., 2011; Raymond et al., 2011; Nadler et al., 2010; Newton et al., 2010; 
Vossenkämper et al., 2010; Gao et al., 2009). This includes the T3SS effector and 
TAB2/3 inhibitor NleE1 (Newton et al., 2010). To determine if NleFE69 functions to 
activate NF-κB at later time points post-infection HeLa cells were infected for 4 h with 
the WT EPEC E69, ΔescN or the ΔnleF strain and p65 localisation was analysed by 
immunofluorescence staining. As a control for activation HeLa cells were also 
infected with the ΔPP4/IE6 strain and the ΔPP4/IE6 strain complemented with 
pnleE1. At 3.5 h post-infection, as a control for inhibition of NF-κB p65 nuclear 
translocation, WT EPEC E69 infected cells or uninfected cells were treated with 20 
ng/ml TNFα. No difference in NF-κB sub-cellular localisation between the 
uninfected/unstimulated or infection with the WT EPEC E69, ΔescN or the ΔnleF 
strain was observed at 4 h post-infection (Fig. 5.8A-B). Furthermore, stimulation of 
WT EPEC E69 infected cells with TNFα did not stimulate p65 nuclear translocation; 
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while stimulation of uninfected cells with TNFα resulted in p65 nuclear translocation 
in almost 100% of cells (Fig. 5.8A-B). This suggested at 4 h post-infection EPEC E69 
inhibits NF-κB activation in a T3SS-dependent manner.   
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Alternatively, as described previously, infection with EPEC ΔPP4/IE6 resulted in 
activation of p65 nuclear translocation in infected cells (Fig. 5.8A-B). This could be 
complemented by NleE1 alone, suggesting T3SS-dependent NF-κB activation at 4 h 
post-infection is TAB2/3 dependent (Fig. 5.8A-B). This determined that at 1.5 h post-
infection, in a T3SS-dependent and NleFE69-dependent manner, WT EPEC E69 
activates NF-κB p65 nuclear translocation; while at later time points, through the 
secretion of NleE1 alone, EPEC is capable of inhibiting NF-κB nuclear translocation 
activated either in a T3SS-dependent manner or through exogenous stimuli.  
  
Figure 5 8 EPEC inhibits exogenous stimulation and T3SS-dependent 
activation of NF-κB at 4 h post-infection. Representative immunofluorescence 
images of NF-κB p65 localisation using anti-N-terminal p65 4 h post-infection with 
WT EPEC E69, ΔescN, ΔnleF, ΔPP4/IE6 or the complemented ΔPP4/IE6 pnleE 
strain. EPEC and the nucleus were stained using anti-eae and DAPI, respectively. 
Uninfected and WT infected cells were treated with 20 ng/ml TNFα for 30 min where 
stated. Bars, 10 µM. (B) The number of cells exhibiting nuclear p65 were counted for 
8 separate fields of view per condition. Average of three biological repeats carried 
out in triplicate. *, P<0.05 for UI vs UI + TNFα and UI vs ΔPP4/IE6. UI; uninfected 
144 
 
1.13  NleFE69 dependent activation of NF-κB is up stream to IκBα 
degradation 
Proteasomal degradation of IκBα is a crucial step in canonical NF-κB signalling and 
activation and is downstream to TAB2/3 recruitment (Li & Verma, 2002). HeLa cells 
were infected with WT EPEC E69, ΔnleF or the complemented ΔnleF pnleFE69 strain 
to determine if NleFE69 acts at the stage of IκBα degradation in the NF-κB signalling 
cascade during infection. At 1.5 h post-infection the level of IκBα relative to tubulin in 
whole cell lysates was analysed by Western blot. Infection with the WT EPEC E69 
strain resulted in degradation of IκBα relative to the uninfected condition (Fig. 5.9A). 
On the other hand there was no difference in the level of IκBα between the 
uninfected and the ΔnleF infected condition (Fig. 5.9A). Infection with the ΔnleF 
pnleFE69 strain partially rescued the ability of EPEC E69 to induce IκBα degradation 
(Fig. 5.9A). This suggested that the NleFE69 dependent activation of NF-κB during 
EPEC E69 infection acts through and upstream to the degradation of IκBα, although 
the host binding partner remains unknown.  
  
Figure 5 9 EPEC E69 induces IκBα degradation in an NleFE69 dependent
manner during infection. (A) HeLa cells were infected for 4 h with the WT EPEC 
E69, ΔnleF or ΔnleF pnleFE69 strain and IκBα (anti-IκBα) levels relative to tubulin 
(anti-tubulin) were analysed by Western blot. Densitometry was carried out using 
imageJ and is an average of two biological repeats.   
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1.14  NleFE69 interacts with human DHFR 
Although caspase-4, -8, and -9 knockdown did not inhibit the pro-inflammatory 
activity of NleFE69, alternative putative binding partners have been identified through 
Y2H screens carried out by other groups. Blasche and colleagues identified 
dihydrofolate reductase (DHFR) as a possible interacting partner (Blasche, 2013). 
DHFR is an essential enzyme required for the de novo synthesis of nucleic and 
amino acids. Recently the previously annotated pseudogene DHFRP4 was reported 
to encode the fully functional mitochondrial localised DHFR homolog DHFRL1 
(McEntee et al., 2011). To investigate if NleFE69 interacts with either DHFR or 
DHFRL1 AH109 were co-transformed with pGBT9-nleFE69/nleF1-185 E69 and pGADT7-
DHFR/DHFRL1 and plated on selective media. Co-transformation with pGBT9-
nleFE69 and pGADT7-CASP4 was used as a positive control. As reported by Blasche 
and colleagues NleFE69 interacted with DHFR in the YDH system (Fig. 5.10A) 
(Blasche, 2013). This interaction, unlike caspase binding, was not dependent on the 
C-terminal motif LQCG (Fig. 5.10A). Strikingly, although DHFR and DHFRL1 share 
93 % amino acid identity NleFE69 did not interact with DHFRL1 in this system (Fig. 
5.10A). Olsen and colleagues further identified TMP21, a transmembrane protein 
involved in vesicular transport, as an interacting partner of NleFE69 through a Y2H 
screen (Olsen et al., 2013).  Using the Clontech YDH system we were unable to 
reproduce this interaction (Fig. 5.10B). Whether NleFE69 activates NF-κB through 
inhibition of DHFR requires further research.  
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The in vitro infection data and biochemical interaction assays used identify two 
possible functions of NleFE69 during EPEC E69 infection. Firstly, that NleFE69 is 
recruited to inhibit caspase-4 activity and inflammasome activation. Thus preventing 
IL-18 activation and secretion and therefore acting as an anti-inflammatory effector. 
Secondly, we identified that NleFE69 is essential for the early activation of NF-κB p65 
nuclear translocation during epithelial cell infection. Subsequently, NleFE69 stimulates 
the NF-κB dependent expression of pro-inflammatory immune modulators. To further 
validate these putative functional roles of NleFE69 we sought to characterise NleFCR 
in vivo using the C. rodentium mouse model of A/E pathogen infection. 
 
Figure 5 10 NleFE69 interacts with DHFR but not DHFRL1. A Yeast-direct-Hybrid 
assay co-transforming AH109 with full length NleFE69 (pGBT9-nleFE69) or the C-
terminal truncated NleFE69 (pGBT9-nleF1-185 E69) with (A) DHFR (pGADT7-DHFR), 
DHFRL1 (pGADT7-DHFRL1) or caspase-4 isoform-γ (pGADT7-CASP4) as a positive 
control. (B) A Yeast-direct-Hybrid assay co-transforming AH109 with full length 
NleFE69 (pGBT9-nleFE69) with TMP21 (pGADT7-TMP21) or caspase-4 isoform-γ 
(pGADT7-CASP4) as a positive control. Results are representative of two biological 
repeats 
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1.15  Discussion  
An NF-κB luciferase reporter assay screen, carried out by our collaborators, against 
ectopically expressed EPEC E69 T3SS effectors previously detected NleFE69 as a 
putative activator of the pro-inflammatory and pro-survival transcription factor NF-κB. 
This study further confirmed that ectopic expression of NleFE69 in the HeLa cell line 
promotes the nuclear translocation of the NF-κB p65 subunit; leading to the up-
regulation of the expression of the pro-inflammatory chemokine IL-8. The C-terminal 
motif of NleFE69, as described above, is required for optimal binding of the interacting 
partner’s caspase-4, -8 and -9. Ectopic expression of an NleFE69 mutant lacking the 
four C-terminal amino acids LQCG abolished the pro-inflammatory activity of NleFE69. 
This suggested that NleFE69 induced NF-κB activation may be caspase-dependent. 
Furthermore this domain was essential for the mitochondrial subcellular localisation 
observed for ectopically expressed NleFE69; although, it is important to note that the 
ability of NleFE69 to activate NF-κB was not dependent on its subcellular localisation.  
Early during infection EPEC E69 activates pro-inflammatory signalling in a T3SS 
dependent-manner. Initially, EPEC E69 induces a pro-inflammatory response 
through activation of ERK1/2 (Czerucka et al., 2001; de Grado et al., 2001; Savkovic 
et al., 2001) and NF-κB (Newton et al., 2010; Savkovic, Koutsouris & Hecht, 1997). 
Although pro-inflammatory effectors have been discovered in other A/E 
pathogens/pathotypes including EspT (Raymond et al., 2011), the effector 
responsible during EPEC E69 infection was previously unknown. In our study we 
observed that NleFE69 was essential for activation of NF-κB and IL-8 expression 
during EPEC E69 infection. Furthermore it was shown that the pro-inflammatory 
activity of NleFE69 was inhibited by the TAB2/3 inhibitor NleE1. This along with the 
evidence that NleFE69 stimulates the degradation of IκBα proposes a model where  
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NleFE69 triggers NF-κB activation upstream to or at TAK1 phosphorylation (Fig. 5.11). 
Whether ERK1/2, JNK or other MAPKs are activated in an NleFE69-dependent 
manner was not investigated in this study and warrant further research. Although 
NleFE69 was identified to be essential for the early activation of NF-κB during 
infection the host target protein and mechanism of activation remain unknown. 
1.15.1 Mechanism of NF-κB activation  
Both caspase-4 and caspase-8 have previously been suggested to be integral for 
canonical and non-canonical activation of NF-κB in response to TNFR/TLR ligand 
binding (Nickles et al., 2012; Lakshmanan & Porter, 2007; Chaudhary et al., 2000). 
Figure 5 11 EPEC E69 initially activates NF-κB then later inhibits inflammatory 
signalling in a T3SS dependent manner. EPEC E69 infection triggers an early 
NleFE69 dependent activation of the transcription factor NF-κB, acting up stream to 
TAB2/3 activation. At later time points post infection the T3SS effectors NleE1, NleB, 
NleC and NleD inhibit pro-inflammatory signalling. 
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NleFE69 shares no structural homology to any known/characterised proteins and is 
not predicted to have any enzymatic activity. With this in mind the current model 
suggests that NleFE69 binds to and inhibits caspases through association with the 
substrate binding domain in a C-terminal dependent-manner (Blasche et al., 2013). 
Subsequently this prevents substrate binding and caspase proteolytic activity, 
preventing downstream signalling. If knockdown of caspase-4/-8 successfully 
prevented the pro-inflammatory activity of NleFE69 it would suggest that NleFE69 
interacts with either caspase to directly promote activation of the intrinsic NF-κB 
signalling cascade. However the pro-inflammatory activity of NleFE69 was determined 
to be independent on its interaction with the known interacting partner’s caspase-4, -
8 or -9. Many viral effector proteins have been identified to bind to caspase-8 both to 
the DED domain of the full length zymogen and to the active form (Mocarski, Upton 
& Kaiser, 2011). While those that bind the active caspase form are restricted to 
interaction with this structural form of caspase-8 (Mocarski, Upton & Kaiser, 2011), 
NleFE69 can bind both the full length and active caspase-8 (Blasche et al., 2013). 
Many of these viral effectors similarly bind caspase-8 to prevent extrinsic apoptosis 
including Cowpox CrmA, Baculovirus p35 (Chaudhary et al., 2000), Human 
papillomavirus Type 16 (HPV-16) E6/E7 (Vandermark et al., 2012) and Herpes 
simplex virus 1 (HSV-1) R1/UL39 (Dufour et al., 2011); although, none have been 
shown to subsequently activate NF-κB. Although this may not be a caspase-8 
dependent mechanism, viral caspase-8 inhibitors have been reported to inhibit NF-
κB activation including HPV-16 E6/E7 (Vandermark et al., 2012). Therefore it is 
unlikely that the pro-inflammatory activity of NleFE69 is a consequence of caspase-8 
inhibition. 
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The host target of NleFE69 responsible for NF-κB activation may be a yet 
uncharacterised or a previously identified but untested host binding partner. Two 
reported putative host binding partners include the transmembrane protein TMP21 
(Olsen et al., 2013) and DHFR (Blasche, 2013) an essential enzyme in the supply of 
biologically active folate for nucleic acid and glycine biosynthesis. Interaction with 
TMP21 through the YDH system could not be reproduced in our hands. DHFR is an 
essential enzyme in the production of thymine and is required for rapid cell division. 
It is therefore an ideal drug target for not only chemotherapy (Methotrexate) but 
through host specific anti-folates it is also targeted in the treatment of a spectrum of 
microbial and parasitic infections including the bacteriostatic trimethoprim and the 
anti-malarial’s pyrimethamine and cycloguanil (Rastelli et al., 2000; Schweitzer, 
Dicker & Bertino, 1990). Thymidylate synthase (TS) is an essential enzyme for the 
conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP) downstream to DHFR. Interestingly, knockout of TS in a 
Human colon carcinoma cell line induces thymineless stress and activation of NF-κB 
and AP-1 (Harwood et al., 2000). Moreover the previously described DHFR 
pseudogene DHFRP4, also known as DHFRL1, was recently shown to be expressed 
and functional. DHRFL1, unlike the cytoplasmic/nuclear DHFR, is localised to the 
mitochondria (McEntee et al., 2011). NleFE69 was confirmed to bind DHFR using the 
YDH system, although DHFR and DHFRL1 share 93 % amino acid sequence 
identity NleFE69 specifically interacted with DHFR only. This may be due to the 
limitation of the YDH assay requiring the proteins to be localised to the nucleus and 
alternative methods need to be used to rule out binding to DHFRL1. More research 
is required to determine if NleFE69 targets DHFR/DHFRL1 during infection and 
whether this interaction is key to NleFE69-dependent activation of NF-κB.  
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To further elucidate the role of NleF and to determine the consequence of either NF-
κB activation or inhibition of caspase-4/-11, during in vivo infection, C57BL/6 mice 
were infected with the EPEC/EHEC-like A/E pathogen C. rodentium.  
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Results: Chapter 6 - NleFCR inhibits IL-18 secretion and neutrophil 
recruitment in vivo 
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6.1  NleFCR inhibits IL-18 secretion and neutrophil recruitment in vivo  
To determine whether NleFE69 manipulates immune signalling during infection and to 
confirm the function of NleFE69, the C. rodentium infection of C57BL/6 mice was used 
as a model of in vivo A/E pathogen infection.      
6.1.1 NleFCR is not required for normal colonisation in vivo 
C57BL/6 mice were infected with the WT ICC169 C. rodentium, C. rodentium ΔnleF 
or the complemented C. rodentium ΔnleF pACYC184-nleFCR (pnleFCR) strain by o.g. 
Initially colonisation fitness of each strain was tested. Faeces were collected on the 
days indicated and CFU were enumerated. The prototypic colonisation pattern of 
C57BL/6 mice was demonstrated by the WT C. rodentium strain (Fig. 6.1A). 
Following inoculation there was a dip in bacterial load which then picked back up at 
day 4 and reached a peak at ~day 8 (Fig. 6.1A). Following day 8 WT C. rodentium 
was slowly cleared and colonisation decreased. No difference in colonisation was 
observed during infection with the C. rodentium ΔnleF or C. rodentium ΔnleF pnleFCR 
strains in comparison to WT C. rodentium (Fig. 6.1A).   
Figure 6 1 NleFCR is not required for C. rodentium colonisation. C57BL/6 mice 
were infected by o.g. with 1x108/ml WT C. rodentium or the ΔnleF C. rodentium and 
ΔnleF C. rodentium pnleFCR strains. Infection was followed from day 0 to day 14 and 
where indicated faeces were collected and plated. A minimum of five mice per group 
were used. Results are representative of two biological repeats 
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6.1.2 C. rodentium delivers NleFCR to inhibit IL-18 secretion 
Both Inflammasome activation and NF-κB are early innate immune responses to 
bacterial infection, occurring at the epithelial cell barrier of the gastrointestinal tract. 
To determine if NleFCR manipulates immune signalling during infection colon ex-
plants were cultured on day 4 and 8 post-infection and IL-18 cytokine secretion was 
measured by ELISA. The inflammasome independent cytokine KC (CXCL1) was 
measured as a control.  
 
 
 
 
Infection with the C. rodentium ΔnleF mutant significantly increased IL-18 secretion 
at day 4 post-infection in comparison to WT C. rodentium infection and the PBS 
control (Fig. 6.2A). Importantly, no difference in the secretion of the NF-κB 
dependent cytokine KC was observed during infection with WT C. rodentium or C. 
rodentium ΔnleF in comparison to the PBS control (Fig. 6.2B). Complementation of 
the C. rodentium ΔnleF strain with the plasmid encoded NleFCR reduced the 
Figure 6 2 NleFCR inhibits early secretion of IL-18 from colonic tissue in vivo. 
C57BL/6 mice were infected by oral gavage with 1x108/ml WT C. rodentium or the 
ΔnleF C. rodentium and ΔnleF C. rodentium pnleFCR strains or inoculated with PBS 
as a control. On day 4 and 8 post-infection 1cm of mouse colons were isolated and 
cultured ex vivo for 24h. (A and C) IL-18 and (B) KC secretion were measured by 
ELISA. Results for day 4 p.i are an average of two biological repeats with 5-6 mice 
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secretion of IL-18 to similar levels observed during infection with WT C. rodentium 
(Fig. 6.2A). Conversely we observed an increase in KC secretion (Fig. 6.2B). The 
latter result is consistent with our finding that NleFE69 activates NF-κB during 
infection. NleFCR-dependent IL-18 secretion inhibitory effects were only observed 
early during infection, as no difference in IL-18 secretion was observed on day 8 p.i. 
(Fig. 6.2C). IL-18 facilitates the emigration of neutrophils and leukocytes to the site of 
infection, although this has not been tested in the gastrointestinal tract (Dinarello & 
Fantuzzi, 2003; Verri et al., 2007; Canetti et al., 2003). 
6.2  Deletion of nleF increases colonic neutrophil recruitment during C. 
rodentium infection  
Colonic tissue from infected mice was extracted on day 4 post-infection with either 
the WT C. rodentium, the C. rodentium ΔnleF or the C. rodentium ΔnleF pnleFCR 
strain. The terminal colon was homogenised and the immune cell population was 
evaluated by flow cytometry. A significant increase in neutrophil recruitment was 
observed upon infection with the C. rodentium ΔnleF strain in comparison to the WT 
C. rodentium strain (Fig. 6.3A). This increase in neutrophil recruitment was 
sequestered upon complementation of the ΔnleF strain with the constitutive 
expression plasmid pACYC184-nleFCR (Fig. 6.3A and Fig. 6.4A). The change in 
neutrophil recruitment was specific and no change in macrophage, dendrocyte or 
lymphocyte recruitment was observed upon infection with the ΔnleF strain in 
comparison to the WT C. rodentium strain (Fig. 6.3A-B). Furthermore no difference 
was observed for neutrophil recruitment between all strains at later time points of 
infection at day 8 or 14 (Fig. 6.3C). This suggested that NleFCR specifically inhibits 
the recruitment of neutrophils early during infection. To determine if neutrophil 
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recruitment during C. rodentium ΔnleF infection is inflammasome dependent, the 
infection was repeated in Casp1/11-/- mice. 
 
Figure 6 3 NleFCR inhibits early colonic recruitment of neutrophils. C57BL/6 mice 
were infected by o.g. with WT, ΔnleF or ΔnleF C. rodentium pnleF strains or inoculated 
with PBS as a control. Immune cell recruitment into the colon was evaluated by flow 
cytometry as described in materials and methods (A) Neutrophils (CD11b+Ly6G+), 
macrophages (CD11b+Ly6G-F4/80+) and dendrocytes (CD11c+CD11b-) are 
presented as percentage of myeloid cells or absolute numbers (B) B cells (B220+CD3-
), cytotoxic T cells (CD8+CD4-) and T helper cells (CD4+CD8-) are presented as a 
percentage of lymphocytes. Results are an average of two biological repeats with 4-6 
mice per group. (C) Recruitment of neutrophils was further analysed on day 8 and 14 
p.i. Results are an average of one biological repeat. *P<0.05, WT vs ΔnleF and ΔnleF 
vs ΔnleF pnleF, Mann-Whitney test. Results are expressed as the mean +/- the 
standard error of the mean. PI, post-infection. 
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6.3  Recruitment of neutrophils and IL-18 secretion early during C. rodentium 
infection is caspase-1/11 dependent.  
Casp1/11-/- mice were infected with the WT C. rodentium or ΔnleF C. rodentium 
strain and as before, at day 4 post infection, IL-18 secretion and immune cell 
infiltrates were analysed by ELISA and FACs. Secretion of IL-18, as expected, was 
completely abolished during C. rodentium infection of Casp1/11-/- mice (Fig. 6.4A). 
As a control KC levels were also tested. No difference in KC was observed between 
infections with either the WT C. rodentium or C. rodentium ΔnleF strain (Fig. 6.4A). 
Furthermore the levels of KC were similar to that seen during WT C. rodentium 
infection of WT C57BL/6 mice. This confirmed that at day 4 post infection, IL-18 
secretion, and the increase observed upon deletion of nleF, is dependent on a 
functional caspase-1/11 inflammasome.  
Figure 6 4 NleFCR dependent inhibition of neutrophil recruitment is via
caspase-1/11. C57BL/6 Casp1/11-/- mice were infected by oral gavage with WT C.
rodentium or the ΔnleF C. rodentium strains. (A) On day 4 post-infection 1cm of
mouse colons were isolated and cultured ex vivo for 24 h. KC and IL-18 secretion
were measured by ELISA. (B) Immune cell recruitment into the colon was evaluated 
by flow cytometry. Forward and side scatter plots were used to identify the myeloid 
cell and lymphocyte populations using FlowJo software. Doublets found within this 
population were excluded using FSC-W/FSC-A and SSC-W/SSC-A. Neutrophils 
(CD11b+Ly6G+) are presented as percentage of myeloid cells or absolute number.
Results are an average of two biological repeats and expressed as the mean +/- the
standard error of the mean. 
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The colonic immune cell population at day 4 post infection of Casp1/11-/- mice was 
evaluated by flow cytometry. In the absence of caspase-1 and caspase-11, infection 
with the C. rodentium ΔnleF mutant no longer induced increased neutrophil influx 
(Fig. 6.5B). Neutrophil recruitment in mice infected with the ΔnleF strain was reduced 
to that observed during WT C. rodentium infection (Fig. 6.5B). As seen previously, 
no difference in the macrophage or leukocyte cell populations was observed during 
infection with either the WT C. rodentium or C. rodentium ΔnleF strain (Data not 
shown). This suggested that caspase-1 and caspase-11, and therefore the 
inflammasome, is required for neutrophil recruitment early during C. rodentium 
infection.   
6.4  Discussion  
C. rodentium NleF shares 84 % amino acid sequence identity with NleF of both 
EPEC E69 and EHEC EDL933. Although little in vitro work with NleFCR has been 
carried out in this study it was identified that NleFCR can inhibit the murine ortholog to 
human caspase-4: caspase-11. We therefore proposed that NleF homologs may 
have a conserved function during A/E pathogen infection. 
As with many non-LEE encoded effectors NleFCR was not essential for colonisation 
of C57BL/6 mice. In order to investigate if NleFE69 manipulates the host immune 
response during infection the colons of infected mice were cultured ex-vivo on day 4 
post-infection. Analysis of the supernatants revealed that C. rodentium inhibited 
caspase-1/11-dependent, and therefore inflammasome-dependent, secretion of the 
pro-inflammatory cytokine IL-18. Importantly, no difference in KC secretion of mice 
infected with either the WT C. rodentium or C. rodentium ΔnleF strain was observed. 
This demonstrated that C. rodentium successfully targets and inhibits the host 
caspase-1/11 dependent inflammasome response during infection in an NleFCR 
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dependent manner. At later time points post infection no difference in IL-18 secretion 
was observed. 
Early during C. rodentium infection IL-18 secretion is epithelial cell dependent and 
NLRP3/NLRC4 independent (Nordlander, Pott & Maloy, 2014; Song-Zhao et al., 
2014). Alternatively at day 14 post infection both NLRC4 and caspase-11/NLRP3 are 
essential for  IL-18 secretion (Gurung et al., 2012; Liu et al., 2012). This is most likely 
due to the influx of myeloid cells and the activation of the classical murine 
macrophage non-canonical inflammasome (Kayagaki et al., 2011). Following this 
model of inflammasome activation during C. rodentium infection we propose that 
NleFCR is delivered into enterocytes to inhibit early activation of the caspase-4/11-
dependent non-canonical inflammasome. At later time points due to immune cell 
infiltration the caspase-1 NLRC4/NLRP3-dependent inflammasomes takes 
precedence. The NLRC4 inflammasome is not caspase-11 dependent and is 
therefore not predicted to be manipulated by NleFCR. Moreover, C. rodentium and 
EPEC E69 are extracellular pathogens and although many in vitro studies have 
identified T3SS dependent mechanisms to prevent myeloid cell specific functions 
including phagocytosis (Tahoun et al., 2011; Marches et al., 2008), whether NleFCR 
is translocated into macrophages or not during C. rodentium infection is unknown. It 
is therefore predicted that NleFCR is unable to prevent IL-18 secretion at later times 
due to cell specificity.   
The infection of Il-18-/- C57BL/6 mice with C. rodentium results in delayed clearance 
and an increase in bacterial burden (Liu et al., 2012). IL-18 is therefore essential for 
bacterial clearance and the host mounted immune response to C. rodentium 
infection. IL-18 has been implicated to facilitate the emigration of neutrophils and 
leukocytes to the site of insult (Verri et al., 2007; Canetti et al., 2003; Dinarello & 
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Fantuzzi, 2003); although, a role for IL-18 in immune cell recruitment in the gastro-
intestinal tract in response to Gram negative bacterial infection has not been studied 
previously. In order to characterise the recruitment of immune cells to the colon 
during infection with either the WT C. rodentium or C. rodentium ΔnleF strain the 
colonic immune cell population was analyzed at day 4 post infection by flow 
cytometry. The increase in IL-18 secretion observed upon deletion of nleF correlated 
with an increase in the infiltration of neutrophils. No change in recruitment of other 
myeloid cell types or leukocytes was observed. Moreover as with the secretion of IL-
18 no change in immune cell recruitment was observed at day 8 post infection. The 
increase in neutrophil recruitment in response to ΔnleF infection was abolished upon 
infection of Casp1/11-/- mice. This suggested that neutrophil recruitment to the colon 
early during infection is in fact inflammasome-dependent.   
It is previously reported that neutrophil recruitment during C. rodentium infection is 
CXCL2R dependent and essential for bacterial clearance and protection against 
progression to diarrheagenic associated disease (Spehlmann et al., 2009). CXCL2 
also commonly known as MIP2α, is the predominant CXCL2 ligand expressed early 
during C. rodentium infection (Spehlmann et al., 2009). Further, it is essential for IL-
18-dependent up-regulation of the potent neutrophil chemokine LTB4 (Verri et al., 
2007; Canetti et al., 2003). Whether IL-18 is responsible for the CXCL2R-dependent 
recruitment of neutrophils during C. rodentium infection requires further study. 
Alternatively, the caspase-4/-11 dependent cytokine IL-1α (Casson et al., 2015; 
Kayagaki et al., 2011) is also a potent neutrophil chemokine (Rider et al., 2011). With 
the current evidence it is not possible to delineate which inflammasome dependent 
cytokine is responsible for neutrophil recruitment observed upon deletion of nleF. To 
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further investigate this, infections must be carried out in the C57BL/6 Il-18-/- and Il-1α-
/- backgrounds or in the presence of IL-18 binding protein, a known IL-18 inhibitor.  
Recent studies have underlined the importance and contribution of non-
hematopoietic cell non-inflammasome and inflammasome- forming NLRs in intestinal 
homeostasis and regulation of the intestinal immune response to enteric infection 
(Elinav, Henao-Mejia & Flavell, 2013). Whilst non-hematopoietic and IEC expressed 
NLRP6, NLRP12 and NLRC4 play integral roles in intestinal homeostasis and the 
host mediated clearance of C. rodentium, the mechanisms by which they are 
identified do so are independent of IL-1 family cytokine secretion (Allen, 2014; 
Nordlander, Pott & Maloy, 2014; Wlodarska et al., 2014; Anand et al., 2012). Here 
we propose the caspase-4 dependent IEC inflammasome is crucial for IL-18 cytokine 
maturation and the early innate immune response to C. rodentium.   
In conclusion we identified a novel in vivo role for the inhibition of IL-18 secretion and 
inflammasome dependent neutrophil recruitment by the T3SS effector NleFCR during 
C. rodentium infection. On the other hand our in vitro data also suggested a role for 
NleFE69 in the T3SS dependent activation of the transcription factor NF-κB.   
6.4.1 NleFCR as a pro-inflammatory effector of C. rodentium   
C. rodentium employs a plethora of anti-inflammatory and immuno-modulatory 
effectors to dampen the host immune response during infection. The extent to which 
C. rodentium has evolved to prevent activation of this pathway with a multi-effector 
and highly redundant approach indicates that the suppression of the inflammatory 
response is critical to its infection strategy. While this may be true C. rodentium 
infection induces a highly pro-inflammatory response in vivo leading to colitis and 
murine colonic crypt hyperplasia (Collins et al., 2014). The host inflammatory 
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response early during colonisation is associated with alterations in the host 
commensal microbiota that is advantageous to bacterial pathogen growth (Lupp et 
al., 2007; Khan et al., 2006). This balance between activation and inhibition may be 
critical for C. rodentium to out-compete commensal bacteria whilst limiting host-
mediated immune clearance. Furthermore deletion of Tlr4 does not dampen the host 
immune response during C. rodentium infection (Khan et al., 2006). Together this 
suggests that inflammation may be directly triggered by C. rodentium to aid in 
colonisation of the host. We identified that the T3SS effector NleFE69 is essential for 
the early activation of NF-κB and IL-8 expression during in vitro EPEC epithelial cell 
infection. While ELISAs were also carried out on supernatants post tissue culture 
infection IL-8 was below detectable limits (data not shown).  Although no difference 
in KC (the murine homolog to IL-8) secretion or crypt hyperplasia (data not shown) 
was observed upon infection of C57BL/6 mice with WT C. rodentium or the C. 
rodentium ΔnleF strain, it was observed that overexpression of NleFCR in the 
complemented strain increased colonic KC secretion while still successfully inhibiting 
IL-18 secretion. C. rodentium and EPEC E69 share many homologous effectors but 
also encode unique pathotype specific effectors (Wong et al., 2011). One such C. 
rodentium effector is the pro-inflammatory GEF WxxE family protein EspT; which 
regulates TNFα and KC expression in vivo (Raymond et al., 2011). Therefore, the 
pro-inflammatory role of NleFCR may be redundant. Alternatively, there was little 
difference in KC secretion between the WT C. rodentium infected and the PBS 
control mice at day 4 p.i.. By applying more sensitive assays over a time course, 
including qPCR, and through the screening of other NF-κB dependent 
genes/cytokines, it may be possible to provide a more thorough analysis and 
understanding of the role of NleFCR during C. rodentium infection of mice. .   
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It is important to consider here that C. rodentium is only a model for EPEC infection. 
Although EPEC and C. rodentium share many genes and a homologus T3SS, the 
diarrhoeal disease associated with EPEC infection differs to that of C. rodentium.   
6.4.2 The role of NleF in the context of EPEC infection  
Both EHEC and C. rodentium trigger what is classified as an inflammatory diarrhoeal 
disease, similar to the invasive and pro-inflammatory enteric pathogens Yersinia, 
Salmonella, and Shigella (Hodges & Gill, 2010). On the other hand EPEC is 
associated with a weak pro-inflammatory, watery diarrhoeal diease (Hodges & Gill, 
2010).  
EPEC E69 is exclusively an extracellular pathogen and therefore unlike other enteric 
pathogens including Salmonella or Shigella it must successfully dampen 
inflammation and immune cell recruitment in order to survive and colonise the host. 
Contrary to this many studies including in vitro (Czerucka et al., 2001; de Grado et 
al., 2001; Newton et al., 2010; Savkovic, Koutsouris & Hecht, 1997), ex vivo 
(Schuller et al. 2009) and in vivo (Fagundes-Neto et al., 2000; Hill, Phillips & Walker-
Smith, 1991) EPEC infections have identified that EPEC induces IL-8 expression 
and low level inflammation in both a flagellin and flagellin-independent mechanism 
and that activation of NF-κB is associated with the acculumaltion of fluid and 
diarrhoeal disease (Hodges & Gill, 2010). Throughout the 1980’s many histological 
studies were conducted on biopsies of the small bowels from patients with acute or 
persistent/chronic infection as well as from patients challenged with the prototypic 
E2348/69 strain (As reviewed in Chen & Frankel, 2005). While all studies 
consistently observed that similarly to C. rodentium EPEC triggers microvilli atrophy 
and A/E lesion formation in vivo (Collins et al., 2014; Kallas, Patricio & Fagundes-
Neto, 1995) there were discrepancies in the ability of EPEC infection to induce 
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inflammation and immune cell infiltration. Several studies identified lymphocyte, 
eosinophil and/or neutrophil infiltration in response to persistent/chronic EPEC 
infection (0119, O111, O125 etc.) (Fagundes-Neto et al., 2000; Hill, Phillips & 
Walker-Smith, 1991) alternatively multiple studies revealed little or no change in 
intestinal lymphocyte numbers in the biopsies obtained from patients diagnosed with 
acute or persistent infection (Fagundes-Neto, Kallas & Patricio, 1997; Kallas, Patricio 
& Fagundes-Neto, 1995). The discrepencies on the human biopsies could be 
explained by differences in patient flora and immune status, strains that were 
ioslated or the limitation and power of the analytical tools used (mostly microscopy). 
Furthermore EPEC infection of mice (strain dependent) results in a similar infection 
phenotype to that of C. rodentium, inducing inflammation and colonic inflammatory 
cell recruitment (Zhang et al. 2012). 
Induction of NF-κB is not only linked to immune cell recruitment. EPEC induced NF-
κB activation is also implicated in the upregulation of the galanin-1 receptor, which 
increases Cl- secretion and fluid accumulation (Hodges & Gill, 2010). Thus linking 
EPEC induced inflammation to the watery diarrhoeal disease associated with EPEC 
infection. The current literature, in vitro and in vivo data and the avaibale biopsies 
from EPEC infected infants and clinical trials support that whilst EPEC is able to 
dampen the host immune response it most likely strikes a balance between pro- and 
anti-inflammatory signals; resulting in a waek inflammatory diarrhoeal disease.  
With regard to this a proposed function of NleFE69 in the inhibition of the host 
caspase-4 dependent inflammasome whilst concurrently activating NF-κB aligns well 
with the histopathological consequences and clinical symptoms of both EPEC and C. 
rodentium infection.  
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Chapter 7: Conclusions   
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7.1  Overview 
EPEC E69 and EHEC belong to a family of A/E pathogens that colonise the human 
gastrointestinal tract inducing a diarrhoeal disease, which in the case of EHEC can 
progress to HUS and renal failure (Wong et al., 2011). Virulence and pathogenesis is 
dependent on the LEE-encoded T3SS and the translocation of numerous effectors to 
manipulate host cell signalling including the innate immune response (Raymond et 
al., 2013). Characterisation of several effectors has expanded our understanding of 
the infection strategy of A/E pathogens and furthermore has increased our 
knowledge of the host mounted immune response to clear infection. To date, the 
functional role of many effectors still remains unknown. The aim of this study was to 
characterise the host interacting partners and the functional role of the T3SS effector 
NleF homologs during A/E pathogen infection.  
7.2  Conclusions and implications 
In this study we conclude that the effector NleFE69 of O126:H7 EPEC E2348/69 is 
delivered during infection to stimulate the activation of the NF-κB pathway and act as 
a caspase-4 inhibitor. Through the C-terminal motif LQCG NleFE69 binds to the 
putative substrate binding domain of the hetero-tetramer active caspase-4 complex, 
inhibiting proteolytic activity. We further confirmed that human caspase-4 is the 
functional ortholog to murine caspase-11 and can functionally complement the 
inflammatory caspase to stimulate IL-1α and IL-1β secretion, in response to Gram-
negative bacterial infection. Following this we further verified that human caspase-4 
is essential for the secretion of active IL-18 during EPEC E69 infection of IECs and 
that NleFE69 is delivered to inhibit the epithelial cell caspase-4 dependent non-
canonical inflammasome. Subsequently NleFCR dependent inhibition of 
inflammasome activity in vivo inhibits IL-18 secretion and neutrophil influx during C. 
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rodentium infection. This highlights a fundamental and novel role for the T3SS 
effector NleF in the pathogenesis and virulence of A/E pathogens. Furthermore the 
the fact that EPEC and C. rodentium have evolved mechanisms to specifically 
prevent the recruitment and infiltration of neutrophils suggests that this cell type may 
play an important role in the host immune response and outcome to A/E pathogen 
infection.  
Further to adding to our understanding of the pathogenesis and virulence 
mechanisms employed by A/E pathogens this study contributes to our understanding 
of the host non-canonical inflammasome response in vivo. The host inflammasome 
response is a major pathogenic mediator of auto-immune, auto-inflammatory and 
infectious disease (Dinarello & Fantuzzi, 2003). IL-18 specifically is a major mediator 
of inflammatory bowel disease, psoriasis, myocardial pathology and sepsis (Dinarello 
& Fantuzzi, 2003), leading to high morbidity and a lower quality of life, whilst being a 
substantial economic burden in the developed world (Kappelman et al., 2011). IL-18 
is as a possible therapeutic target for many of these complications and diseases 
including IBD (Kanai, Kamada & Hisamatsu, 2013). This research further contributes 
to our understanding and knowledge of how IL-18 secretion is regulated in the G.I 
tract in response to bacterial infection and further expands on the role of the non-
hematopoietic inflammasome in the host innate immune response.   
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